<SEC-DOCUMENT>0001493152-25-027541.txt : 20251212
<SEC-HEADER>0001493152-25-027541.hdr.sgml : 20251212
<ACCEPTANCE-DATETIME>20251212171038
ACCESSION NUMBER:		0001493152-25-027541
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		18
CONFORMED PERIOD OF REPORT:	20251211
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Unregistered Sales of Equity Securities
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20251212
DATE AS OF CHANGE:		20251212

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Enveric Biosciences, Inc.
		CENTRAL INDEX KEY:			0000890821
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				954484725
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38286
		FILM NUMBER:		251569070

	BUSINESS ADDRESS:	
		STREET 1:		245 FIRST STREET RIVERVIEW II 18TH FLOOR
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142
		BUSINESS PHONE:		(617) 444-8400

	MAIL ADDRESS:	
		STREET 1:		245 FIRST STREET RIVERVIEW II 18TH FLOOR
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AMERI Holdings, Inc.
		DATE OF NAME CHANGE:	20150527

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SPATIALIZER AUDIO LABORATORIES INC
		DATE OF NAME CHANGE:	19950323
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>form8-k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:us-roles="http://fasb.org/us-roles/2025" xmlns:country="http://xbrl.sec.gov/country/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:ENVB="http://enveric.com/20251211">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02E_US%2DGAAP%2D2025 -->
<!-- Field: Set; Name: xdx; ID: xdx_035_ENVB_enveric.com_20251211 -->
<!-- Field: Set; Name: xdx; ID: xdx_04F_20251211_20251211 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_05D_edei%2D%2DEntityCentralIndexKey_0000890821 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="AsOf2025-12-11" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2025-12-11" id="Fact000004" name="dei:EntityCentralIndexKey">0000890821</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="envb-20251211.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="AsOf2025-12-11">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-12-11</xbrli:startDate>
        <xbrli:endDate>2025-12-11</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 4pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>UNITED
STATES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>SECURITIES
AND EXCHANGE COMMISSION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt"><b>Washington,
D.C. 20549</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>FORM
<span id="xdx_905_edei--DocumentType_c20251211__20251211_zGoxud1JBKX4"><ix:nonNumeric contextRef="AsOf2025-12-11" id="Fact000009" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CURRENT
REPORT</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90C_edei--DocumentPeriodEndDate_c20251211__20251211_zye7dvXS8dMj"><ix:nonNumeric contextRef="AsOf2025-12-11" format="ixt:datemonthdayyearen" id="Fact000010" name="dei:DocumentPeriodEndDate">December
11, 2025</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Date
of Report (Date of earliest event reported)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b><span id="xdx_909_edei--EntityRegistrantName_c20251211__20251211_z6sWRCaXIo4e"><ix:nonNumeric contextRef="AsOf2025-12-11" id="Fact000011" name="dei:EntityRegistrantName">Enveric
Biosciences, Inc.</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Exact
name of registrant as specified in its charter)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_900_edei--EntityIncorporationStateCountryCode_c20251211__20251211_zeiP8JitmRbe"><ix:nonNumeric contextRef="AsOf2025-12-11" format="ixt-sec:stateprovnameen" id="Fact000012" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90F_edei--EntityFileNumber_c20251211__20251211_zchb4Za9vL8i"><ix:nonNumeric contextRef="AsOf2025-12-11" id="Fact000013" name="dei:EntityFileNumber">001-38286</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90C_edei--EntityTaxIdentificationNumber_c20251211__20251211_zrxUjd4wmXFd"><ix:nonNumeric contextRef="AsOf2025-12-11" id="Fact000014" name="dei:EntityTaxIdentificationNumber">95-4484725</ix:nonNumeric></span></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(State
                                            or other jurisdiction</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>of
    incorporation)</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Commission</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>File
    Number)</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(I.R.S.
                                            Employer</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Identification
    No.)</b></span></p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_903_edei--EntityAddressAddressLine1_c20251211__20251211_z0tq7WtbJeme"><ix:nonNumeric contextRef="AsOf2025-12-11" id="Fact000015" name="dei:EntityAddressAddressLine1">Enveric
Biosciences, Inc.</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_902_edei--EntityAddressAddressLine2_c20251211__20251211_z9jaK4OqjiKg"><ix:nonNumeric contextRef="AsOf2025-12-11" id="Fact000016" name="dei:EntityAddressAddressLine2">245
First Street, Riverview II</ix:nonNumeric></span>, <span id="xdx_909_edei--EntityAddressAddressLine3_c20251211__20251211_z0yvLVBOoCha"><ix:nonNumeric contextRef="AsOf2025-12-11" id="Fact000017" name="dei:EntityAddressAddressLine3">18th Floor</ix:nonNumeric></span><br/>
<span id="xdx_907_edei--EntityAddressCityOrTown_c20251211__20251211_zFbPdO8xuFD4"><ix:nonNumeric contextRef="AsOf2025-12-11" id="Fact000018" name="dei:EntityAddressCityOrTown">Cambridge</ix:nonNumeric></span>, <span id="xdx_908_edei--EntityAddressStateOrProvince_c20251211__20251211_zSEelhD2qJwe"><ix:nonNumeric contextRef="AsOf2025-12-11" id="Fact000019" name="dei:EntityAddressStateOrProvince">MA</ix:nonNumeric></span>, <span id="xdx_90C_edei--EntityAddressPostalZipCode_c20251211__20251211_zsMt7yiB2qnf"><ix:nonNumeric contextRef="AsOf2025-12-11" id="Fact000020" name="dei:EntityAddressPostalZipCode">02142</ix:nonNumeric> </span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Address
of principal executive offices) (Zip code)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Registrant&#8217;s
telephone number, including area code: <span id="xdx_900_edei--CityAreaCode_c20251211__20251211_zpiEfZ94YIH"><ix:nonNumeric contextRef="AsOf2025-12-11" id="Fact000021" name="dei:CityAreaCode">(617)</ix:nonNumeric></span> <span id="xdx_907_edei--LocalPhoneNumber_c20251211__20251211_zqYQowh2Oxzc"><ix:nonNumeric contextRef="AsOf2025-12-11" id="Fact000022" name="dei:LocalPhoneNumber">444-8400</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>N/A</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Former
name or former address, if changed since last report.)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_edei--WrittenCommunications_c20251211__20251211_zc2q99dzuEs5"><ix:nonNumeric contextRef="AsOf2025-12-11" format="ixt:booleanfalse" id="Fact000023" name="dei:WrittenCommunications">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Written
    communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_edei--SolicitingMaterial_c20251211__20251211_zDHqSaSsaAd6"><ix:nonNumeric contextRef="AsOf2025-12-11" format="ixt:booleanfalse" id="Fact000024" name="dei:SolicitingMaterial">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Soliciting
    material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_edei--PreCommencementTenderOffer_c20251211__20251211_zTMUe9SVmpJi"><ix:nonNumeric contextRef="AsOf2025-12-11" format="ixt:booleanfalse" id="Fact000025" name="dei:PreCommencementTenderOffer">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement
    communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_edei--PreCommencementIssuerTenderOffer_c20251211__20251211_zCQM5u4NBDlk"><ix:nonNumeric contextRef="AsOf2025-12-11" format="ixt:booleanfalse" id="Fact000026" name="dei:PreCommencementIssuerTenderOffer">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement
    communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
registered pursuant to Section 12(b) of the Act:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 38%; padding-right: 0.8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title
    of each class</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 2%; padding-right: 0.8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 18%; padding-right: 0.8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Trading
    Symbol(s)</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 2%; padding-right: 0.8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 40%; padding-right: 0.8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name
    of each exchange on which registered</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_edei--Security12bTitle_c20251211__20251211_zNFBxOy260c4"><ix:nonNumeric contextRef="AsOf2025-12-11" id="Fact000027" name="dei:Security12bTitle">Common
    stock, par value $0.01 per share</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_edei--TradingSymbol_c20251211__20251211_zrDY7SzBFyid"><ix:nonNumeric contextRef="AsOf2025-12-11" id="Fact000028" name="dei:TradingSymbol">ENVB</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_edei--SecurityExchangeName_c20251211__20251211_zSFiEO3WqgOa"><ix:nonNumeric contextRef="AsOf2025-12-11" format="ixt-sec:exchnameen" id="Fact000029" name="dei:SecurityExchangeName">The
    Nasdaq Stock Market</ix:nonNumeric></span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging
growth company <span id="xdx_907_edei--EntityEmergingGrowthCompany_c20251211__20251211_zIGkUtfa8oHf"><ix:nonNumeric contextRef="AsOf2025-12-11" format="ixt:booleanfalse" id="Fact000030" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 4pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
1.01 Entry into a Material Definitive Agreement. </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 11, 2025, Enveric Biosciences, Inc., a Delaware corporation (the &#8220;Company&#8221;) entered into warrant exercise inducement
offer letters (the &#8220;Inducement Letters&#8221;) with certain institutional investors (the &#8220;Holders&#8221;) that held certain
outstanding warrants to purchase up to an aggregate of 426,390 shares originally issued in February 2025 and September 2025, having exercise
prices of $36.00 and $10.98 per share, respectively (collectively, the &#8220;Existing Warrants&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Inducement Letters, the Holders agreed to exercise for cash their Existing Warrants at a reduced exercise price of $7.05 per share
and pay a purchase price of $0.125 per share in consideration for the Company&#8217;s agreement to issue in a private placement (x) new
Series E Common Stock Purchase Warrants (&#8220;New Series E Warrants&#8221;) to purchase up to 426,390 shares of Common Stock (&#8220;New
Series E Warrant Shares&#8221;) and (y) new Series F Common Stock Purchase Warrants (&#8220;New Series F Warrants&#8221; and, together
with the New Series E Warrants, the &#8220;New Warrants&#8221;) to purchase up to 426,390 shares of Common Stock (the &#8220;New Series
F Warrant Shares&#8221; and, together with the New Series E Warrant Shares, the &#8220;New Warrant Shares.&#8221;) The Company received
aggregate gross proceeds of approximately $3.1 million from the exercise of the Existing Warrants by the Holders, before deducing placement
agent fees and other offering expenses payable by the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company engaged H.C. Wainwright &amp; Co., LLC (the &#8220;Placement Agent&#8221;) to act as its exclusive placement agent in connection
with the transactions summarized above and have agreed to pay the Placement Agent a cash fee equal to 7.0% of the aggregate gross proceeds
received from the Holders&#8217; exercise of their Existing Warrants, as well as a management fee equal to 1.0% of the aggregate gross
proceeds from the exercise of the Existing Warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has also agreed to reimburse the Placement Agent for its expenses in connection with the exercise of the Existing Warrants and
the issuance of the New Warrants of $35,000 for its non-accountable expenses, up to $50,000 for its accountable expenses and $15,950
for its clearing costs. The Company has also agreed to issue to the Placement Agent or its designees warrants (the &#8220;Placement Agent
Warrants&#8221;) to purchase up to 29,847 shares of Common Stock (7.0% of the Existing Warrants being exercised) which will have
the same terms as the New Series E Warrants, except the Placement Agent Warrants will have an exercise price equal to $9.125 per
share (125% of the offering price). The Placement Agent Warrants will be exercisable immediately and will expire five years after the
effective date of the Resale Registration Statement (as defined below). The closing of the transactions contemplated pursuant to the
Inducement Letters was December 12, 2025 (the &#8220;Closing Date&#8221;), which was subject to satisfaction of customary closing conditions.
The Company expects to use the net proceeds from these transactions for product development, working capital and general corporate purposes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
resale of the shares of Common Stock underlying the Existing Warrants has been registered pursuant to existing registration statements
on Form S-1, as amended (File No. 333-284277), declared effective by the Securities and Exchange Commission (the &#8220;SEC&#8221;) on
January 30, 2025, and Form S-3, as amended (File No. 333-290580), declared effective by the SEC on December 8, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 23.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company also agreed to file a registration statement on Form S-3 (or other appropriate form if it is not then Form S-3 eligible) providing
for the resale of the New Warrant Shares issued or issuable upon the exercise of the New Warrants (the &#8220;Resale Registration Statement&#8221;),
as soon as practicable (and in any event within ten calendar days of the date of the Inducement Letters), and to use commercially reasonable
efforts to have such Resale Registration Statement declared effective by the SEC within 45 calendar days following the date of the Inducement
Letters (or within 75 calendar days following the date of the Inducement Letters in case of a &#8220;full review&#8221; of such registration
statement by the SEC) and to keep the Resale Registration Statement effective at all times until no Holder of the New Warrants owns any
New Warrants or New Warrant Shares. In the Inducement Letters, the Company agreed not to issue any shares of Common Stock or Common Stock
equivalents or to file any other registration statement with the SEC (in each case, subject to certain exceptions) until five days after
the Closing Date. The Company also agreed not to effect or agree to effect any Variable Rate Transaction (as defined in the Inducement
Letters) until one year after the Closing Date (subject to an exception).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>New
Warrant Terms</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following summary of certain terms and provisions of the New Warrants is not complete and is subject to, and qualified in its entirety
by, the provisions of the New Warrants, the forms of which are filed as Exhibits 4.1 and 4.2 to this Current Report on Form 8-K and are
incorporated herein by reference. The following description of the New Warrants is qualified in its entirety by reference to such exhibits.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Duration
and Exercise Price</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
New Warrant will have an exercise price equal to $7.05 per share. The New Series E Warrants will be exercisable immediately and will
expire five years after the effective date of the Resale Registration Statement. The New Series F Warrants will be exercisable immediately
and will expire eighteen months after the effective date of the Resale Registration Statement. The exercise price and number of New Warrant
Shares issuable upon exercise of the New Warrants are subject to customary adjustment in the event of stock dividends, stock splits,
subsequent rights offerings, pro rata distributions, reorganizations, or similar events affecting the Common Stock and the exercise price.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Exercisability</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 13.5pt; text-align: justify; text-indent: 45pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
New Warrants will be exercisable, at the option of each Holder, in whole or in part, by delivering to the Company a duly executed exercise
notice accompanied by payment in full for the number of shares of the Company&#8217;s Common Stock purchased upon such exercise (except
in the case of a cashless exercise as discussed below). A Holder (together with its affiliates) may not exercise any portion of such
Holder&#8217;s New Warrants to the extent that the Holder would own more than 4.99% of the outstanding Common Stock immediately after
exercise, except that upon at least 61 days&#8217; prior notice from the Holder to us, the Holder may increase the amount of ownership
of outstanding stock after exercising the Holder&#8217;s New Warrants up to 9.99% of the number of shares of Common Stock outstanding
immediately after giving effect to the exercise, as such percentage ownership is determined in accordance with the terms of the New Warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 13.5pt; text-align: justify; text-indent: 45pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 13.5pt; text-align: justify; text-indent: 45pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 13.5pt; text-align: justify; text-indent: 45pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Cashless
Exercise</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 13.5pt; text-align: justify; text-indent: 45pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If,
at the time a Holder exercises its New Warrants, a registration statement registering the issuance of the shares of Common Stock underlying
the New Warrants under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;) is not then effective or available for
the issuance of such shares, then in lieu of making the cash payment otherwise contemplated to be made to the Company upon such exercise
in payment of the aggregate exercise price, the Holder may elect instead to receive upon such exercise (either in whole or in part) the
net number of shares of Common Stock determined according to a formula set forth in the New Warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 13.5pt; text-align: justify; text-indent: 45pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Fundamental
Transactions</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 13.5pt; text-align: justify; text-indent: 45pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the event of any fundamental transaction, as described in the New Warrants and generally including any merger with or into another entity,
sale of all or substantially all of the Company&#8217;s assets, tender offer or exchange offer, or reclassification of the Company&#8217;s
Common Stock, then upon any subsequent exercise of a New Warrant, the Holder will have the right to receive as alternative consideration,
for each share of the Company&#8217;s Common Stock that would have been issuable upon such exercise immediately prior to the occurrence
of such fundamental transaction, the number of shares of Common Stock of the successor or acquiring corporation or of the Company, if
it is the surviving corporation, and any additional consideration receivable upon or as a result of such transaction by a Holder of the
number of shares of Common Stock for which the New Warrant is exercisable immediately prior to such event. Notwithstanding the foregoing,
in the event of a fundamental transaction (other than for the purposes listed in the New Warrants), the Holders of the New Warrants have
the right to require the Company or a successor entity to redeem the New Warrants for cash in the amount of the Black-Scholes Value (as
defined in each New Warrant) of the unexercised portion of the New Warrants concurrently with or within 30 days following the consummation
of a fundamental transaction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 13.5pt; text-align: justify; text-indent: 45pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">However,
in the event of a fundamental transaction which is not in the Company&#8217;s control, including a fundamental transaction not approved
by its board of directors, the Holders of the New Warrants will only be entitled to receive from the Company or its successor entity,
as of the date of consummation of such fundamental transaction, the same type or form of consideration (and in the same proportion),
at the Black Scholes Value of the unexercised portion of the New Warrant that is being offered and paid to the Holders of Common Stock
in connection with the fundamental transaction, whether that consideration is in the form of cash, stock or any combination of cash and
stock, or whether the Holders of Common Stock are given the choice to receive alternative forms of consideration in connection with the
fundamental transaction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 13.5pt; text-align: justify; text-indent: 45pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Transferability</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 13.5pt; text-align: justify; text-indent: 45pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to applicable laws, a New Warrant may be transferred at the option of the Holder upon surrender of the New Warrant to the Company together
with the appropriate instruments of transfer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 13.5pt; text-align: justify; text-indent: 45pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Fractional
Shares</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 13.5pt; text-align: justify; text-indent: 45pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
fractional shares of Common Stock will be issued upon the exercise of the New Warrants. Rather, the number of shares of Common Stock
to be issued will, at the Company&#8217;s election, either be rounded up to the next whole share or the Company will pay a cash adjustment
in respect of such final fraction in an amount equal to such fraction multiplied by the exercise price.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Trading
Market</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 13.5pt; text-align: justify; text-indent: 45pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
is no established trading market for the New Warrants, and the Company does not expect an active trading market to develop. The Company
does not intend to apply to list the New Warrants on any securities exchange or other trading market. Without a trading market, the liquidity
of the New Warrants will be extremely limited.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 13.5pt; text-align: justify; text-indent: 45pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Right
as a Stockholder</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 13.5pt; text-align: justify; text-indent: 45pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
as otherwise provided in the New Warrants or by virtue of the Holder&#8217;s ownership of shares of Common Stock, such Holder of New
Warrants does not have the rights or privileges of a Holder of Company Common Stock, including any voting rights, until such Holder exercises
such Holder&#8217;s New Warrants. The New Warrants will provide that the Holders of the New Warrants have the right to participate in
distributions or dividends paid on shares of Common Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 13.5pt; text-align: justify; text-indent: 45pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Waivers
and Amendments</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 13.5pt; text-align: justify; text-indent: 45pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
New Warrants may be modified or amended or the provisions of the New Warrants waived with the Company and the Holder&#8217;s written
consent.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
forms of Inducement Letter, New Series E Warrant, New Series F Warrant, and the Placement Agent Warrant are attached as Exhibits 10.1,
4.1, 4.2, and 4.3, respectively. The descriptions of the terms of the Inducement Letter, New Series E Warrant, New Series F Warrant,
and the Placement Agent Warrant are not intended to be complete and is qualified in its entirety by reference to such exhibits. The Inducement
Letters contain customary representations, warranties and covenants by the Company which were made only for the purposes of such agreements
and as of specific dates, were solely for the benefit of the parties to such agreements and may be subject to limitations agreed upon
by the contracting parties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 13.5pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 11, 2025 and December 12, 2025, the Company issued press releases disclosing the transactions described in this Item 1.01, copies
of which are filed as Exhibits 99.1 and 99.2 to this Current Report on Form 8-K.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 13.5pt; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 13.5pt; text-align: justify; text-indent: 0.5in; background-color: white"></p>

<!-- Field: Page; Sequence: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 13.5pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
3.02 Unregistered Sales of Equity Securities.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company issued the New Warrants and Placement Agent Warrants pursuant to the exemption from the registration requirements of the Securities
Act, available under Section 4(a)(2) and/or Rule 506(b) of Regulation D promulgated thereunder and intends to issue the New Warrant Shares
and Placement Agent Shares pursuant to the same exemption or pursuant to the exemption provided by Section 3(a)(9) of the Securities
Act. The descriptions of the New Warrants and Placement Agent Warrants under Item 1.01 of this Form 8-K are incorporated by reference
herein. The forms of the New Warrants and Placement Agent Warrants have been filed as exhibits to this Form 8-K and are incorporated
by reference herein.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
9.01. Financial Statements and Exhibits.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
Exhibits</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">
  <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit
  No.</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Description</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">
  <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif"><a href="ex4-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Series E Common Stock Purchase Warrant</span></a></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">
  <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif"><a href="ex4-2.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Series F Common Stock Purchase Warrant</span></a></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">
  <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif"><a href="ex4-3.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Placement Agent Warrant</span></a></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">
  <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif"><a href="ex10-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Inducement Letter</span></a></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">
  <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif"><a href="ex99-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Press Release, dated December 11 2025</span></a></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">
  <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.2</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif"><a href="ex99-2.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Press Release, dated December 12, 2025</span></a></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">
  <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover
  Page Interactive Data File (embedded within Inline XBRL document)</span></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white">&#160;</p>

<!-- Field: Page; Sequence: 4 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SIGNATURES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    December 12, 2025</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVERIC
    BIOSCIENCES, INC.</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 47%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Joseph Tucker</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Joseph
    Tucker, Ph.D.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<!-- Field: Page; Sequence: 5; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjd0KgkAQhZ/Adxj2Wkrt58LLxCSyEInodskxlnRHZrfSR+ot25RoGBhmzvnOCOGLjLaqQYbLpszhhG3XSItQYo2M+orOkez2MbhZ4k0Zy1Lbcf2BCTkGHbOeLaS7j86nMljFEEbzMJxHKwhW8XINxUF4Xz0hXasKtVWyAakrKJg6VmglD1PCSfakqR3GT2dko0i7uFkwyW+IgjCCIz3li/huIM8T4fljeSJjenTOlfYW9ZeEtMHWvTMT/W/vA8voSl0= -->
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>2
<FILENAME>ex4-1.htm
<DESCRIPTION>EX-4.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
4.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NEITHER
THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION
OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED
(THE &ldquo;SECURITIES ACT&rdquo;), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT
UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS
OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS. THIS SECURITY AND THE SECURITIES ISSUABLE UPON EXERCISE
OF THIS SECURITY MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN SECURED BY SUCH SECURITIES.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SERIES
E COMMON STOCK PURCHASE WARRANT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>Enveric
Biosciences, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrant
    Shares: __________</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Initial
    Exercise Date: _______, 2025</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">THIS
SERIES E COMMON STOCK PURCHASE WARRANT (the &ldquo;<U>Warrant</U>&rdquo;) certifies that, for value received, _____________ or its assigns
(the &ldquo;<U>Holder</U>&rdquo;) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter
set forth, at any time on or after the date hereof (the &ldquo;<U>Initial Exercise Date</U>&rdquo;) and on or prior to 5:00 p.m. (New
York City time) on the date that is the five (5) year anniversary of the Effective Date, provided that, if such date is not a Trading
Day, the date that is the immediately following Trading Day (the &ldquo;<U>Termination Date</U>&rdquo;) but not thereafter, to subscribe
for and purchase from Enveric Biosciences, Inc., a Delaware corporation (the &ldquo;<U>Company</U>&rdquo;), up to ______ shares (as subject
to adjustment hereunder, the &ldquo;<U>Warrant Shares</U>&rdquo;) of Common Stock. The purchase price of one share of Common Stock under
this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
1</U>. <U>Definitions</U>. In addition to the terms defined elsewhere in this Warrant, the following terms have the meanings indicated
in this Section 1:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Affiliate</U>&rdquo;
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control
with a Person, as such terms are used in and construed under Rule 405 under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Bid
Price</U>&rdquo; means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock
is then listed or quoted on a Trading Market, the bid price of the Common Stock for the time in question (or the nearest preceding date)
on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30
a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted average
price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not
then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on the Pink Open Market (or
a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common
Stock so reported, or (d) in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser
selected in good faith by the Holders of a majority in interest of the Warrants then outstanding and reasonably acceptable to the Company,
the fees and expenses of which shall be paid by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Board
of Directors</U>&rdquo; means the board of directors of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Business
Day</U>&rdquo; means any day other than Saturday, Sunday or other day on which commercial banks in The City of New York are authorized
or required by law to remain closed; <U>provided</U>, <U>however</U>, for clarification, commercial banks shall not be deemed to be authorized
or required by law to remain closed due to &ldquo;stay at home&rdquo;, &ldquo;shelter-in-place&rdquo;, &ldquo;non-essential employee&rdquo;
or any other similar orders or restrictions or the closure of any physical branch locations at the direction of any governmental authority
so long as the electronic funds transfer systems (including for wire transfers) of commercial banks in The City of New York generally
are open for use by customers on such day.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Commission</U>&rdquo;
means the United States Securities and Exchange Commission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Common
Stock</U>&rdquo; means the common stock of the Company, par value $0.01 per share, and any other class of securities into which such
securities may hereafter be reclassified or changed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Common
Stock Equivalents</U>&rdquo; means any securities of the Company or the Subsidiaries which would entitle the holder thereof to acquire
at any time Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument that is
at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Effective
Date</U>&rdquo; means the date that the Resale Registration Statement (as defined in the Letter Agreement) has been declared effective
by the Commission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Exchange
Act</U>&rdquo; means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Letter
Agreement</U>&rdquo; means that certain letter agreement between the initial Holder hereof and the Company, dated as of December 11,
2025, pursuant to which such initial Holder agreed to exercise one or more warrants to purchase shares of Common Stock and the Company
agreed to issue to the initial Holder this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Person</U>&rdquo;
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability
company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Rule
144</U>&rdquo; means Rule 144 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted
from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect
as such Rule.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Securities
Act</U>&rdquo; means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Subsidiary</U>&rdquo;
means any subsidiary of the Company and shall, where applicable, also include any direct or indirect subsidiary of the Company formed
or acquired after the date hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Trading
Day</U>&rdquo; means a day on which the Common Stock is traded on a Trading Market.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Trading
Market</U>&rdquo; means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date
in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market or the New York
Stock Exchange (or any successors to any of the foregoing).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Transfer
Agent</U>&rdquo; means Equiniti Trust Company, the current transfer agent of the Company, and any successor transfer agent of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>VWAP</U>&rdquo;
means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed
or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date)
on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30
a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted average
price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not
then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on the Pink Open Market (or
a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common
Stock so reported, or (d) in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser
selected in good faith by the holders of a majority in interest of the Warrants then outstanding and reasonably acceptable to the Company,
the fees and expenses of which shall be paid by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Warrants</U>&rdquo;
means this Warrant and other Common Stock purchase warrants issued by the Company pursuant to the Letter Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
2</U>. <U>Exercise</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)
<U>Exercise of Warrant</U>. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time
or times on or after the Initial Exercise Date and on or before the Termination Date by delivery to the Company of a duly executed PDF
copy submitted by e-mail (or e-mail attachment) of the Notice of Exercise in the form annexed hereto (the &ldquo;<U>Notice of Exercise</U>&rdquo;).
Within the earlier of (i) one (1) Trading Day and (ii) the number of Trading Days comprising the Standard Settlement Period (as defined
in Section 2(d)(i) herein) following the date of exercise as aforesaid, the Holder shall deliver the aggregate Exercise Price for the
shares specified in the applicable Notice of Exercise by wire transfer or cashier&rsquo;s check drawn on a United States bank unless
the cashless exercise procedure specified in Section 2(c) below is specified in the applicable Notice of Exercise. No ink-original Notice
of Exercise shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise
be required. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to
the Company until the Holder has purchased all of the Warrant Shares available hereunder and the Warrant has been exercised in full,
in which case, the Holder shall surrender this Warrant to the Company for cancellation within three (3) Trading Days of the date on which
the final Notice of Exercise is delivered to the Company. Partial exercises of this Warrant resulting in purchases of a portion of the
total number of Warrant Shares available hereunder shall have the effect of lowering the outstanding number of Warrant Shares purchasable
hereunder in an amount equal to the applicable number of Warrant Shares purchased. The Holder and the Company shall maintain records
showing the number of Warrant Shares purchased and the date of such purchases. The Company shall deliver any objection to any Notice
of Exercise on the Trading Day of receipt of such notice. <B>The Holder and any assignee, by acceptance of this Warrant, acknowledge
and agree that, by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant Shares hereunder, the
number of Warrant Shares available for purchase hereunder at any given time may be less than the amount stated on the face hereof.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)
<U>Exercise Price</U>. The exercise price per share of Common Stock under this Warrant shall be $7.05, subject to adjustment hereunder
(the &ldquo;<U>Exercise Price</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)
<U>Cashless Exercise</U>. If at the time of exercise hereof there is no effective registration statement registering, or the prospectus
contained therein is not available for the resale of the Warrant Shares by the Holder, then this Warrant may also be exercised, in whole
or in part, at such time by means of a &ldquo;cashless exercise&rdquo; in which the Holder shall be entitled to receive a number of Warrant
Shares equal to the quotient obtained by dividing [(A-B) (X)] by (A), where:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(A)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">=
    as applicable: (i) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise if such Notice
    of Exercise is (1) delivered pursuant to Section 2(a) hereof on a day that is not a Trading Day or (2) delivered pursuant to Section
    2(a) hereof on a Trading Day prior to the opening of &ldquo;regular trading hours&rdquo; (as defined in Rule 600(b) of Regulation
    NMS promulgated under the federal securities laws) on such Trading Day, (ii) the highest Bid Price of the Common Stock on the principal
    Trading Market as reported by Bloomberg L.P. (&ldquo;<U>Bloomberg</U>&rdquo;) within two (2) hours of the time of the Holder&rsquo;s
    delivery of the Notice of Exercise pursuant to Section 2(a) hereof if such Notice of Exercise is delivered during &ldquo;regular
    trading hours,&rdquo; or within two (2) hours after the close of &ldquo;regular trading hours,&rdquo; on a Trading Day or (iii) the
    VWAP on the date of the applicable Notice of Exercise if the date of such Notice of Exercise is a Trading Day and such Notice of
    Exercise is delivered pursuant to Section 2(a) hereof after two (2) hours following the close of &ldquo;regular trading hours&rdquo;
    on such Trading Day;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(B)
    = </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    Exercise Price of this Warrant, as adjusted hereunder; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(X)
    = </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    number of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant if such
    exercise were by means of a cash exercise rather than a cashless exercise.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">If
Warrant Shares are issued in such a cashless exercise, the parties acknowledge and agree that in accordance with Section 3(a)(9) of the
Securities Act, the holding period of the Warrant Shares being issued may be tacked on to the holding period of this Warrant. The Company
agrees not to take any position contrary to this Section 2(c).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 103.5pt; text-align: justify; text-indent: -31.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstanding
anything herein to the contrary, on the Termination Date, this Warrant shall be automatically exercised via cashless exercise pursuant
to this Section 2(c).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 103.5pt; text-align: justify; text-indent: -31.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)
<U>Mechanics of Exercise</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.
<U>Delivery of Warrant Shares Upon Exercise</U>. The Company shall cause the Warrant Shares purchased hereunder to be transmitted by
the Transfer Agent to the Holder by crediting the account of the Holder&rsquo;s or its designee&rsquo;s balance account with The Depository
Trust Company through its Deposit or Withdrawal at Custodian system (&ldquo;<U>DWAC</U>&rdquo;) if the Company is then a participant
in such system and either (A) there is an effective registration statement permitting the issuance of the Warrant Shares to or resale
of the Warrant Shares by Holder or (B) the Warrant Shares are eligible for resale by the Holder without volume or manner-of-sale limitations
pursuant to Rule 144 (assuming cashless exercise of the Warrants), and otherwise by physical delivery of a certificate, registered in
the Company&rsquo;s share register in the name of the Holder or its designee, for the number of Warrant Shares to which the Holder is
entitled pursuant to such exercise to the address specified by the Holder in the Notice of Exercise by the date that is the earlier of
(i) one (1) Trading Day after the delivery to the Company of the Notice of Exercise and (ii) the number of Trading Days comprising the
Standard Settlement Period after the delivery to the Company of the Notice of Exercise (such date, the &ldquo;<U>Warrant Share Delivery
Date</U>&rdquo;). Upon delivery of the Notice of Exercise, the Holder shall be deemed for all corporate purposes to have become the holder
of record of the Warrant Shares with respect to which this Warrant has been exercised, irrespective of the date of delivery of the Warrant
Shares, provided that payment of the aggregate Exercise Price (other than in the case of a cashless exercise) is received within the
earlier of (i) one (1) Trading Day and (ii) the number of Trading Days comprising the Standard Settlement Period following delivery of
the Notice of Exercise. If the Company fails for any reason to deliver to the Holder the Warrant Shares subject to a Notice of Exercise
by the Warrant Share Delivery Date, the Company shall pay to the Holder, in cash, as liquidated damages and not as a penalty, for each
$1,000 of Warrant Shares subject to such exercise (based on the VWAP of the Common Stock on the date of the applicable Notice of Exercise),
$10 per Trading Day (increasing to $20 per Trading Day on the third Trading Day after the Warrant Share Delivery Date) for each Trading
Day after such Warrant Share Delivery Date until such Warrant Shares are delivered or Holder rescinds such exercise. The Company agrees
to maintain a transfer agent that is a participant in the FAST program so long as this Warrant remains outstanding and exercisable. As
used herein, &ldquo;<U>Standard Settlement Period</U>&rdquo; means the standard settlement period, expressed in a number of Trading Days,
on the Company&rsquo;s primary Trading Market with respect to the Common Stock as in effect on the date of delivery of the Notice of
Exercise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: -9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii.
<U>Delivery of New Warrants Upon Exercise</U>. If this Warrant shall have been exercised in part, the Company shall, at the request of
a Holder and upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new Warrant
evidencing the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall in
all other respects be identical with this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">iii.
<U>Rescission Rights</U>. If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant to Section
2(d)(i) by the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">iv.
<U>Compensation for Buy-In on Failure to Timely Deliver Warrant Shares Upon Exercise</U>. In addition to any other rights available to
the Holder, if the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in accordance with the provisions
of Section 2(d)(i) above pursuant to an exercise on or before the Warrant Share Delivery Date, and if after such date the Holder is required
by its broker to purchase (in an open market transaction or otherwise) or the Holder&rsquo;s brokerage firm otherwise purchases, shares
of Common Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon
such exercise (a &ldquo;<U>Buy-In</U>&rdquo;), then the Company shall (A) pay in cash to the Holder the amount, if any, by which (x)
the Holder&rsquo;s total purchase price (including brokerage commissions, if any) for the shares of Common Stock so purchased exceeds
(y) the amount obtained by multiplying (1) the number of Warrant Shares that the Company was required to deliver to the Holder in connection
with the exercise at issue times (2) the price at which the sell order giving rise to such purchase obligation was executed, and (B)
at the option of the Holder, either reinstate the portion of the Warrant and equivalent number of Warrant Shares for which such exercise
was not honored (in which case such exercise shall be deemed rescinded) or deliver to the Holder the number of shares of Common Stock
that would have been issued had the Company timely complied with its exercise and delivery obligations hereunder. For example, if the
Holder purchases Common Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise of shares
of Common Stock with an aggregate sale price giving rise to such purchase obligation of $10,000, under clause (A) of the immediately
preceding sentence the Company shall be required to pay the Holder $1,000. The Holder shall provide the Company written notice indicating
the amounts payable to the Holder in respect of the Buy-In and, upon request of the Company, evidence of the amount of such loss. Nothing
herein shall limit a Holder&rsquo;s right to pursue any other remedies available to it hereunder, at law or in equity including, without
limitation, a decree of specific performance and/or injunctive relief with respect to the Company&rsquo;s failure to timely deliver shares
of Common Stock upon exercise of the Warrant as required pursuant to the terms hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">v.
<U>No Fractional Shares or Scrip</U>. No fractional shares or scrip representing fractional shares shall be issued upon the exercise
of this Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company
shall, at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied
by the Exercise Price or round up to the next whole share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">vi.
<U>Charges, Taxes and Expenses</U>. Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer tax
or other incidental expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the Company,
and such Warrant Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder; <U>provided</U>,
<U>however</U>, that, in the event that Warrant Shares are to be issued in a name other than the name of the Holder, this Warrant when
surrendered for exercise shall be accompanied by the Assignment Form attached hereto duly executed by the Holder and the Company may
require, as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto. The Company
shall pay all Transfer Agent fees required for same-day processing of any Notice of Exercise and all fees to the Depository Trust Company
(or another established clearing corporation performing similar functions) required for same-day electronic delivery of the Warrant Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">vii.
<U>Closing of Books</U>. The Company will not close its stockholder books or records in any manner which prevents the timely exercise
of this Warrant, pursuant to the terms hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)
<U>Holder&rsquo;s Exercise Limitations</U>. The Company shall not effect any exercise of this Warrant, and a Holder shall not have the
right to exercise any portion of this Warrant, pursuant to Section 2 or otherwise, to the extent that after giving effect to such issuance
after exercise as set forth on the applicable Notice of Exercise, the Holder (together with the Holder&rsquo;s Affiliates, and any other
Persons acting as a group together with the Holder or any of the Holder&rsquo;s Affiliates (such Persons, &ldquo;<U>Attribution Parties</U>&rdquo;)),
would beneficially own in excess of the Beneficial Ownership Limitation (as defined below). For purposes of the foregoing sentence, the
number of shares of Common Stock beneficially owned by the Holder and its Affiliates and Attribution Parties shall include the number
of shares of Common Stock issuable upon exercise of this Warrant with respect to which such determination is being made, but shall exclude
the number of shares of Common Stock which would be issuable upon (i) exercise of the remaining, nonexercised portion of this Warrant
beneficially owned by the Holder or any of its Affiliates or Attribution Parties and (ii) exercise or conversion of the unexercised or
nonconverted portion of any other securities of the Company (including, without limitation, any other Common Stock Equivalents) subject
to a limitation on conversion or exercise analogous to the limitation contained herein beneficially owned by the Holder or any of its
Affiliates or Attribution Parties. Except as set forth in the preceding sentence, for purposes of this Section 2(e), beneficial ownership
shall be calculated in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder, it being
acknowledged by the Holder that the Company is not representing to the Holder that such calculation is in compliance with Section 13(d)
of the Exchange Act and the Holder is solely responsible for any schedules required to be filed in accordance therewith. To the extent
that the limitation contained in this Section 2(e) applies, the determination of whether this Warrant is exercisable (in relation to
other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable
shall be in the sole discretion of the Holder, and the submission of a Notice of Exercise shall be deemed to be the Holder&rsquo;s determination
of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates and Attribution
Parties) and of which portion of this Warrant is exercisable, in each case subject to the Beneficial Ownership Limitation, and the Company
shall have no obligation to verify or confirm the accuracy of such determination. In addition, a determination as to any group status
as contemplated above shall be determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated
thereunder. For purposes of this Section 2(e), in determining the number of outstanding shares of Common Stock, a Holder may rely on
the number of outstanding shares of Common Stock as reflected in (A) the Company&rsquo;s most recent periodic or annual report filed
with the Commission, as the case may be, (B) a more recent public announcement by the Company or (C) a more recent written notice by
the Company or the Transfer Agent setting forth the number of shares of Common Stock outstanding. Upon the written or oral request of
a Holder, the Company shall within one Trading Day confirm orally and in writing to the Holder the number of shares of Common Stock then
outstanding. In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion
or exercise of securities of the Company, including this Warrant, by the Holder or its Affiliates or Attribution Parties since the date
as of which such number of outstanding shares of Common Stock was reported. The &ldquo;<U>Beneficial Ownership Limitation</U>&rdquo;
shall be 4.99% (or, upon election by a Holder prior to the issuance of any Warrants, 9.99%) of the number of shares of Common Stock outstanding
immediately after giving effect to the issuance of shares of Common Stock issuable upon exercise of this Warrant. The Holder, upon notice
to the Company, may increase or decrease the Beneficial Ownership Limitation provisions of this Section 2(e), provided that the Beneficial
Ownership Limitation in no event exceeds 9.99% of the number of shares of the Common Stock outstanding immediately after giving effect
to the issuance of shares of Common Stock upon exercise of this Warrant held by the Holder and the provisions of this Section 2(e) shall
continue to apply. Any increase in the Beneficial Ownership Limitation will not be effective until the 61<SUP>st</SUP> day after such
notice is delivered to the Company. The provisions of this paragraph shall be construed and implemented in a manner otherwise than in
strict conformity with the terms of this Section 2(e) to correct this paragraph (or any portion hereof) which may be defective or inconsistent
with the intended Beneficial Ownership Limitation herein contained or to make changes or supplements necessary or desirable to properly
give effect to such limitation. The limitations contained in this paragraph shall apply to a successor holder of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
3</U>. <U>Certain Adjustments</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)
<U>Stock Dividends and Splits</U>. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or otherwise
makes a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable in shares
of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company upon exercise of this
Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines (including by way of reverse
stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv) issues by reclassification of shares of the
Common Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied by a fraction of which
the numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately before such event
and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event, and the number of
shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this Warrant
shall remain unchanged. Any adjustment made pursuant to this Section 3(a) shall become effective immediately after the record date for
the determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately after the
effective date in the case of a subdivision, combination or re-classification.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)
<U>Subsequent Rights Offerings</U>. In addition to any adjustments pursuant to Section 3(a) above, if at any time the Company grants,
issues or sells any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to the record
holders of any class of shares of Common Stock (the &ldquo;<U>Purchase Rights</U>&rdquo;), then the Holder will be entitled to acquire,
upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had
held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise
hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date on which a record is taken for
the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of shares
of Common Stock are to be determined for the grant, issue or sale of such Purchase Rights (provided, however, that, to the extent that
the Holder&rsquo;s right to participate in any such Purchase Right would result in the Holder exceeding the Beneficial Ownership Limitation,
then the Holder shall not be entitled to participate in such Purchase Right to such extent (or beneficial ownership of such shares of
Common Stock as a result of such Purchase Right to such extent) and such Purchase Right to such extent shall be held in abeyance for
the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)
<U>Pro Rata Distributions</U>. During such time as this Warrant is outstanding, if the Company shall declare or make any dividend or
other distribution of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital
or otherwise (including, without limitation, any distribution of cash, stock or other securities, property or options by way of a dividend,
spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction) (a &ldquo;<U>Distribution</U>&rdquo;),
at any time after the issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution
to the same extent that the Holder would have participated therein if the Holder had held the number of shares of Common Stock acquirable
upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial
Ownership Limitation) immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the
date as of which the record holders of shares of Common Stock are to be determined for the participation in such Distribution (<U>provided</U>,
<U>however</U>, that, to the extent that the Holder&rsquo;s right to participate in any such Distribution would result in the Holder
exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Distribution to such extent
(or in the beneficial ownership of any shares of Common Stock as a result of such Distribution to such extent) and the portion of such
Distribution shall be held in abeyance for the benefit of the Holder until such time, if ever, as its right thereto would not result
in the Holder exceeding the Beneficial Ownership Limitation).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)
<U>Fundamental Transaction</U>. If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in one or
more related transactions effects any merger or consolidation of the Company with or into another Person, (ii) the Company or any Subsidiary,
directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially
all of its assets in one or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange
offer (whether by the Company or another Person) is completed pursuant to which holders of Common Stock are permitted to sell, tender
or exchange their shares for other securities, cash or property and has been accepted by the holders of greater than 50% of the outstanding
Common Stock or greater than 50% of the voting power of the common equity of the Company, (iv) the Company, directly or indirectly, in
one or more related transactions effects any reclassification, reorganization or recapitalization of the Common Stock or any compulsory
share exchange pursuant to which the Common Stock is effectively converted into or exchanged for other securities, cash or property,
or (v) the Company, directly or indirectly, in one or more related transactions consummates a stock or share purchase agreement or other
business combination (including, without limitation, a reorganization, recapitalization, spin-off, merger or scheme of arrangement) with
another Person or group of Persons whereby such other Person or group acquires greater than 50% of the outstanding shares of Common Stock
or greater than 50% of the voting power of the common equity of the Company (each a &ldquo;<U>Fundamental Transaction</U>&rdquo;), then,
upon any subsequent exercise of this Warrant, the Holder shall have the right to receive, for each Warrant Share that would have been
issuable upon such exercise immediately prior to the occurrence of such Fundamental Transaction, at the option of the Holder (without
regard to any limitation in Section 2(e) on the exercise of this Warrant), the number of shares of Common Stock of the successor or acquiring
corporation or of the Company, if it is the surviving corporation, and any additional consideration (the &ldquo;<U>Alternate Consideration</U>&rdquo;)
receivable as a result of such Fundamental Transaction by a holder of the number of shares of Common Stock for which this Warrant is
exercisable immediately prior to such Fundamental Transaction (without regard to any limitation in Section 2(e) on the exercise of this
Warrant). For purposes of any such exercise, the determination of the Exercise Price shall be appropriately adjusted to apply to such
Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one share of Common Stock in such Fundamental
Transaction, and the Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the
relative value of any different components of the Alternate Consideration. If holders of Common Stock are given any choice as to the
securities, cash or property to be received in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate
Consideration it receives upon any exercise of this Warrant following such Fundamental Transaction. Notwithstanding anything to the contrary,
in the event of a Fundamental Transaction, the Company or any Successor Entity (as defined below) shall, at the Holder&rsquo;s option,
exercisable at any time concurrently with, or within 30 days after, the consummation of the Fundamental Transaction (or, if later, the
date of the public announcement of the applicable Fundamental Transaction), purchase this Warrant from the Holder by paying to the Holder
an amount of cash equal to the Black Scholes Value (as defined below) of the remaining unexercised portion of this Warrant on the date
of the consummation of such Fundamental Transaction; <U>provided</U>, <U>however</U>, that, if the Fundamental Transaction is not within
the Company&rsquo;s control, including not approved by the Company&rsquo;s Board of Directors, the Holder shall only be entitled to receive
from the Company or any Successor Entity the same type or form of consideration (and in the same proportion), at the Black Scholes Value
of the unexercised portion of this Warrant, that is being offered and paid to the holders of Common Stock of the Company in connection
with the Fundamental Transaction, whether that consideration be in the form of cash, stock or any combination thereof, or whether the
holders of Common Stock are given the choice to receive from among alternative forms of consideration in connection with the Fundamental
Transaction; <U>provided</U>, <U>further</U>, that if holders of Common Stock of the Company are not offered or paid any consideration
in such Fundamental Transaction, such holders of Common Stock will be deemed to have received common stock of the Successor Entity (which
Successor Entity may be the Company following such Fundamental Transaction) in such Fundamental Transaction. &ldquo;<U>Black Scholes
Value</U>&rdquo; means the value of this Warrant based on the Black-Scholes Option Pricing Model obtained from the &ldquo;OV&rdquo; function
on Bloomberg, L.P. (&ldquo;<U>Bloomberg</U>&rdquo;) determined as of the day of consummation of the applicable Fundamental Transaction
for pricing purposes and reflecting (A) a risk-free interest rate corresponding to the U.S. Treasury rate for a period equal to the time
between the date of the public announcement of the applicable contemplated Fundamental Transaction and the Termination Date, (B) an expected
volatility equal to the 100 day volatility as obtained from the HVT function on Bloomberg (determined utilizing a 365 day annualization
factor) as of the Trading Day immediately following the public announcement of the applicable contemplated Fundamental Transaction, (C)
the underlying price per share used in such calculation shall be the greater of (i) the sum of the price per share being offered in cash,
if any, plus the value of any non-cash consideration, if any, being offered in such Fundamental Transaction and (ii) the VWAP immediately
preceding the public announcement of the applicable contemplated Fundamental Transaction (or the consummation of the applicable Fundamental
Transaction, if earlier), (D) a remaining option time equal to the time between the date of the public announcement of the applicable
contemplated Fundamental Transaction and the Termination Date and (E) a zero cost of borrow. The payment of the Black Scholes Value will
be made by wire transfer of immediately available funds (or such other consideration) within the later of (i) five Business Days of the
Holder&rsquo;s election and (ii) the date of consummation of the Fundamental Transaction. The Company shall cause any successor entity
in a Fundamental Transaction in which the Company is not the survivor (the &ldquo;<U>Successor Entity</U>&rdquo;) to assume in writing
all of the obligations of the Company under this Warrant in accordance with the provisions of this Section 3(d) pursuant to written agreements
in form and substance reasonably satisfactory to the Holder and approved by the Holder (without unreasonable delay) prior to such Fundamental
Transaction and shall, at the option of the Holder, deliver to the Holder in exchange for this Warrant a security of the Successor Entity
evidenced by a written instrument substantially similar in form and substance to this Warrant which is exercisable for a corresponding
number of shares of capital stock of such Successor Entity (or its parent entity) equivalent to the shares of Common Stock acquirable
and receivable upon exercise of this Warrant (without regard to any limitations on the exercise of this Warrant) prior to such Fundamental
Transaction, and with an exercise price which applies the exercise price hereunder to such shares of capital stock (but taking into account
the relative value of the shares of Common Stock pursuant to such Fundamental Transaction and the value of such shares of capital stock,
such number of shares of capital stock and such exercise price being for the purpose of protecting the economic value of this Warrant
immediately prior to the consummation of such Fundamental Transaction), and which is reasonably satisfactory in form and substance to
the Holder. Upon the occurrence of any such Fundamental Transaction, the Successor Entity shall be added to the term &ldquo;Company&rdquo;
under this Warrant (so that from and after the occurrence or consummation of such Fundamental Transaction, each and every provision of
this Warrant referring to the &ldquo;Company&rdquo; shall refer instead to each of the Company and the Successor Entity or Successor
Entities, jointly and severally), and the Successor Entity or Successor Entities, jointly and severally with the Company, may exercise
every right and power of the Company prior thereto and the Successor Entity or Successor Entities shall assume all of the obligations
of the Company prior thereto under this Warrant with the same effect as if the Company and such Successor Entity or Successor Entities,
jointly and severally, had been named as the Company herein. For the avoidance of doubt, the Holder shall be entitled to the benefits
of the provisions of this Section 3(d) regardless of (i) whether the Company has sufficient authorized shares of Common Stock for the
issuance of Warrant Shares and/or (ii) whether a Fundamental Transaction occurs prior to the Initial Exercise Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)
<U>Calculations</U>. All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share, as the
case may be. For purposes of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding as of a given date
shall be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">f)
<U>Notice to Holder</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.
<U>Adjustment to Exercise Price</U>. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the Company
shall promptly deliver to the Holder by email a notice setting forth the Exercise Price after such adjustment and any resulting adjustment
to the number of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii.
<U>Notice to Allow Exercise by Holder</U>. If (A) the Company shall declare a dividend (or any other distribution in whatever form) on
the Common Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C) the
Company shall authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares of
capital stock of any class or of any rights, (D) the approval of any stockholders of the Company shall be required in connection with
any reclassification of the Common Stock, any consolidation or merger to which the Company (or any of its Subsidiaries) is a party, any
sale or transfer of all or substantially all of its assets, or any compulsory share exchange whereby the Common Stock is converted into
other securities, cash or property, or (E) the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding
up of the affairs of the Company, then, in each case, the Company shall cause to be delivered by email to the Holder at its last email
address as it shall appear upon the Warrant Register of the Company, at least 20 calendar days prior to the applicable record or effective
date hereinafter specified, a notice stating (x) the date on which a record is to be taken for the purpose of such dividend, distribution,
redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of the Common Stock of record to
be entitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y) the date on which such reclassification,
consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and the date as of which it is expected
that holders of the Common Stock of record shall be entitled to exchange their shares of the Common Stock for securities, cash or other
property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange; provided that the failure to
deliver such notice or any defect therein or in the delivery thereof shall not affect the validity of the corporate action required to
be specified in such notice. To the extent that any notice provided in this Warrant constitutes, or contains, material, non-public information
regarding the Company or any of the Subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant to a
Current Report on Form 8-K. The Holder shall remain entitled to exercise this Warrant during the period commencing on the date of such
notice to the effective date of the event triggering such notice except as may otherwise be expressly set forth herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
4</U>. <U>Transfer of Warrant</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)
<U>Transferability</U>. Subject to compliance with any applicable securities laws and the conditions set forth in Section 4(d) hereof,
this Warrant and all rights hereunder (including, without limitation, any registration rights) are transferable, in whole or in part,
upon surrender of this Warrant at the principal office of the Company or its designated agent, together with a written assignment of
this Warrant substantially in the form attached hereto duly executed by the Holder or its agent or attorney and funds sufficient to pay
any transfer taxes payable upon the making of such transfer. Upon such surrender and, if required, such payment, the Company shall execute
and deliver a new Warrant or Warrants in the name of the assignee or assignees, as applicable, and in the denomination or denominations
specified in such instrument of assignment, and shall issue to the assignor a new Warrant evidencing the portion of this Warrant not
so assigned, and this Warrant shall promptly be cancelled. Notwithstanding anything herein to the contrary, the Holder shall not be required
to physically surrender this Warrant to the Company unless the Holder has assigned this Warrant in full, in which case, the Holder shall
surrender this Warrant to the Company within three (3) Trading Days of the date on which the Holder delivers an assignment form to the
Company assigning this Warrant in full. The Warrant, if properly assigned in accordance herewith, may be exercised by a new holder for
the purchase of Warrant Shares without having a new Warrant issued.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)
<U>New Warrants</U>. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of
the Company, together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by
the Holder or its agent or attorney. Subject to compliance with Section 4(a), as to any transfer which may be involved in such division
or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided
or combined in accordance with such notice. All Warrants issued on transfers or exchanges shall be dated the initial issuance date of
this Warrant and shall be identical with this Warrant except as to the number of Warrant Shares issuable pursuant thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)
<U>Warrant Register</U>. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the
&ldquo;<U>Warrant Register</U>&rdquo;), in the name of the record Holder hereof from time to time. The Company may deem and treat the
registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder,
and for all other purposes, absent actual notice to the contrary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)
<U>Transfer Restrictions</U>. If, at the time of the surrender of this Warrant in connection with any transfer of this Warrant, the transfer
of this Warrant shall not be either (i) registered pursuant to an effective registration statement under the Securities Act and under
applicable state securities or blue sky laws or (ii) eligible for resale without volume or manner-of-sale restrictions or current public
information requirements pursuant to Rule 144, the Company may require, as a condition of allowing such transfer, that the Holder or
transferee of this Warrant, as the case may be, provides to the Company an opinion of counsel, the form and substance of which opinion
shall be reasonably satisfactory to the Company, to the effect that the transfer of this Warrant does not require registration under
the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)
<U>Representation by the Holder</U>. The Holder, by the acceptance hereof, represents and warrants that it is acquiring this Warrant
and, upon any exercise hereof, will acquire the Warrant Shares issuable upon such exercise, for its own account and not with a view to
or for distributing or reselling such Warrant Shares or any part thereof in violation of the Securities Act or any applicable state securities
law, except pursuant to sales registered or exempted under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
5</U>. <U>Miscellaneous</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)
<U>No Rights as Stockholder Until Exercise; No Settlement in Cash</U>. This Warrant does not entitle the Holder to any voting rights,
dividends or other rights as a stockholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i), except as expressly
set forth in Section 3. Without limiting any rights of a Holder to receive Warrant Shares on a &ldquo;cashless exercise&rdquo; pursuant
to Section 2(c) or to receive cash payments pursuant to Section 2(d)(i) and Section 2(d)(iv) herein, in no event shall the Company be
required to net cash settle an exercise of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)
<U>Loss, Theft, Destruction or Mutilation of Warrant</U>. The Company covenants that upon receipt by the Company of evidence reasonably
satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant Shares,
and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the Warrant,
shall not include the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the
Company will make and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant
or stock certificate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)
<U>Saturdays, Sundays, Holidays, etc</U>. If the last or appointed day for the taking of any action or the expiration of any right required
or granted herein shall not be a Business Day, then such action may be taken or such right may be exercised on the next succeeding Business
Day.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)
<U>Authorized Shares</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company covenants that, during the period the Warrant is outstanding, it will reserve from its authorized and unissued Common Stock a
sufficient number of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights under this Warrant.
The Company further covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged with
the duty of issuing the necessary Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company will take all
such reasonable action as may be necessary to assure that such Warrant Shares may be issued as provided herein without violation of any
applicable law or regulation, or of any requirements of the Trading Market upon which the Common Stock may be listed. The Company covenants
that all Warrant Shares which may be issued upon the exercise of the purchase rights represented by this Warrant will, upon exercise
of the purchase rights represented by this Warrant and payment for such Warrant Shares in accordance herewith, be duly authorized, validly
issued, fully paid and nonassessable and free from all taxes, liens and charges created by the Company in respect of the issue thereof
(other than taxes in respect of any transfer occurring contemporaneously with such issue).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
and to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending
its certificate of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale
of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant,
but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary
or appropriate to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality of the
foregoing, the Company will (i) not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise
immediately prior to such increase in par value, (ii) take all such action as may be necessary or appropriate in order that the Company
may validly and legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant and (iii) use commercially
reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof,
as may be, necessary to enable the Company to perform its obligations under this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Before
taking any action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the
Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from
any public regulatory body or bodies having jurisdiction thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)
<U>Governing Law</U>. All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be governed
by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles of conflicts
of law thereof. Each party agrees that all legal proceedings concerning the interpretations, enforcement and defense of the transactions
contemplated by this Warrant (whether brought against a party hereto or their respective affiliates, directors, officers, shareholders,
partners, members, employees or agents) shall be commenced exclusively in the state and federal courts sitting in the City of New York.
Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in the City of New York,
Borough of Manhattan for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby
or discussed herein, and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is
not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is improper or is an inconvenient
venue for such proceeding. Each party hereby irrevocably waives personal service of process and consents to process being served in any
such suit, action or proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery)
to such party at the address in effect for notices to it under this Warrant and agrees that such service shall constitute good and sufficient
service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any
other manner permitted by law. If either party shall commence an action, suit or proceeding to enforce any provisions of this Warrant,
the prevailing party in such action, suit or proceeding shall be reimbursed by the other party for their reasonable attorneys&rsquo;
fees and other costs and expenses incurred with the investigation, preparation and prosecution of such action or proceeding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">f)
<U>Restrictions</U>. The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered, and
the Holder does not utilize cashless exercise, will have restrictions upon resale imposed by state and federal securities laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">g)
<U>Nonwaiver and Expenses</U>. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall
operate as a waiver of such right or otherwise prejudice the Holder&rsquo;s rights, powers or remedies. Without limiting any other provision
of this Warrant, if the Company willfully and knowingly fails to comply with any provision of this Warrant, which results in any material
damages to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to cover any costs and expenses including,
but not limited to, reasonable attorneys&rsquo; fees, including those of appellate proceedings, incurred by the Holder in collecting
any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">h)
<U>Notices</U>. Any and all notices or other communications or deliveries to be provided by the Holders hereunder including, without
limitation, any Notice of Exercise, shall be in writing and delivered personally, by e-mail, or sent by a nationally recognized overnight
courier service, addressed to the Company, at 10 Cleveland Street, Unit A, Summerville, MA 02143, Attention: Kevin Coveney, email address:
kcoveney@enveric.com, or such other email address or address as the Company may specify for such purposes by notice to the Holders. Any
and all notices or other communications or deliveries to be provided by the Company hereunder shall be in writing and delivered personally,
by e-mail, or sent by a nationally recognized overnight courier service addressed to each Holder at the e-mail address or address of
such Holder appearing on the books of the Company. Any notice or other communication or deliveries hereunder shall be deemed given and
effective on the earliest of (i) the time of transmission, if such notice or communication is delivered via e-mail at the e-mail address
set forth in this Section prior to 5:30 p.m. (New York City time) on any date, (ii) the next Trading Day after the time of transmission,
if such notice or communication is delivered via e-mail at the e-mail address set forth in this Section on a day that is not a Trading
Day or later than 5:30 p.m. (New York City time) on any Trading Day, (iii) the second Trading Day following the date of mailing, if sent
by U.S. nationally recognized overnight courier service, or (iv) upon actual receipt by the party to whom such notice is required to
be given. To the extent that any notice provided hereunder constitutes, or contains, material, non-public information regarding the Company
or any Subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant to a Current Report on Form 8-K.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i)
<U>Limitation of Liability</U>. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant
to purchase Warrant Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of
the Holder for the purchase price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company
or by creditors of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">j)
<U>Remedies</U>. The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will
be entitled to specific performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate
compensation for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to
assert the defense in any action for specific performance that a remedy at law would be adequate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">k)
<U>Successors and Assigns</U>. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall
inure to the benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns
of Holder. The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and shall
be enforceable by the Holder or holder of Warrant Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">l)
<U>Amendment</U>. Other than Section 2(e) above and this Section 5(l), which may not be amended, modified or waived, this Warrant may
be modified or amended or the provisions hereof waived with the written consent of the Company, on the one hand, and the Holder, on the
other hand.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">m)
<U>Severability</U>. Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid
under applicable law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall
be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining
provisions of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">n)
<U>Headings</U>. The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed
a part of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">********************</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(Signature
Page Follows)</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>


<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the Company has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above
indicated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>Enveric
    Biosciences, Inc.</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: &nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTICE
OF EXERCISE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">To:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">Enveric
    Biosciences, Inc.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)
The undersigned hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant (only
if exercised in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)
Payment shall take the form of (check applicable box):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[
&nbsp;&nbsp;&nbsp;&nbsp;] in lawful money of the United States; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[
&nbsp;&nbsp;&nbsp;&nbsp;] if permitted the cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth in subsection
2(c), to exercise this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure
set forth in subsection 2(c).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)
Please issue said Warrant Shares in the name of the undersigned or in such other name as is specified below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 20%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 30%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Warrant Shares shall be delivered to the following DWAC Account Number:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 20%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 30%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)
<U>Accredited Investor</U>. The undersigned is an &ldquo;accredited investor&rdquo; as defined in Regulation D promulgated under the
Securities Act of 1933, as amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">[SIGNATURE
OF HOLDER]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
of Investing Entity: ___________________________________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Signature
of Authorized Signatory of Investing Entity</I>: _________________________________________________</FONT>____</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
of Authorized Signatory: ___________________________________________________________________</FONT>____</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title
of Authorized Signatory: ____________________________________________________________________</FONT>____</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
________________________________________________________________________________________</FONT>__</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 17 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ASSIGNMENT
FORM</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(To
assign the foregoing Warrant, execute this form and supply required information. Do not use this form to purchase shares.)</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 10.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FOR
VALUE RECEIVED, the foregoing Warrant and all rights evidenced thereby are hereby assigned to</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 10.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 49%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Please
    Print)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address:</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phone
    Number:</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Please
    Print)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email
    Address:</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated:
    _______________ __, ______</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holder&rsquo;s
    Signature:________________________________</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holder&rsquo;s
    Address:</FONT>________________________________</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 18; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.2
<SEQUENCE>3
<FILENAME>ex4-2.htm
<DESCRIPTION>EX-4.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
4.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NEITHER
THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION
OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED
(THE &ldquo;SECURITIES ACT&rdquo;), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT
UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS
OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS. THIS SECURITY AND THE SECURITIES ISSUABLE UPON EXERCISE
OF THIS SECURITY MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN SECURED BY SUCH SECURITIES.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SERIES
F COMMON STOCK PURCHASE WARRANT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>Enveric
Biosciences, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrant
    Shares: __________</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Initial
    Exercise Date: _______, 2025</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">THIS
SERIES F COMMON STOCK PURCHASE WARRANT (the &ldquo;<U>Warrant</U>&rdquo;) certifies that, for value received, _____________ or its
assigns (the &ldquo;<U>Holder</U>&rdquo;) is entitled, upon the terms and subject to the limitations on exercise and the conditions
hereinafter set forth, at any time on or after the date hereof (the &ldquo;<U>Initial Exercise Date</U>&rdquo;) and on or prior to
5:00 p.m. (New York City time) on the date that is the eighteen (18) month anniversary of the Effective Date, provided that, if such date
is not a Trading Day, the date that is the immediately following Trading Day (the &ldquo;<U>Termination Date</U>&rdquo;) but not
thereafter, to subscribe for and purchase from Enveric Biosciences, Inc., a Delaware corporation (the &ldquo;<U>Company</U>&rdquo;),
up to ______ shares (as subject to adjustment hereunder, the &ldquo;<U>Warrant Shares</U>&rdquo;) of Common Stock. The purchase
price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
1</U>. <U>Definitions</U>. In addition to the terms defined elsewhere in this Warrant, the following terms have the meanings indicated
in this Section 1:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Affiliate</U>&rdquo;
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control
with a Person, as such terms are used in and construed under Rule 405 under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Bid
Price</U>&rdquo; means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock
is then listed or quoted on a Trading Market, the bid price of the Common Stock for the time in question (or the nearest preceding date)
on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30
a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted average
price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not
then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on the Pink Open Market (or
a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common
Stock so reported, or (d) in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser
selected in good faith by the Holders of a majority in interest of the Warrants then outstanding and reasonably acceptable to the Company,
the fees and expenses of which shall be paid by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Board
of Directors</U>&rdquo; means the board of directors of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Business
Day</U>&rdquo; means any day other than Saturday, Sunday or other day on which commercial banks in The City of New York are authorized
or required by law to remain closed; <U>provided</U>, <U>however</U>, for clarification, commercial banks shall not be deemed to be authorized
or required by law to remain closed due to &ldquo;stay at home&rdquo;, &ldquo;shelter-in-place&rdquo;, &ldquo;non-essential employee&rdquo;
or any other similar orders or restrictions or the closure of any physical branch locations at the direction of any governmental authority
so long as the electronic funds transfer systems (including for wire transfers) of commercial banks in The City of New York generally
are open for use by customers on such day.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Commission</U>&rdquo;
means the United States Securities and Exchange Commission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Common
Stock</U>&rdquo; means the common stock of the Company, par value $0.01 per share, and any other class of securities into which such
securities may hereafter be reclassified or changed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Common
Stock Equivalents</U>&rdquo; means any securities of the Company or the Subsidiaries which would entitle the holder thereof to acquire
at any time Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument that is
at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Effective
Date</U>&rdquo; means the date that the Resale Registration Statement (as defined in the Letter Agreement) has been declared effective
by the Commission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Exchange
Act</U>&rdquo; means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Letter
Agreement</U>&rdquo; means that certain letter agreement between the initial Holder hereof and the Company, dated as of December 11,
2025, pursuant to which such initial Holder agreed to exercise one or more warrants to purchase shares of Common Stock and the Company
agreed to issue to the initial Holder this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Person</U>&rdquo;
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability
company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Rule
144</U>&rdquo; means Rule 144 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted
from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect
as such Rule.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Securities
Act</U>&rdquo; means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Subsidiary</U>&rdquo;
means any subsidiary of the Company and shall, where applicable, also include any direct or indirect subsidiary of the Company formed
or acquired after the date hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Trading
Day</U>&rdquo; means a day on which the Common Stock is traded on a Trading Market.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Trading
Market</U>&rdquo; means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date
in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market or the New York
Stock Exchange (or any successors to any of the foregoing).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Transfer
Agent</U>&rdquo; means Equiniti Trust Company, the current transfer agent of the Company, and any successor transfer agent of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>VWAP</U>&rdquo;
means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed
or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date)
on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30
a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted average
price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not
then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on the Pink Open Market (or
a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common
Stock so reported, or (d) in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser
selected in good faith by the holders of a majority in interest of the Warrants then outstanding and reasonably acceptable to the Company,
the fees and expenses of which shall be paid by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Warrants</U>&rdquo;
means this Warrant and other Common Stock purchase warrants issued by the Company pursuant to the Letter Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
2</U>. <U>Exercise</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)
<U>Exercise of Warrant</U>. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time
or times on or after the Initial Exercise Date and on or before the Termination Date by delivery to the Company of a duly executed PDF
copy submitted by e-mail (or e-mail attachment) of the Notice of Exercise in the form annexed hereto (the &ldquo;<U>Notice of Exercise</U>&rdquo;).
Within the earlier of (i) one (1) Trading Day and (ii) the number of Trading Days comprising the Standard Settlement Period (as defined
in Section 2(d)(i) herein) following the date of exercise as aforesaid, the Holder shall deliver the aggregate Exercise Price for the
shares specified in the applicable Notice of Exercise by wire transfer or cashier&rsquo;s check drawn on a United States bank unless
the cashless exercise procedure specified in Section 2(c) below is specified in the applicable Notice of Exercise. No ink-original Notice
of Exercise shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise
be required. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to
the Company until the Holder has purchased all of the Warrant Shares available hereunder and the Warrant has been exercised in full,
in which case, the Holder shall surrender this Warrant to the Company for cancellation within three (3) Trading Days of the date on which
the final Notice of Exercise is delivered to the Company. Partial exercises of this Warrant resulting in purchases of a portion of the
total number of Warrant Shares available hereunder shall have the effect of lowering the outstanding number of Warrant Shares purchasable
hereunder in an amount equal to the applicable number of Warrant Shares purchased. The Holder and the Company shall maintain records
showing the number of Warrant Shares purchased and the date of such purchases. The Company shall deliver any objection to any Notice
of Exercise on the Trading Day of receipt of such notice. <B>The Holder and any assignee, by acceptance of this Warrant, acknowledge
and agree that, by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant Shares hereunder, the
number of Warrant Shares available for purchase hereunder at any given time may be less than the amount stated on the face hereof.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)
<U>Exercise Price</U>. The exercise price per share of Common Stock under this Warrant shall be $7.05, subject to adjustment hereunder
(the &ldquo;<U>Exercise Price</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)
<U>Cashless Exercise</U>. If at the time of exercise hereof there is no effective registration statement registering, or the prospectus
contained therein is not available for the resale of the Warrant Shares by the Holder, then this Warrant may also be exercised, in whole
or in part, at such time by means of a &ldquo;cashless exercise&rdquo; in which the Holder shall be entitled to receive a number of Warrant
Shares equal to the quotient obtained by dividing [(A-B) (X)] by (A), where:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(A)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">=
    as applicable: (i) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise if such Notice
    of Exercise is (1) delivered pursuant to Section 2(a) hereof on a day that is not a Trading Day or (2) delivered pursuant to Section
    2(a) hereof on a Trading Day prior to the opening of &ldquo;regular trading hours&rdquo; (as defined in Rule 600(b) of Regulation
    NMS promulgated under the federal securities laws) on such Trading Day, (ii) the highest Bid Price of the Common Stock on the principal
    Trading Market as reported by Bloomberg L.P. (&ldquo;<U>Bloomberg</U>&rdquo;) within two (2) hours of the time of the Holder&rsquo;s
    delivery of the Notice of Exercise pursuant to Section 2(a) hereof if such Notice of Exercise is delivered during &ldquo;regular
    trading hours,&rdquo; or within two (2) hours after the close of &ldquo;regular trading hours,&rdquo; on a Trading Day or (iii) the
    VWAP on the date of the applicable Notice of Exercise if the date of such Notice of Exercise is a Trading Day and such Notice of
    Exercise is delivered pursuant to Section 2(a) hereof after two (2) hours following the close of &ldquo;regular trading hours&rdquo;
    on such Trading Day;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(B)
    = </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    Exercise Price of this Warrant, as adjusted hereunder; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(X)
    = </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    number of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant if such
    exercise were by means of a cash exercise rather than a cashless exercise.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">If
Warrant Shares are issued in such a cashless exercise, the parties acknowledge and agree that in accordance with Section 3(a)(9) of the
Securities Act, the holding period of the Warrant Shares being issued may be tacked on to the holding period of this Warrant. The Company
agrees not to take any position contrary to this Section 2(c).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 103.5pt; text-align: justify; text-indent: -31.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstanding
anything herein to the contrary, on the Termination Date, this Warrant shall be automatically exercised via cashless exercise pursuant
to this Section 2(c).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 103.5pt; text-align: justify; text-indent: -31.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)
<U>Mechanics of Exercise</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.
<U>Delivery of Warrant Shares Upon Exercise</U>. The Company shall cause the Warrant Shares purchased hereunder to be transmitted by
the Transfer Agent to the Holder by crediting the account of the Holder&rsquo;s or its designee&rsquo;s balance account with The Depository
Trust Company through its Deposit or Withdrawal at Custodian system (&ldquo;<U>DWAC</U>&rdquo;) if the Company is then a participant
in such system and either (A) there is an effective registration statement permitting the issuance of the Warrant Shares to or resale
of the Warrant Shares by Holder or (B) the Warrant Shares are eligible for resale by the Holder without volume or manner-of-sale limitations
pursuant to Rule 144 (assuming cashless exercise of the Warrants), and otherwise by physical delivery of a certificate, registered in
the Company&rsquo;s share register in the name of the Holder or its designee, for the number of Warrant Shares to which the Holder is
entitled pursuant to such exercise to the address specified by the Holder in the Notice of Exercise by the date that is the earlier of
(i) one (1) Trading Day after the delivery to the Company of the Notice of Exercise and (ii) the number of Trading Days comprising the
Standard Settlement Period after the delivery to the Company of the Notice of Exercise (such date, the &ldquo;<U>Warrant Share Delivery
Date</U>&rdquo;). Upon delivery of the Notice of Exercise, the Holder shall be deemed for all corporate purposes to have become the holder
of record of the Warrant Shares with respect to which this Warrant has been exercised, irrespective of the date of delivery of the Warrant
Shares, provided that payment of the aggregate Exercise Price (other than in the case of a cashless exercise) is received within the
earlier of (i) one (1) Trading Day and (ii) the number of Trading Days comprising the Standard Settlement Period following delivery of
the Notice of Exercise. If the Company fails for any reason to deliver to the Holder the Warrant Shares subject to a Notice of Exercise
by the Warrant Share Delivery Date, the Company shall pay to the Holder, in cash, as liquidated damages and not as a penalty, for each
$1,000 of Warrant Shares subject to such exercise (based on the VWAP of the Common Stock on the date of the applicable Notice of Exercise),
$10 per Trading Day (increasing to $20 per Trading Day on the third Trading Day after the Warrant Share Delivery Date) for each Trading
Day after such Warrant Share Delivery Date until such Warrant Shares are delivered or Holder rescinds such exercise. The Company agrees
to maintain a transfer agent that is a participant in the FAST program so long as this Warrant remains outstanding and exercisable. As
used herein, &ldquo;<U>Standard Settlement Period</U>&rdquo; means the standard settlement period, expressed in a number of Trading Days,
on the Company&rsquo;s primary Trading Market with respect to the Common Stock as in effect on the date of delivery of the Notice of
Exercise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: -9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii.
<U>Delivery of New Warrants Upon Exercise</U>. If this Warrant shall have been exercised in part, the Company shall, at the request of
a Holder and upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new Warrant
evidencing the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall in
all other respects be identical with this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">iii.
<U>Rescission Rights</U>. If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant to Section
2(d)(i) by the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">iv.
<U>Compensation for Buy-In on Failure to Timely Deliver Warrant Shares Upon Exercise</U>. In addition to any other rights available to
the Holder, if the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in accordance with the provisions
of Section 2(d)(i) above pursuant to an exercise on or before the Warrant Share Delivery Date, and if after such date the Holder is required
by its broker to purchase (in an open market transaction or otherwise) or the Holder&rsquo;s brokerage firm otherwise purchases, shares
of Common Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon
such exercise (a &ldquo;<U>Buy-In</U>&rdquo;), then the Company shall (A) pay in cash to the Holder the amount, if any, by which (x)
the Holder&rsquo;s total purchase price (including brokerage commissions, if any) for the shares of Common Stock so purchased exceeds
(y) the amount obtained by multiplying (1) the number of Warrant Shares that the Company was required to deliver to the Holder in connection
with the exercise at issue times (2) the price at which the sell order giving rise to such purchase obligation was executed, and (B)
at the option of the Holder, either reinstate the portion of the Warrant and equivalent number of Warrant Shares for which such exercise
was not honored (in which case such exercise shall be deemed rescinded) or deliver to the Holder the number of shares of Common Stock
that would have been issued had the Company timely complied with its exercise and delivery obligations hereunder. For example, if the
Holder purchases Common Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise of shares
of Common Stock with an aggregate sale price giving rise to such purchase obligation of $10,000, under clause (A) of the immediately
preceding sentence the Company shall be required to pay the Holder $1,000. The Holder shall provide the Company written notice indicating
the amounts payable to the Holder in respect of the Buy-In and, upon request of the Company, evidence of the amount of such loss. Nothing
herein shall limit a Holder&rsquo;s right to pursue any other remedies available to it hereunder, at law or in equity including, without
limitation, a decree of specific performance and/or injunctive relief with respect to the Company&rsquo;s failure to timely deliver shares
of Common Stock upon exercise of the Warrant as required pursuant to the terms hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">v.
<U>No Fractional Shares or Scrip</U>. No fractional shares or scrip representing fractional shares shall be issued upon the exercise
of this Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company
shall, at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied
by the Exercise Price or round up to the next whole share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">vi.
<U>Charges, Taxes and Expenses</U>. Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer tax
or other incidental expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the Company,
and such Warrant Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder; <U>provided</U>,
<U>however</U>, that, in the event that Warrant Shares are to be issued in a name other than the name of the Holder, this Warrant when
surrendered for exercise shall be accompanied by the Assignment Form attached hereto duly executed by the Holder and the Company may
require, as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto. The Company
shall pay all Transfer Agent fees required for same-day processing of any Notice of Exercise and all fees to the Depository Trust Company
(or another established clearing corporation performing similar functions) required for same-day electronic delivery of the Warrant Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">vii.
<U>Closing of Books</U>. The Company will not close its stockholder books or records in any manner which prevents the timely exercise
of this Warrant, pursuant to the terms hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)
<U>Holder&rsquo;s Exercise Limitations</U>. The Company shall not effect any exercise of this Warrant, and a Holder shall not have the
right to exercise any portion of this Warrant, pursuant to Section 2 or otherwise, to the extent that after giving effect to such issuance
after exercise as set forth on the applicable Notice of Exercise, the Holder (together with the Holder&rsquo;s Affiliates, and any other
Persons acting as a group together with the Holder or any of the Holder&rsquo;s Affiliates (such Persons, &ldquo;<U>Attribution Parties</U>&rdquo;)),
would beneficially own in excess of the Beneficial Ownership Limitation (as defined below). For purposes of the foregoing sentence, the
number of shares of Common Stock beneficially owned by the Holder and its Affiliates and Attribution Parties shall include the number
of shares of Common Stock issuable upon exercise of this Warrant with respect to which such determination is being made, but shall exclude
the number of shares of Common Stock which would be issuable upon (i) exercise of the remaining, nonexercised portion of this Warrant
beneficially owned by the Holder or any of its Affiliates or Attribution Parties and (ii) exercise or conversion of the unexercised or
nonconverted portion of any other securities of the Company (including, without limitation, any other Common Stock Equivalents) subject
to a limitation on conversion or exercise analogous to the limitation contained herein beneficially owned by the Holder or any of its
Affiliates or Attribution Parties. Except as set forth in the preceding sentence, for purposes of this Section 2(e), beneficial ownership
shall be calculated in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder, it being
acknowledged by the Holder that the Company is not representing to the Holder that such calculation is in compliance with Section 13(d)
of the Exchange Act and the Holder is solely responsible for any schedules required to be filed in accordance therewith. To the extent
that the limitation contained in this Section 2(e) applies, the determination of whether this Warrant is exercisable (in relation to
other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable
shall be in the sole discretion of the Holder, and the submission of a Notice of Exercise shall be deemed to be the Holder&rsquo;s determination
of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates and Attribution
Parties) and of which portion of this Warrant is exercisable, in each case subject to the Beneficial Ownership Limitation, and the Company
shall have no obligation to verify or confirm the accuracy of such determination. In addition, a determination as to any group status
as contemplated above shall be determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated
thereunder. For purposes of this Section 2(e), in determining the number of outstanding shares of Common Stock, a Holder may rely on
the number of outstanding shares of Common Stock as reflected in (A) the Company&rsquo;s most recent periodic or annual report filed
with the Commission, as the case may be, (B) a more recent public announcement by the Company or (C) a more recent written notice by
the Company or the Transfer Agent setting forth the number of shares of Common Stock outstanding. Upon the written or oral request of
a Holder, the Company shall within one Trading Day confirm orally and in writing to the Holder the number of shares of Common Stock then
outstanding. In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion
or exercise of securities of the Company, including this Warrant, by the Holder or its Affiliates or Attribution Parties since the date
as of which such number of outstanding shares of Common Stock was reported. The &ldquo;<U>Beneficial Ownership Limitation</U>&rdquo;
shall be 4.99% (or, upon election by a Holder prior to the issuance of any Warrants, 9.99%) of the number of shares of Common Stock outstanding
immediately after giving effect to the issuance of shares of Common Stock issuable upon exercise of this Warrant. The Holder, upon notice
to the Company, may increase or decrease the Beneficial Ownership Limitation provisions of this Section 2(e), provided that the Beneficial
Ownership Limitation in no event exceeds 9.99% of the number of shares of the Common Stock outstanding immediately after giving effect
to the issuance of shares of Common Stock upon exercise of this Warrant held by the Holder and the provisions of this Section 2(e) shall
continue to apply. Any increase in the Beneficial Ownership Limitation will not be effective until the 61<SUP>st</SUP> day after such
notice is delivered to the Company. The provisions of this paragraph shall be construed and implemented in a manner otherwise than in
strict conformity with the terms of this Section 2(e) to correct this paragraph (or any portion hereof) which may be defective or inconsistent
with the intended Beneficial Ownership Limitation herein contained or to make changes or supplements necessary or desirable to properly
give effect to such limitation. The limitations contained in this paragraph shall apply to a successor holder of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
3</U>. <U>Certain Adjustments</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)
<U>Stock Dividends and Splits</U>. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or otherwise
makes a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable in shares
of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company upon exercise of this
Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines (including by way of reverse
stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv) issues by reclassification of shares of the
Common Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied by a fraction of which
the numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately before such event
and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event, and the number of
shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this Warrant
shall remain unchanged. Any adjustment made pursuant to this Section 3(a) shall become effective immediately after the record date for
the determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately after the
effective date in the case of a subdivision, combination or re-classification.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)
<U>Subsequent Rights Offerings</U>. In addition to any adjustments pursuant to Section 3(a) above, if at any time the Company grants,
issues or sells any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to the record
holders of any class of shares of Common Stock (the &ldquo;<U>Purchase Rights</U>&rdquo;), then the Holder will be entitled to acquire,
upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had
held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise
hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date on which a record is taken for
the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of shares
of Common Stock are to be determined for the grant, issue or sale of such Purchase Rights (provided, however, that, to the extent that
the Holder&rsquo;s right to participate in any such Purchase Right would result in the Holder exceeding the Beneficial Ownership Limitation,
then the Holder shall not be entitled to participate in such Purchase Right to such extent (or beneficial ownership of such shares of
Common Stock as a result of such Purchase Right to such extent) and such Purchase Right to such extent shall be held in abeyance for
the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)
<U>Pro Rata Distributions</U>. During such time as this Warrant is outstanding, if the Company shall declare or make any dividend or
other distribution of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital
or otherwise (including, without limitation, any distribution of cash, stock or other securities, property or options by way of a dividend,
spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction) (a &ldquo;<U>Distribution</U>&rdquo;),
at any time after the issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution
to the same extent that the Holder would have participated therein if the Holder had held the number of shares of Common Stock acquirable
upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial
Ownership Limitation) immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the
date as of which the record holders of shares of Common Stock are to be determined for the participation in such Distribution (<U>provided</U>,
<U>however</U>, that, to the extent that the Holder&rsquo;s right to participate in any such Distribution would result in the Holder
exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Distribution to such extent
(or in the beneficial ownership of any shares of Common Stock as a result of such Distribution to such extent) and the portion of such
Distribution shall be held in abeyance for the benefit of the Holder until such time, if ever, as its right thereto would not result
in the Holder exceeding the Beneficial Ownership Limitation).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)
<U>Fundamental Transaction</U>. If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in one or
more related transactions effects any merger or consolidation of the Company with or into another Person, (ii) the Company or any Subsidiary,
directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially
all of its assets in one or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange
offer (whether by the Company or another Person) is completed pursuant to which holders of Common Stock are permitted to sell, tender
or exchange their shares for other securities, cash or property and has been accepted by the holders of greater than 50% of the outstanding
Common Stock or greater than 50% of the voting power of the common equity of the Company, (iv) the Company, directly or indirectly, in
one or more related transactions effects any reclassification, reorganization or recapitalization of the Common Stock or any compulsory
share exchange pursuant to which the Common Stock is effectively converted into or exchanged for other securities, cash or property,
or (v) the Company, directly or indirectly, in one or more related transactions consummates a stock or share purchase agreement or other
business combination (including, without limitation, a reorganization, recapitalization, spin-off, merger or scheme of arrangement) with
another Person or group of Persons whereby such other Person or group acquires greater than 50% of the outstanding shares of Common Stock
or greater than 50% of the voting power of the common equity of the Company (each a &ldquo;<U>Fundamental Transaction</U>&rdquo;), then,
upon any subsequent exercise of this Warrant, the Holder shall have the right to receive, for each Warrant Share that would have been
issuable upon such exercise immediately prior to the occurrence of such Fundamental Transaction, at the option of the Holder (without
regard to any limitation in Section 2(e) on the exercise of this Warrant), the number of shares of Common Stock of the successor or acquiring
corporation or of the Company, if it is the surviving corporation, and any additional consideration (the &ldquo;<U>Alternate Consideration</U>&rdquo;)
receivable as a result of such Fundamental Transaction by a holder of the number of shares of Common Stock for which this Warrant is
exercisable immediately prior to such Fundamental Transaction (without regard to any limitation in Section 2(e) on the exercise of this
Warrant). For purposes of any such exercise, the determination of the Exercise Price shall be appropriately adjusted to apply to such
Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one share of Common Stock in such Fundamental
Transaction, and the Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the
relative value of any different components of the Alternate Consideration. If holders of Common Stock are given any choice as to the
securities, cash or property to be received in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate
Consideration it receives upon any exercise of this Warrant following such Fundamental Transaction. Notwithstanding anything to the contrary,
in the event of a Fundamental Transaction, the Company or any Successor Entity (as defined below) shall, at the Holder&rsquo;s option,
exercisable at any time concurrently with, or within 30 days after, the consummation of the Fundamental Transaction (or, if later, the
date of the public announcement of the applicable Fundamental Transaction), purchase this Warrant from the Holder by paying to the Holder
an amount of cash equal to the Black Scholes Value (as defined below) of the remaining unexercised portion of this Warrant on the date
of the consummation of such Fundamental Transaction; <U>provided</U>, <U>however</U>, that, if the Fundamental Transaction is not within
the Company&rsquo;s control, including not approved by the Company&rsquo;s Board of Directors, the Holder shall only be entitled to receive
from the Company or any Successor Entity the same type or form of consideration (and in the same proportion), at the Black Scholes Value
of the unexercised portion of this Warrant, that is being offered and paid to the holders of Common Stock of the Company in connection
with the Fundamental Transaction, whether that consideration be in the form of cash, stock or any combination thereof, or whether the
holders of Common Stock are given the choice to receive from among alternative forms of consideration in connection with the Fundamental
Transaction; <U>provided</U>, <U>further</U>, that if holders of Common Stock of the Company are not offered or paid any consideration
in such Fundamental Transaction, such holders of Common Stock will be deemed to have received common stock of the Successor Entity (which
Successor Entity may be the Company following such Fundamental Transaction) in such Fundamental Transaction. &ldquo;<U>Black Scholes
Value</U>&rdquo; means the value of this Warrant based on the Black-Scholes Option Pricing Model obtained from the &ldquo;OV&rdquo; function
on Bloomberg, L.P. (&ldquo;<U>Bloomberg</U>&rdquo;) determined as of the day of consummation of the applicable Fundamental Transaction
for pricing purposes and reflecting (A) a risk-free interest rate corresponding to the U.S. Treasury rate for a period equal to the time
between the date of the public announcement of the applicable contemplated Fundamental Transaction and the Termination Date, (B) an expected
volatility equal to the 100 day volatility as obtained from the HVT function on Bloomberg (determined utilizing a 365 day annualization
factor) as of the Trading Day immediately following the public announcement of the applicable contemplated Fundamental Transaction, (C)
the underlying price per share used in such calculation shall be the greater of (i) the sum of the price per share being offered in cash,
if any, plus the value of any non-cash consideration, if any, being offered in such Fundamental Transaction and (ii) the VWAP immediately
preceding the public announcement of the applicable contemplated Fundamental Transaction (or the consummation of the applicable Fundamental
Transaction, if earlier), (D) a remaining option time equal to the time between the date of the public announcement of the applicable
contemplated Fundamental Transaction and the Termination Date and (E) a zero cost of borrow. The payment of the Black Scholes Value will
be made by wire transfer of immediately available funds (or such other consideration) within the later of (i) five Business Days of the
Holder&rsquo;s election and (ii) the date of consummation of the Fundamental Transaction. The Company shall cause any successor entity
in a Fundamental Transaction in which the Company is not the survivor (the &ldquo;<U>Successor Entity</U>&rdquo;) to assume in writing
all of the obligations of the Company under this Warrant in accordance with the provisions of this Section 3(d) pursuant to written agreements
in form and substance reasonably satisfactory to the Holder and approved by the Holder (without unreasonable delay) prior to such Fundamental
Transaction and shall, at the option of the Holder, deliver to the Holder in exchange for this Warrant a security of the Successor Entity
evidenced by a written instrument substantially similar in form and substance to this Warrant which is exercisable for a corresponding
number of shares of capital stock of such Successor Entity (or its parent entity) equivalent to the shares of Common Stock acquirable
and receivable upon exercise of this Warrant (without regard to any limitations on the exercise of this Warrant) prior to such Fundamental
Transaction, and with an exercise price which applies the exercise price hereunder to such shares of capital stock (but taking into account
the relative value of the shares of Common Stock pursuant to such Fundamental Transaction and the value of such shares of capital stock,
such number of shares of capital stock and such exercise price being for the purpose of protecting the economic value of this Warrant
immediately prior to the consummation of such Fundamental Transaction), and which is reasonably satisfactory in form and substance to
the Holder. Upon the occurrence of any such Fundamental Transaction, the Successor Entity shall be added to the term &ldquo;Company&rdquo;
under this Warrant (so that from and after the occurrence or consummation of such Fundamental Transaction, each and every provision of
this Warrant referring to the &ldquo;Company&rdquo; shall refer instead to each of the Company and the Successor Entity or Successor
Entities, jointly and severally), and the Successor Entity or Successor Entities, jointly and severally with the Company, may exercise
every right and power of the Company prior thereto and the Successor Entity or Successor Entities shall assume all of the obligations
of the Company prior thereto under this Warrant with the same effect as if the Company and such Successor Entity or Successor Entities,
jointly and severally, had been named as the Company herein. For the avoidance of doubt, the Holder shall be entitled to the benefits
of the provisions of this Section 3(d) regardless of (i) whether the Company has sufficient authorized shares of Common Stock for the
issuance of Warrant Shares and/or (ii) whether a Fundamental Transaction occurs prior to the Initial Exercise Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)
<U>Calculations</U>. All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share, as the
case may be. For purposes of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding as of a given date
shall be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">f)
<U>Notice to Holder</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.
<U>Adjustment to Exercise Price</U>. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the Company
shall promptly deliver to the Holder by email a notice setting forth the Exercise Price after such adjustment and any resulting adjustment
to the number of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii.
<U>Notice to Allow Exercise by Holder</U>. If (A) the Company shall declare a dividend (or any other distribution in whatever form) on
the Common Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C) the
Company shall authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares of
capital stock of any class or of any rights, (D) the approval of any stockholders of the Company shall be required in connection with
any reclassification of the Common Stock, any consolidation or merger to which the Company (or any of its Subsidiaries) is a party, any
sale or transfer of all or substantially all of its assets, or any compulsory share exchange whereby the Common Stock is converted into
other securities, cash or property, or (E) the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding
up of the affairs of the Company, then, in each case, the Company shall cause to be delivered by email to the Holder at its last email
address as it shall appear upon the Warrant Register of the Company, at least 20 calendar days prior to the applicable record or effective
date hereinafter specified, a notice stating (x) the date on which a record is to be taken for the purpose of such dividend, distribution,
redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of the Common Stock of record to
be entitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y) the date on which such reclassification,
consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and the date as of which it is expected
that holders of the Common Stock of record shall be entitled to exchange their shares of the Common Stock for securities, cash or other
property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange; provided that the failure to
deliver such notice or any defect therein or in the delivery thereof shall not affect the validity of the corporate action required to
be specified in such notice. To the extent that any notice provided in this Warrant constitutes, or contains, material, non-public information
regarding the Company or any of the Subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant to a
Current Report on Form 8-K. The Holder shall remain entitled to exercise this Warrant during the period commencing on the date of such
notice to the effective date of the event triggering such notice except as may otherwise be expressly set forth herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
4</U>. <U>Transfer of Warrant</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)
<U>Transferability</U>. Subject to compliance with any applicable securities laws and the conditions set forth in Section 4(d) hereof,
this Warrant and all rights hereunder (including, without limitation, any registration rights) are transferable, in whole or in part,
upon surrender of this Warrant at the principal office of the Company or its designated agent, together with a written assignment of
this Warrant substantially in the form attached hereto duly executed by the Holder or its agent or attorney and funds sufficient to pay
any transfer taxes payable upon the making of such transfer. Upon such surrender and, if required, such payment, the Company shall execute
and deliver a new Warrant or Warrants in the name of the assignee or assignees, as applicable, and in the denomination or denominations
specified in such instrument of assignment, and shall issue to the assignor a new Warrant evidencing the portion of this Warrant not
so assigned, and this Warrant shall promptly be cancelled. Notwithstanding anything herein to the contrary, the Holder shall not be required
to physically surrender this Warrant to the Company unless the Holder has assigned this Warrant in full, in which case, the Holder shall
surrender this Warrant to the Company within three (3) Trading Days of the date on which the Holder delivers an assignment form to the
Company assigning this Warrant in full. The Warrant, if properly assigned in accordance herewith, may be exercised by a new holder for
the purchase of Warrant Shares without having a new Warrant issued.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)
<U>New Warrants</U>. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of
the Company, together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by
the Holder or its agent or attorney. Subject to compliance with Section 4(a), as to any transfer which may be involved in such division
or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided
or combined in accordance with such notice. All Warrants issued on transfers or exchanges shall be dated the initial issuance date of
this Warrant and shall be identical with this Warrant except as to the number of Warrant Shares issuable pursuant thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)
<U>Warrant Register</U>. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the
&ldquo;<U>Warrant Register</U>&rdquo;), in the name of the record Holder hereof from time to time. The Company may deem and treat the
registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder,
and for all other purposes, absent actual notice to the contrary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)
<U>Transfer Restrictions</U>. If, at the time of the surrender of this Warrant in connection with any transfer of this Warrant, the transfer
of this Warrant shall not be either (i) registered pursuant to an effective registration statement under the Securities Act and under
applicable state securities or blue sky laws or (ii) eligible for resale without volume or manner-of-sale restrictions or current public
information requirements pursuant to Rule 144, the Company may require, as a condition of allowing such transfer, that the Holder or
transferee of this Warrant, as the case may be, provides to the Company an opinion of counsel, the form and substance of which opinion
shall be reasonably satisfactory to the Company, to the effect that the transfer of this Warrant does not require registration under
the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)
<U>Representation by the Holder</U>. The Holder, by the acceptance hereof, represents and warrants that it is acquiring this Warrant
and, upon any exercise hereof, will acquire the Warrant Shares issuable upon such exercise, for its own account and not with a view to
or for distributing or reselling such Warrant Shares or any part thereof in violation of the Securities Act or any applicable state securities
law, except pursuant to sales registered or exempted under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
5</U>. <U>Miscellaneous</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)
<U>No Rights as Stockholder Until Exercise; No Settlement in Cash</U>. This Warrant does not entitle the Holder to any voting rights,
dividends or other rights as a stockholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i), except as expressly
set forth in Section 3. Without limiting any rights of a Holder to receive Warrant Shares on a &ldquo;cashless exercise&rdquo; pursuant
to Section 2(c) or to receive cash payments pursuant to Section 2(d)(i) and Section 2(d)(iv) herein, in no event shall the Company be
required to net cash settle an exercise of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)
<U>Loss, Theft, Destruction or Mutilation of Warrant</U>. The Company covenants that upon receipt by the Company of evidence reasonably
satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant Shares,
and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the Warrant,
shall not include the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the
Company will make and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant
or stock certificate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)
<U>Saturdays, Sundays, Holidays, etc</U>. If the last or appointed day for the taking of any action or the expiration of any right required
or granted herein shall not be a Business Day, then such action may be taken or such right may be exercised on the next succeeding Business
Day.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)
<U>Authorized Shares</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company covenants that, during the period the Warrant is outstanding, it will reserve from its authorized and unissued Common Stock a
sufficient number of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights under this Warrant.
The Company further covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged with
the duty of issuing the necessary Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company will take all
such reasonable action as may be necessary to assure that such Warrant Shares may be issued as provided herein without violation of any
applicable law or regulation, or of any requirements of the Trading Market upon which the Common Stock may be listed. The Company covenants
that all Warrant Shares which may be issued upon the exercise of the purchase rights represented by this Warrant will, upon exercise
of the purchase rights represented by this Warrant and payment for such Warrant Shares in accordance herewith, be duly authorized, validly
issued, fully paid and nonassessable and free from all taxes, liens and charges created by the Company in respect of the issue thereof
(other than taxes in respect of any transfer occurring contemporaneously with such issue).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
and to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending
its certificate of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale
of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant,
but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary
or appropriate to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality of the
foregoing, the Company will (i) not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise
immediately prior to such increase in par value, (ii) take all such action as may be necessary or appropriate in order that the Company
may validly and legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant and (iii) use commercially
reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof,
as may be, necessary to enable the Company to perform its obligations under this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Before
taking any action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the
Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from
any public regulatory body or bodies having jurisdiction thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)
<U>Governing Law</U>. All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be governed
by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles of conflicts
of law thereof. Each party agrees that all legal proceedings concerning the interpretations, enforcement and defense of the transactions
contemplated by this Warrant (whether brought against a party hereto or their respective affiliates, directors, officers, shareholders,
partners, members, employees or agents) shall be commenced exclusively in the state and federal courts sitting in the City of New York.
Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in the City of New York,
Borough of Manhattan for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby
or discussed herein, and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is
not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is improper or is an inconvenient
venue for such proceeding. Each party hereby irrevocably waives personal service of process and consents to process being served in any
such suit, action or proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery)
to such party at the address in effect for notices to it under this Warrant and agrees that such service shall constitute good and sufficient
service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any
other manner permitted by law. If either party shall commence an action, suit or proceeding to enforce any provisions of this Warrant,
the prevailing party in such action, suit or proceeding shall be reimbursed by the other party for their reasonable attorneys&rsquo;
fees and other costs and expenses incurred with the investigation, preparation and prosecution of such action or proceeding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">f)
<U>Restrictions</U>. The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered, and
the Holder does not utilize cashless exercise, will have restrictions upon resale imposed by state and federal securities laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">g)
<U>Nonwaiver and Expenses</U>. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall
operate as a waiver of such right or otherwise prejudice the Holder&rsquo;s rights, powers or remedies. Without limiting any other provision
of this Warrant, if the Company willfully and knowingly fails to comply with any provision of this Warrant, which results in any material
damages to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to cover any costs and expenses including,
but not limited to, reasonable attorneys&rsquo; fees, including those of appellate proceedings, incurred by the Holder in collecting
any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">h)
<U>Notices</U>. Any and all notices or other communications or deliveries to be provided by the Holders hereunder including, without
limitation, any Notice of Exercise, shall be in writing and delivered personally, by e-mail, or sent by a nationally recognized overnight
courier service, addressed to the Company, at 10 Cleveland Street, Unit A, Summerville, MA 02143, Attention: Kevin Coveney, email address:
kcoveney@enveric.com, or such other email address or address as the Company may specify for such purposes by notice to the Holders. Any
and all notices or other communications or deliveries to be provided by the Company hereunder shall be in writing and delivered personally,
by e-mail, or sent by a nationally recognized overnight courier service addressed to each Holder at the e-mail address or address of
such Holder appearing on the books of the Company. Any notice or other communication or deliveries hereunder shall be deemed given and
effective on the earliest of (i) the time of transmission, if such notice or communication is delivered via e-mail at the e-mail address
set forth in this Section prior to 5:30 p.m. (New York City time) on any date, (ii) the next Trading Day after the time of transmission,
if such notice or communication is delivered via e-mail at the e-mail address set forth in this Section on a day that is not a Trading
Day or later than 5:30 p.m. (New York City time) on any Trading Day, (iii) the second Trading Day following the date of mailing, if sent
by U.S. nationally recognized overnight courier service, or (iv) upon actual receipt by the party to whom such notice is required to
be given. To the extent that any notice provided hereunder constitutes, or contains, material, non-public information regarding the Company
or any Subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant to a Current Report on Form 8-K.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i)
<U>Limitation of Liability</U>. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant
to purchase Warrant Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of
the Holder for the purchase price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company
or by creditors of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">j)
<U>Remedies</U>. The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will
be entitled to specific performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate
compensation for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to
assert the defense in any action for specific performance that a remedy at law would be adequate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">k)
<U>Successors and Assigns</U>. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall
inure to the benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns
of Holder. The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and shall
be enforceable by the Holder or holder of Warrant Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">l)
<U>Amendment</U>. Other than Section 2(e) above and this Section 5(l), which may not be amended, modified or waived, this Warrant may
be modified or amended or the provisions hereof waived with the written consent of the Company, on the one hand, and the Holder, on the
other hand.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">m)
<U>Severability</U>. Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid
under applicable law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall
be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining
provisions of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">n)
<U>Headings</U>. The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed
a part of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">********************</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(Signature
Page Follows)</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>


<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the Company has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above
indicated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>Enveric
    Biosciences, Inc.</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: &nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTICE
OF EXERCISE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">To:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">Enveric
    Biosciences, Inc.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)
The undersigned hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant (only
if exercised in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)
Payment shall take the form of (check applicable box):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[
&nbsp;&nbsp;&nbsp;&nbsp;] in lawful money of the United States; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[
&nbsp;&nbsp;&nbsp;&nbsp;] if permitted the cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth in subsection
2(c), to exercise this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure
set forth in subsection 2(c).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)
Please issue said Warrant Shares in the name of the undersigned or in such other name as is specified below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 20%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 30%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Warrant Shares shall be delivered to the following DWAC Account Number:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 20%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 30%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)
<U>Accredited Investor</U>. The undersigned is an &ldquo;accredited investor&rdquo; as defined in Regulation D promulgated under the
Securities Act of 1933, as amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">[SIGNATURE
OF HOLDER]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
of Investing Entity: ___________________________________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Signature
of Authorized Signatory of Investing Entity</I>: _________________________________________________</FONT>____</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
of Authorized Signatory: ___________________________________________________________________</FONT>____</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title
of Authorized Signatory: ____________________________________________________________________</FONT>____</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
________________________________________________________________________________________</FONT>__</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 17 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ASSIGNMENT
FORM</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(To
assign the foregoing Warrant, execute this form and supply required information. Do not use this form to purchase shares.)</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 10.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FOR
VALUE RECEIVED, the foregoing Warrant and all rights evidenced thereby are hereby assigned to</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 10.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 49%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Please
    Print)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address:</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phone
    Number:</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Please
    Print)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email
    Address:</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated:
    _______________ __, ______</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holder&rsquo;s
    Signature:________________________________</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holder&rsquo;s
    Address:</FONT>________________________________</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 18; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.3
<SEQUENCE>4
<FILENAME>ex4-3.htm
<DESCRIPTION>EX-4.3
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
4.3</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NEITHER
THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION
OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED
(THE &ldquo;SECURITIES ACT&rdquo;), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT
UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS
OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS. THIS SECURITY AND THE SECURITIES ISSUABLE UPON EXERCISE
OF THIS SECURITY MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN SECURED BY SUCH SECURITIES.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>Enveric
Biosciences, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrant
    Shares: __________</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Initial
    Exercise Date:December 12, 2025</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">THIS
PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT (the &ldquo;<U>Warrant</U>&rdquo;) certifies that, for value received, _____________
or its assigns (the &ldquo;<U>Holder</U>&rdquo;) is entitled, upon the terms and subject to the limitations on exercise and the
conditions hereinafter set forth, at any time on or after the date hereof (the &ldquo;<U>Initial Exercise Date</U>&rdquo;) and on or
prior to 5:00 p.m. (New York City time) on the date that is the five (5) year anniversary of the Effective Date, provided that, if
such date is not a Trading Day, the date that is the immediately following Trading Day (the &ldquo;<U>Termination Date</U>&rdquo;)
but not thereafter, to subscribe for and purchase from Enveric Biosciences, Inc., a Delaware corporation (the
&ldquo;<U>Company</U>&rdquo;), up to ______ shares (as subject to adjustment hereunder, the &ldquo;<U>Warrant Shares</U>&rdquo;) of
Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in
Section 2(b). This Warrant is issued pursuant to that certain Engagement Agreement, by and between the Company and H.C. Wainwright
&amp; Co., LLC, dated as of December 8, 2024, as amended on January 14, 2025, June 5, 2025, and November 11, 2025 (the
&ldquo;Engagement Agreement&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
1</U>. <U>Definitions</U>. In addition to the terms defined elsewhere in this Warrant, the following terms have the meanings indicated
in this Section 1:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Affiliate</U>&rdquo;
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control
with a Person, as such terms are used in and construed under Rule 405 under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Bid
Price</U>&rdquo; means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock
is then listed or quoted on a Trading Market, the bid price of the Common Stock for the time in question (or the nearest preceding date)
on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30
a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted average
price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not
then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on the Pink Open Market (or
a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common
Stock so reported, or (d) in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser
selected in good faith by the Holders of a majority in interest of the Warrants then outstanding and reasonably acceptable to the Company,
the fees and expenses of which shall be paid by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Board
of Directors</U>&rdquo; means the board of directors of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Business
Day</U>&rdquo; means any day other than Saturday, Sunday or other day on which commercial banks in The City of New York are authorized
or required by law to remain closed; <U>provided</U>, <U>however</U>, for clarification, commercial banks shall not be deemed to be authorized
or required by law to remain closed due to &ldquo;stay at home&rdquo;, &ldquo;shelter-in-place&rdquo;, &ldquo;non-essential employee&rdquo;
or any other similar orders or restrictions or the closure of any physical branch locations at the direction of any governmental authority
so long as the electronic funds transfer systems (including for wire transfers) of commercial banks in The City of New York generally
are open for use by customers on such day.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Commission</U>&rdquo;
means the United States Securities and Exchange Commission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Common
Stock</U>&rdquo; means the common stock of the Company, par value $0.01 per share, and any other class of securities into which such
securities may hereafter be reclassified or changed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Common
Stock Equivalents</U>&rdquo; means any securities of the Company or the Subsidiaries which would entitle the holder thereof to acquire
at any time Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument that is
at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Effective
Date</U>&rdquo; means the date that the Resale Registration Statement (as defined in the Letter Agreement) has been declared effective
by the Commission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Exchange
Act</U>&rdquo; means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Person</U>&rdquo;
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability
company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Rule
144</U>&rdquo; means Rule 144 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted
from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect
as such Rule.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Securities
Act</U>&rdquo; means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Subsidiary</U>&rdquo;
means any subsidiary of the Company and shall, where applicable, also include any direct or indirect subsidiary of the Company formed
or acquired after the date hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Trading
Day</U>&rdquo; means a day on which the Common Stock is traded on a Trading Market.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Trading
Market</U>&rdquo; means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date
in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market or the New York
Stock Exchange (or any successors to any of the foregoing).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Transfer
Agent</U>&rdquo; means Equiniti Trust Company, the current transfer agent of the Company, and any successor transfer agent of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>VWAP</U>&rdquo;
means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed
or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date)
on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30
a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted average
price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not
then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on the Pink Open Market (or
a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common
Stock so reported, or (d) in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser
selected in good faith by the holders of a majority in interest of the Warrants then outstanding and reasonably acceptable to the Company,
the fees and expenses of which shall be paid by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Warrants</U>&rdquo;
means this Warrant and other Common Stock purchase warrants issued by the Company pursuant to the Engagement Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
2</U>. <U>Exercise</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)
<U>Exercise of Warrant</U>. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time
or times on or after the Initial Exercise Date and on or before the Termination Date by delivery to the Company of a duly executed PDF
copy submitted by e-mail (or e-mail attachment) of the Notice of Exercise in the form annexed hereto (the &ldquo;<U>Notice of Exercise</U>&rdquo;).
Within the earlier of (i) one (1) Trading Day and (ii) the number of Trading Days comprising the Standard Settlement Period (as defined
in Section 2(d)(i) herein) following the date of exercise as aforesaid, the Holder shall deliver the aggregate Exercise Price for the
shares specified in the applicable Notice of Exercise by wire transfer or cashier&rsquo;s check drawn on a United States bank unless
the cashless exercise procedure specified in Section 2(c) below is specified in the applicable Notice of Exercise. No ink-original Notice
of Exercise shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise
be required. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to
the Company until the Holder has purchased all of the Warrant Shares available hereunder and the Warrant has been exercised in full,
in which case, the Holder shall surrender this Warrant to the Company for cancellation within three (3) Trading Days of the date on which
the final Notice of Exercise is delivered to the Company. Partial exercises of this Warrant resulting in purchases of a portion of the
total number of Warrant Shares available hereunder shall have the effect of lowering the outstanding number of Warrant Shares purchasable
hereunder in an amount equal to the applicable number of Warrant Shares purchased. The Holder and the Company shall maintain records
showing the number of Warrant Shares purchased and the date of such purchases. The Company shall deliver any objection to any Notice
of Exercise on the Trading Day of receipt of such notice. <B>The Holder and any assignee, by acceptance of this Warrant, acknowledge
and agree that, by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant Shares hereunder, the
number of Warrant Shares available for purchase hereunder at any given time may be less than the amount stated on the face hereof.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)
<U>Exercise Price</U>. The exercise price per share of Common Stock under this Warrant shall be $9.1250, subject to adjustment hereunder
(the &ldquo;<U>Exercise Price</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)
<U>Cashless Exercise</U>. If at the time of exercise hereof there is no effective registration statement registering, or the prospectus
contained therein is not available for the resale of the Warrant Shares by the Holder, then this Warrant may also be exercised, in whole
or in part, at such time by means of a &ldquo;cashless exercise&rdquo; in which the Holder shall be entitled to receive a number of Warrant
Shares equal to the quotient obtained by dividing [(A-B) (X)] by (A), where:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(A)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">=
    as applicable: (i) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise if such Notice
    of Exercise is (1) delivered pursuant to Section 2(a) hereof on a day that is not a Trading Day or (2) delivered pursuant to Section
    2(a) hereof on a Trading Day prior to the opening of &ldquo;regular trading hours&rdquo; (as defined in Rule 600(b) of Regulation
    NMS promulgated under the federal securities laws) on such Trading Day, (ii) the highest Bid Price of the Common Stock on the principal
    Trading Market as reported by Bloomberg L.P. (&ldquo;<U>Bloomberg</U>&rdquo;) within two (2) hours of the time of the Holder&rsquo;s
    delivery of the Notice of Exercise pursuant to Section 2(a) hereof if such Notice of Exercise is delivered during &ldquo;regular
    trading hours,&rdquo; or within two (2) hours after the close of &ldquo;regular trading hours,&rdquo; on a Trading Day or (iii) the
    VWAP on the date of the applicable Notice of Exercise if the date of such Notice of Exercise is a Trading Day and such Notice of
    Exercise is delivered pursuant to Section 2(a) hereof after two (2) hours following the close of &ldquo;regular trading hours&rdquo;
    on such Trading Day;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(B)
    = </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    Exercise Price of this Warrant, as adjusted hereunder; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(X)
    = </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    number of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant if such
    exercise were by means of a cash exercise rather than a cashless exercise.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">If
Warrant Shares are issued in such a cashless exercise, the parties acknowledge and agree that in accordance with Section 3(a)(9) of the
Securities Act, the holding period of the Warrant Shares being issued may be tacked on to the holding period of this Warrant. The Company
agrees not to take any position contrary to this Section 2(c).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 103.5pt; text-align: justify; text-indent: -31.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstanding
anything herein to the contrary, on the Termination Date, this Warrant shall be automatically exercised via cashless exercise pursuant
to this Section 2(c).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 103.5pt; text-align: justify; text-indent: -31.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)
<U>Mechanics of Exercise</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.
<U>Delivery of Warrant Shares Upon Exercise</U>. The Company shall cause the Warrant Shares purchased hereunder to be transmitted by
the Transfer Agent to the Holder by crediting the account of the Holder&rsquo;s or its designee&rsquo;s balance account with The Depository
Trust Company through its Deposit or Withdrawal at Custodian system (&ldquo;<U>DWAC</U>&rdquo;) if the Company is then a participant
in such system and either (A) there is an effective registration statement permitting the issuance of the Warrant Shares to or resale
of the Warrant Shares by Holder or (B) the Warrant Shares are eligible for resale by the Holder without volume or manner-of-sale limitations
pursuant to Rule 144 (assuming cashless exercise of the Warrants), and otherwise by physical delivery of a certificate, registered in
the Company&rsquo;s share register in the name of the Holder or its designee, for the number of Warrant Shares to which the Holder is
entitled pursuant to such exercise to the address specified by the Holder in the Notice of Exercise by the date that is the earlier of
(i) one (1) Trading Day after the delivery to the Company of the Notice of Exercise and (ii) the number of Trading Days comprising the
Standard Settlement Period after the delivery to the Company of the Notice of Exercise (such date, the &ldquo;<U>Warrant Share Delivery
Date</U>&rdquo;). Upon delivery of the Notice of Exercise, the Holder shall be deemed for all corporate purposes to have become the holder
of record of the Warrant Shares with respect to which this Warrant has been exercised, irrespective of the date of delivery of the Warrant
Shares, provided that payment of the aggregate Exercise Price (other than in the case of a cashless exercise) is received within the
earlier of (i) one (1) Trading Day and (ii) the number of Trading Days comprising the Standard Settlement Period following delivery of
the Notice of Exercise. If the Company fails for any reason to deliver to the Holder the Warrant Shares subject to a Notice of Exercise
by the Warrant Share Delivery Date, the Company shall pay to the Holder, in cash, as liquidated damages and not as a penalty, for each
$1,000 of Warrant Shares subject to such exercise (based on the VWAP of the Common Stock on the date of the applicable Notice of Exercise),
$10 per Trading Day (increasing to $20 per Trading Day on the third Trading Day after the Warrant Share Delivery Date) for each Trading
Day after such Warrant Share Delivery Date until such Warrant Shares are delivered or Holder rescinds such exercise. The Company agrees
to maintain a transfer agent that is a participant in the FAST program so long as this Warrant remains outstanding and exercisable. As
used herein, &ldquo;<U>Standard Settlement Period</U>&rdquo; means the standard settlement period, expressed in a number of Trading Days,
on the Company&rsquo;s primary Trading Market with respect to the Common Stock as in effect on the date of delivery of the Notice of
Exercise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: -9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii.
<U>Delivery of New Warrants Upon Exercise</U>. If this Warrant shall have been exercised in part, the Company shall, at the request of
a Holder and upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new Warrant
evidencing the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall in
all other respects be identical with this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">iii.
<U>Rescission Rights</U>. If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant to Section
2(d)(i) by the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">iv.
<U>Compensation for Buy-In on Failure to Timely Deliver Warrant Shares Upon Exercise</U>. In addition to any other rights available to
the Holder, if the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in accordance with the provisions
of Section 2(d)(i) above pursuant to an exercise on or before the Warrant Share Delivery Date, and if after such date the Holder is required
by its broker to purchase (in an open market transaction or otherwise) or the Holder&rsquo;s brokerage firm otherwise purchases, shares
of Common Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon
such exercise (a &ldquo;<U>Buy-In</U>&rdquo;), then the Company shall (A) pay in cash to the Holder the amount, if any, by which (x)
the Holder&rsquo;s total purchase price (including brokerage commissions, if any) for the shares of Common Stock so purchased exceeds
(y) the amount obtained by multiplying (1) the number of Warrant Shares that the Company was required to deliver to the Holder in connection
with the exercise at issue times (2) the price at which the sell order giving rise to such purchase obligation was executed, and (B)
at the option of the Holder, either reinstate the portion of the Warrant and equivalent number of Warrant Shares for which such exercise
was not honored (in which case such exercise shall be deemed rescinded) or deliver to the Holder the number of shares of Common Stock
that would have been issued had the Company timely complied with its exercise and delivery obligations hereunder. For example, if the
Holder purchases Common Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise of shares
of Common Stock with an aggregate sale price giving rise to such purchase obligation of $10,000, under clause (A) of the immediately
preceding sentence the Company shall be required to pay the Holder $1,000. The Holder shall provide the Company written notice indicating
the amounts payable to the Holder in respect of the Buy-In and, upon request of the Company, evidence of the amount of such loss. Nothing
herein shall limit a Holder&rsquo;s right to pursue any other remedies available to it hereunder, at law or in equity including, without
limitation, a decree of specific performance and/or injunctive relief with respect to the Company&rsquo;s failure to timely deliver shares
of Common Stock upon exercise of the Warrant as required pursuant to the terms hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">v.
<U>No Fractional Shares or Scrip</U>. No fractional shares or scrip representing fractional shares shall be issued upon the exercise
of this Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company
shall, at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied
by the Exercise Price or round up to the next whole share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">vi.
<U>Charges, Taxes and Expenses</U>. Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer tax
or other incidental expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the Company,
and such Warrant Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder; <U>provided</U>,
<U>however</U>, that, in the event that Warrant Shares are to be issued in a name other than the name of the Holder, this Warrant when
surrendered for exercise shall be accompanied by the Assignment Form attached hereto duly executed by the Holder and the Company may
require, as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto. The Company
shall pay all Transfer Agent fees required for same-day processing of any Notice of Exercise and all fees to the Depository Trust Company
(or another established clearing corporation performing similar functions) required for same-day electronic delivery of the Warrant Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">vii.
<U>Closing of Books</U>. The Company will not close its stockholder books or records in any manner which prevents the timely exercise
of this Warrant, pursuant to the terms hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e) <U>Holder&rsquo;s
Exercise Limitations</U>. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">The Company shall
not effect any exercise of this Warrant, and a Holder shall not have the right to exercise any portion of this Warrant, pursuant to Section
2 or otherwise, to the extent that after giving effect to such issuance after exercise as set forth on the applicable Notice of Exercise,
the Holder (together with the Holder&rsquo;s Affiliates, and any other Persons acting as a group together with the Holder or any of the
Holder&rsquo;s Affiliates (such Persons, &ldquo;<U>Attribution Parties</U>&rdquo;)), would beneficially own in excess of the Beneficial
Ownership Limitation (as defined below). For purposes of the foregoing sentence, the number of shares of Common Stock beneficially owned
by the Holder and its Affiliates and Attribution Parties shall include the number of shares of Common Stock issuable upon exercise of
this Warrant with respect to which such determination is being made, but shall exclude the number of shares of Common Stock which would
be issuable upon (i) exercise of the remaining, nonexercised portion of this Warrant beneficially owned by the Holder or any of its Affiliates
or Attribution Parties and (ii) exercise or conversion of the unexercised or nonconverted portion of any other securities of the Company
(including, without limitation, any other Common Stock Equivalents) subject to a limitation on conversion or exercise analogous to the
limitation contained herein beneficially owned by the Holder or any of its Affiliates or Attribution Parties. Except as set forth in the
preceding sentence, for purposes of this Section 2(e), beneficial ownership shall be calculated in accordance with Section 13(d) of the
Exchange Act and the rules and regulations promulgated thereunder, it being acknowledged by the Holder that the Company is not representing
to the Holder that such calculation is in compliance with Section 13(d) of the Exchange Act and the Holder is solely responsible for any
schedules required to be filed in accordance therewith. To the extent that the limitation contained in this Section 2(e) applies, the
determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates
and Attribution Parties) and of which portion of this Warrant is exercisable shall be in the sole discretion of the Holder, and the submission
of a Notice of Exercise shall be deemed to be the Holder&rsquo;s determination of whether this Warrant is exercisable (in relation to
other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable,
in each case subject to the Beneficial Ownership Limitation, and the Company shall have no obligation to verify or confirm the accuracy
of such determination. In addition, a determination as to any group status as contemplated above shall be determined in accordance with
Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder. For purposes of this Section 2(e), in determining
the number of outstanding shares of Common Stock, a Holder may rely on the number of outstanding shares of Common Stock as reflected in
(A) the Company&rsquo;s most recent periodic or annual report filed with the Commission, as the case may be, (B) a more recent public
announcement by the Company or (C) a more recent written notice by the Company or the Transfer Agent setting forth the number of shares
of Common Stock outstanding. Upon the written or oral request of a Holder, the Company shall within one Trading Day confirm orally and
in writing to the Holder the number of shares of Common Stock then outstanding. In any case, the number of outstanding shares of Common
Stock shall be determined after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by the
Holder or its Affiliates or Attribution Parties since the date as of which such number of outstanding shares of Common Stock was reported.
The &ldquo;<U>Beneficial Ownership Limitation</U>&rdquo; shall be 4.99% of the number of shares of Common Stock outstanding immediately
after giving effect to the issuance of shares of Common Stock issuable upon exercise of this Warrant. The Holder, upon notice to the Company,
may increase or decrease the Beneficial Ownership Limitation provisions of this Section 2(e), provided that the Beneficial Ownership Limitation
in no event exceeds 9.99% of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares
of Common Stock upon exercise of this Warrant held by the Holder and the provisions of this Section 2(e) shall continue to apply. Any
increase in the Beneficial Ownership Limitation will not be effective until the 61<SUP>st</SUP> day after such notice is delivered to
the Company. The provisions of this paragraph shall be construed and implemented in a manner otherwise than in strict conformity with
the terms of this Section 2(e) to correct this paragraph (or any portion hereof) which may be defective or inconsistent with the intended
Beneficial Ownership Limitation herein contained or to make changes or supplements necessary or desirable to properly give effect to such
limitation. The limitations contained in this paragraph shall apply to a successor holder of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>


<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
3</U>. <U>Certain Adjustments</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)
<U>Stock Dividends and Splits</U>. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or otherwise
makes a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable in shares
of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company upon exercise of this
Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines (including by way of reverse
stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv) issues by reclassification of shares of the
Common Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied by a fraction of which
the numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately before such event
and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event, and the number of
shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this Warrant
shall remain unchanged. Any adjustment made pursuant to this Section 3(a) shall become effective immediately after the record date for
the determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately after the
effective date in the case of a subdivision, combination or re-classification.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)
<U>Subsequent Rights Offerings</U>. In addition to any adjustments pursuant to Section 3(a) above, if at any time the Company grants,
issues or sells any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to the record
holders of any class of shares of Common Stock (the &ldquo;<U>Purchase Rights</U>&rdquo;), then the Holder will be entitled to acquire,
upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had
held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise
hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date on which a record is taken for
the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of shares
of Common Stock are to be determined for the grant, issue or sale of such Purchase Rights (provided, however, that, to the extent that
the Holder&rsquo;s right to participate in any such Purchase Right would result in the Holder exceeding the Beneficial Ownership Limitation,
then the Holder shall not be entitled to participate in such Purchase Right to such extent (or beneficial ownership of such shares of
Common Stock as a result of such Purchase Right to such extent) and such Purchase Right to such extent shall be held in abeyance for
the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)
<U>Pro Rata Distributions</U>. During such time as this Warrant is outstanding, if the Company shall declare or make any dividend or
other distribution of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital
or otherwise (including, without limitation, any distribution of cash, stock or other securities, property or options by way of a dividend,
spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction) (a &ldquo;<U>Distribution</U>&rdquo;),
at any time after the issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution
to the same extent that the Holder would have participated therein if the Holder had held the number of shares of Common Stock acquirable
upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial
Ownership Limitation) immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the
date as of which the record holders of shares of Common Stock are to be determined for the participation in such Distribution (<U>provided</U>,
<U>however</U>, that, to the extent that the Holder&rsquo;s right to participate in any such Distribution would result in the Holder
exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Distribution to such extent
(or in the beneficial ownership of any shares of Common Stock as a result of such Distribution to such extent) and the portion of such
Distribution shall be held in abeyance for the benefit of the Holder until such time, if ever, as its right thereto would not result
in the Holder exceeding the Beneficial Ownership Limitation).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)
<U>Fundamental Transaction</U>. If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in one or
more related transactions effects any merger or consolidation of the Company with or into another Person, (ii) the Company or any Subsidiary,
directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially
all of its assets in one or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange
offer (whether by the Company or another Person) is completed pursuant to which holders of Common Stock are permitted to sell, tender
or exchange their shares for other securities, cash or property and has been accepted by the holders of greater than 50% of the outstanding
Common Stock or greater than 50% of the voting power of the common equity of the Company, (iv) the Company, directly or indirectly, in
one or more related transactions effects any reclassification, reorganization or recapitalization of the Common Stock or any compulsory
share exchange pursuant to which the Common Stock is effectively converted into or exchanged for other securities, cash or property,
or (v) the Company, directly or indirectly, in one or more related transactions consummates a stock or share purchase agreement or other
business combination (including, without limitation, a reorganization, recapitalization, spin-off, merger or scheme of arrangement) with
another Person or group of Persons whereby such other Person or group acquires greater than 50% of the outstanding shares of Common Stock
or greater than 50% of the voting power of the common equity of the Company (each a &ldquo;<U>Fundamental Transaction</U>&rdquo;), then,
upon any subsequent exercise of this Warrant, the Holder shall have the right to receive, for each Warrant Share that would have been
issuable upon such exercise immediately prior to the occurrence of such Fundamental Transaction, at the option of the Holder (without
regard to any limitation in Section 2(e) on the exercise of this Warrant), the number of shares of Common Stock of the successor or acquiring
corporation or of the Company, if it is the surviving corporation, and any additional consideration (the &ldquo;<U>Alternate Consideration</U>&rdquo;)
receivable as a result of such Fundamental Transaction by a holder of the number of shares of Common Stock for which this Warrant is
exercisable immediately prior to such Fundamental Transaction (without regard to any limitation in Section 2(e) on the exercise of this
Warrant). For purposes of any such exercise, the determination of the Exercise Price shall be appropriately adjusted to apply to such
Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one share of Common Stock in such Fundamental
Transaction, and the Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the
relative value of any different components of the Alternate Consideration. If holders of Common Stock are given any choice as to the
securities, cash or property to be received in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate
Consideration it receives upon any exercise of this Warrant following such Fundamental Transaction. Notwithstanding anything to the contrary,
in the event of a Fundamental Transaction, the Company or any Successor Entity (as defined below) shall, at the Holder&rsquo;s option,
exercisable at any time concurrently with, or within 30 days after, the consummation of the Fundamental Transaction (or, if later, the
date of the public announcement of the applicable Fundamental Transaction), purchase this Warrant from the Holder by paying to the Holder
an amount of cash equal to the Black Scholes Value (as defined below) of the remaining unexercised portion of this Warrant on the date
of the consummation of such Fundamental Transaction; <U>provided</U>, <U>however</U>, that, if the Fundamental Transaction is not within
the Company&rsquo;s control, including not approved by the Company&rsquo;s Board of Directors, the Holder shall only be entitled to receive
from the Company or any Successor Entity the same type or form of consideration (and in the same proportion), at the Black Scholes Value
of the unexercised portion of this Warrant, that is being offered and paid to the holders of Common Stock of the Company in connection
with the Fundamental Transaction, whether that consideration be in the form of cash, stock or any combination thereof, or whether the
holders of Common Stock are given the choice to receive from among alternative forms of consideration in connection with the Fundamental
Transaction; <U>provided</U>, <U>further</U>, that if holders of Common Stock of the Company are not offered or paid any consideration
in such Fundamental Transaction, such holders of Common Stock will be deemed to have received common stock of the Successor Entity (which
Successor Entity may be the Company following such Fundamental Transaction) in such Fundamental Transaction. &ldquo;<U>Black Scholes
Value</U>&rdquo; means the value of this Warrant based on the Black-Scholes Option Pricing Model obtained from the &ldquo;OV&rdquo; function
on Bloomberg, L.P. (&ldquo;<U>Bloomberg</U>&rdquo;) determined as of the day of consummation of the applicable Fundamental Transaction
for pricing purposes and reflecting (A) a risk-free interest rate corresponding to the U.S. Treasury rate for a period equal to the time
between the date of the public announcement of the applicable contemplated Fundamental Transaction and the Termination Date, (B) an expected
volatility equal to the 100 day volatility as obtained from the HVT function on Bloomberg (determined utilizing a 365 day annualization
factor) as of the Trading Day immediately following the public announcement of the applicable contemplated Fundamental Transaction, (C)
the underlying price per share used in such calculation shall be the greater of (i) the sum of the price per share being offered in cash,
if any, plus the value of any non-cash consideration, if any, being offered in such Fundamental Transaction and (ii) the VWAP immediately
preceding the public announcement of the applicable contemplated Fundamental Transaction (or the consummation of the applicable Fundamental
Transaction, if earlier), (D) a remaining option time equal to the time between the date of the public announcement of the applicable
contemplated Fundamental Transaction and the Termination Date and (E) a zero cost of borrow. The payment of the Black Scholes Value will
be made by wire transfer of immediately available funds (or such other consideration) within the later of (i) five Business Days of the
Holder&rsquo;s election and (ii) the date of consummation of the Fundamental Transaction. The Company shall cause any successor entity
in a Fundamental Transaction in which the Company is not the survivor (the &ldquo;<U>Successor Entity</U>&rdquo;) to assume in writing
all of the obligations of the Company under this Warrant in accordance with the provisions of this Section 3(d) pursuant to written agreements
in form and substance reasonably satisfactory to the Holder and approved by the Holder (without unreasonable delay) prior to such Fundamental
Transaction and shall, at the option of the Holder, deliver to the Holder in exchange for this Warrant a security of the Successor Entity
evidenced by a written instrument substantially similar in form and substance to this Warrant which is exercisable for a corresponding
number of shares of capital stock of such Successor Entity (or its parent entity) equivalent to the shares of Common Stock acquirable
and receivable upon exercise of this Warrant (without regard to any limitations on the exercise of this Warrant) prior to such Fundamental
Transaction, and with an exercise price which applies the exercise price hereunder to such shares of capital stock (but taking into account
the relative value of the shares of Common Stock pursuant to such Fundamental Transaction and the value of such shares of capital stock,
such number of shares of capital stock and such exercise price being for the purpose of protecting the economic value of this Warrant
immediately prior to the consummation of such Fundamental Transaction), and which is reasonably satisfactory in form and substance to
the Holder. Upon the occurrence of any such Fundamental Transaction, the Successor Entity shall be added to the term &ldquo;Company&rdquo;
under this Warrant (so that from and after the occurrence or consummation of such Fundamental Transaction, each and every provision of
this Warrant referring to the &ldquo;Company&rdquo; shall refer instead to each of the Company and the Successor Entity or Successor
Entities, jointly and severally), and the Successor Entity or Successor Entities, jointly and severally with the Company, may exercise
every right and power of the Company prior thereto and the Successor Entity or Successor Entities shall assume all of the obligations
of the Company prior thereto under this Warrant with the same effect as if the Company and such Successor Entity or Successor Entities,
jointly and severally, had been named as the Company herein. For the avoidance of doubt, the Holder shall be entitled to the benefits
of the provisions of this Section 3(d) regardless of (i) whether the Company has sufficient authorized shares of Common Stock for the
issuance of Warrant Shares and/or (ii) whether a Fundamental Transaction occurs prior to the Initial Exercise Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)
<U>Calculations</U>. All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share, as the
case may be. For purposes of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding as of a given date
shall be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">f)
<U>Notice to Holder</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.
<U>Adjustment to Exercise Price</U>. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the Company
shall promptly deliver to the Holder by email a notice setting forth the Exercise Price after such adjustment and any resulting adjustment
to the number of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii.
<U>Notice to Allow Exercise by Holder</U>. If (A) the Company shall declare a dividend (or any other distribution in whatever form) on
the Common Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C) the
Company shall authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares of
capital stock of any class or of any rights, (D) the approval of any stockholders of the Company shall be required in connection with
any reclassification of the Common Stock, any consolidation or merger to which the Company (or any of its Subsidiaries) is a party, any
sale or transfer of all or substantially all of its assets, or any compulsory share exchange whereby the Common Stock is converted into
other securities, cash or property, or (E) the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding
up of the affairs of the Company, then, in each case, the Company shall cause to be delivered by email to the Holder at its last email
address as it shall appear upon the Warrant Register of the Company, at least 20 calendar days prior to the applicable record or effective
date hereinafter specified, a notice stating (x) the date on which a record is to be taken for the purpose of such dividend, distribution,
redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of the Common Stock of record to
be entitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y) the date on which such reclassification,
consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and the date as of which it is expected
that holders of the Common Stock of record shall be entitled to exchange their shares of the Common Stock for securities, cash or other
property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange; provided that the failure to
deliver such notice or any defect therein or in the delivery thereof shall not affect the validity of the corporate action required to
be specified in such notice. To the extent that any notice provided in this Warrant constitutes, or contains, material, non-public information
regarding the Company or any of the Subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant to a
Current Report on Form 8-K. The Holder shall remain entitled to exercise this Warrant during the period commencing on the date of such
notice to the effective date of the event triggering such notice except as may otherwise be expressly set forth herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
4</U>. <U>Transfer of Warrant</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)
<U>Transferability</U>. Subject to compliance with any applicable securities laws and the conditions set forth in Section 4(d) hereof,
this Warrant and all rights hereunder (including, without limitation, any registration rights) are transferable, in whole or in part,
upon surrender of this Warrant at the principal office of the Company or its designated agent, together with a written assignment of
this Warrant substantially in the form attached hereto duly executed by the Holder or its agent or attorney and funds sufficient to pay
any transfer taxes payable upon the making of such transfer. Upon such surrender and, if required, such payment, the Company shall execute
and deliver a new Warrant or Warrants in the name of the assignee or assignees, as applicable, and in the denomination or denominations
specified in such instrument of assignment, and shall issue to the assignor a new Warrant evidencing the portion of this Warrant not
so assigned, and this Warrant shall promptly be cancelled. Notwithstanding anything herein to the contrary, the Holder shall not be required
to physically surrender this Warrant to the Company unless the Holder has assigned this Warrant in full, in which case, the Holder shall
surrender this Warrant to the Company within three (3) Trading Days of the date on which the Holder delivers an assignment form to the
Company assigning this Warrant in full. The Warrant, if properly assigned in accordance herewith, may be exercised by a new holder for
the purchase of Warrant Shares without having a new Warrant issued.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)
<U>New Warrants</U>. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of
the Company, together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by
the Holder or its agent or attorney. Subject to compliance with Section 4(a), as to any transfer which may be involved in such division
or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided
or combined in accordance with such notice. All Warrants issued on transfers or exchanges shall be dated the initial issuance date of
this Warrant and shall be identical with this Warrant except as to the number of Warrant Shares issuable pursuant thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)
<U>Warrant Register</U>. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the
&ldquo;<U>Warrant Register</U>&rdquo;), in the name of the record Holder hereof from time to time. The Company may deem and treat the
registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder,
and for all other purposes, absent actual notice to the contrary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)
<U>Transfer Restrictions</U>. If, at the time of the surrender of this Warrant in connection with any transfer of this Warrant, the transfer
of this Warrant shall not be either (i) registered pursuant to an effective registration statement under the Securities Act and under
applicable state securities or blue sky laws or (ii) eligible for resale without volume or manner-of-sale restrictions or current public
information requirements pursuant to Rule 144, the Company may require, as a condition of allowing such transfer, that the Holder or
transferee of this Warrant, as the case may be, provides to the Company an opinion of counsel, the form and substance of which opinion
shall be reasonably satisfactory to the Company, to the effect that the transfer of this Warrant does not require registration under
the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)
<U>Representation by the Holder</U>. The Holder, by the acceptance hereof, represents and warrants that it is acquiring this Warrant
and, upon any exercise hereof, will acquire the Warrant Shares issuable upon such exercise, for its own account and not with a view to
or for distributing or reselling such Warrant Shares or any part thereof in violation of the Securities Act or any applicable state securities
law, except pursuant to sales registered or exempted under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
5</U>. <U>Miscellaneous</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)
<U>No Rights as Stockholder Until Exercise; No Settlement in Cash</U>. This Warrant does not entitle the Holder to any voting rights,
dividends or other rights as a stockholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i), except as expressly
set forth in Section 3. Without limiting any rights of a Holder to receive Warrant Shares on a &ldquo;cashless exercise&rdquo; pursuant
to Section 2(c) or to receive cash payments pursuant to Section 2(d)(i) and Section 2(d)(iv) herein, in no event shall the Company be
required to net cash settle an exercise of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)
<U>Loss, Theft, Destruction or Mutilation of Warrant</U>. The Company covenants that upon receipt by the Company of evidence reasonably
satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant Shares,
and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the Warrant,
shall not include the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the
Company will make and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant
or stock certificate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)
<U>Saturdays, Sundays, Holidays, etc</U>. If the last or appointed day for the taking of any action or the expiration of any right required
or granted herein shall not be a Business Day, then such action may be taken or such right may be exercised on the next succeeding Business
Day.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)
<U>Authorized Shares</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company covenants that, during the period the Warrant is outstanding, it will reserve from its authorized and unissued Common Stock a
sufficient number of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights under this Warrant.
The Company further covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged with
the duty of issuing the necessary Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company will take all
such reasonable action as may be necessary to assure that such Warrant Shares may be issued as provided herein without violation of any
applicable law or regulation, or of any requirements of the Trading Market upon which the Common Stock may be listed. The Company covenants
that all Warrant Shares which may be issued upon the exercise of the purchase rights represented by this Warrant will, upon exercise
of the purchase rights represented by this Warrant and payment for such Warrant Shares in accordance herewith, be duly authorized, validly
issued, fully paid and nonassessable and free from all taxes, liens and charges created by the Company in respect of the issue thereof
(other than taxes in respect of any transfer occurring contemporaneously with such issue).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
and to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending
its certificate of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale
of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant,
but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary
or appropriate to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality of the
foregoing, the Company will (i) not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise
immediately prior to such increase in par value, (ii) take all such action as may be necessary or appropriate in order that the Company
may validly and legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant and (iii) use commercially
reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof,
as may be, necessary to enable the Company to perform its obligations under this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Before
taking any action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the
Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from
any public regulatory body or bodies having jurisdiction thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)
<U>Governing Law</U>. All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be governed
by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles of conflicts
of law thereof. Each party agrees that all legal proceedings concerning the interpretations, enforcement and defense of the transactions
contemplated by this Warrant (whether brought against a party hereto or their respective affiliates, directors, officers, shareholders,
partners, members, employees or agents) shall be commenced exclusively in the state and federal courts sitting in the City of New York.
Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in the City of New York,
Borough of Manhattan for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby
or discussed herein, and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is
not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is improper or is an inconvenient
venue for such proceeding. Each party hereby irrevocably waives personal service of process and consents to process being served in any
such suit, action or proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery)
to such party at the address in effect for notices to it under this Warrant and agrees that such service shall constitute good and sufficient
service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any
other manner permitted by law. If either party shall commence an action, suit or proceeding to enforce any provisions of this Warrant,
the prevailing party in such action, suit or proceeding shall be reimbursed by the other party for their reasonable attorneys&rsquo;
fees and other costs and expenses incurred with the investigation, preparation and prosecution of such action or proceeding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">f)
<U>Restrictions</U>. The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered, and
the Holder does not utilize cashless exercise, will have restrictions upon resale imposed by state and federal securities laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">g)
<U>Nonwaiver and Expenses</U>. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall
operate as a waiver of such right or otherwise prejudice the Holder&rsquo;s rights, powers or remedies. Without limiting any other provision
of this Warrant, if the Company willfully and knowingly fails to comply with any provision of this Warrant, which results in any material
damages to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to cover any costs and expenses including,
but not limited to, reasonable attorneys&rsquo; fees, including those of appellate proceedings, incurred by the Holder in collecting
any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">h)
<U>Notices</U>. Any and all notices or other communications or deliveries to be provided by the Holders hereunder including, without
limitation, any Notice of Exercise, shall be in writing and delivered personally, by e-mail, or sent by a nationally recognized overnight
courier service, addressed to the Company, at 10 Cleveland Street, Unit A, Summerville, MA 02143, Attention: Kevin Coveney, email address:
kcoveney@enveric.com, or such other email address or address as the Company may specify for such purposes by notice to the Holders. Any
and all notices or other communications or deliveries to be provided by the Company hereunder shall be in writing and delivered personally,
by e-mail, or sent by a nationally recognized overnight courier service addressed to each Holder at the e-mail address or address of
such Holder appearing on the books of the Company. Any notice or other communication or deliveries hereunder shall be deemed given and
effective on the earliest of (i) the time of transmission, if such notice or communication is delivered via e-mail at the e-mail address
set forth in this Section prior to 5:30 p.m. (New York City time) on any date, (ii) the next Trading Day after the time of transmission,
if such notice or communication is delivered via e-mail at the e-mail address set forth in this Section on a day that is not a Trading
Day or later than 5:30 p.m. (New York City time) on any Trading Day, (iii) the second Trading Day following the date of mailing, if sent
by U.S. nationally recognized overnight courier service, or (iv) upon actual receipt by the party to whom such notice is required to
be given. To the extent that any notice provided hereunder constitutes, or contains, material, non-public information regarding the Company
or any Subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant to a Current Report on Form 8-K.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i)
<U>Limitation of Liability</U>. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant
to purchase Warrant Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of
the Holder for the purchase price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company
or by creditors of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">j)
<U>Remedies</U>. The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will
be entitled to specific performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate
compensation for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to
assert the defense in any action for specific performance that a remedy at law would be adequate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">k)
<U>Successors and Assigns</U>. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall
inure to the benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns
of Holder. The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and shall
be enforceable by the Holder or holder of Warrant Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">l)
<U>Amendment</U>. Other than Section 2(e) above and this Section 5(l), which may not be amended, modified or waived, this Warrant may
be modified or amended or the provisions hereof waived with the written consent of the Company, on the one hand, and the Holder, on the
other hand.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">m)
<U>Severability</U>. Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid
under applicable law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall
be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining
provisions of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">n)
<U>Headings</U>. The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed
a part of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">********************</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(Signature
Page Follows)</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>


<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the Company has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above
indicated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>Enveric
    Biosciences, Inc.</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: &nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTICE
OF EXERCISE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">To:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">Enveric
    Biosciences, Inc.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)
The undersigned hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant (only
if exercised in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)
Payment shall take the form of (check applicable box):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[
&nbsp;&nbsp;&nbsp;&nbsp;] in lawful money of the United States; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[
&nbsp;&nbsp;&nbsp;&nbsp;] if permitted the cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth in subsection
2(c), to exercise this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure
set forth in subsection 2(c).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)
Please issue said Warrant Shares in the name of the undersigned or in such other name as is specified below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 20%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 30%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Warrant Shares shall be delivered to the following DWAC Account Number:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 20%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 30%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)
<U>Accredited Investor</U>. The undersigned is an &ldquo;accredited investor&rdquo; as defined in Regulation D promulgated under the
Securities Act of 1933, as amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">[SIGNATURE
OF HOLDER]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
of Investing Entity: ___________________________________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Signature
of Authorized Signatory of Investing Entity</I>: _________________________________________________</FONT>____</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
of Authorized Signatory: ___________________________________________________________________</FONT>____</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title
of Authorized Signatory: ____________________________________________________________________</FONT>____</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
________________________________________________________________________________________</FONT>__</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 17 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ASSIGNMENT
FORM</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(To
assign the foregoing Warrant, execute this form and supply required information. Do not use this form to purchase shares.)</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 10.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FOR
VALUE RECEIVED, the foregoing Warrant and all rights evidenced thereby are hereby assigned to</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 10.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 49%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Please
    Print)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address:</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phone
    Number:</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Please
    Print)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email
    Address:</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated:
    _______________ __, ______</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holder&rsquo;s
    Signature:________________________________</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holder&rsquo;s
    Address:</FONT>________________________________</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 18; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>5
<FILENAME>ex10-1.htm
<DESCRIPTION>EX-10.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt"><B>Exhibit 10.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>Enveric
Biosciences, Inc.</B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 364.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
11, 2025</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holder
of Common Stock Purchase Warrants</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Re:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Inducement
    Offer to Exercise Common Stock Purchase Warrants</U></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dear
Holder:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Enveric
Biosciences, Inc. (the &ldquo;<U>Company</U>&rdquo;) is pleased to offer to you (&ldquo;<U>Holder</U>&rdquo;, &ldquo;<U>you</U>&rdquo;
or similar terminology) (i) the opportunity to receive new warrants to purchase shares of the Company&rsquo;s common stock, par value
$0.001 per share (the &ldquo;<U>Common Stock</U>&rdquo;) and (ii) a reduction in the Exercise Price (as defined in the respective Existing
Warrants) of the warrants set forth on <U>Exhibit A</U> hereto (the &ldquo;<U>Existing Warrants</U>&rdquo;) held by you in consideration
for exercising by you for cash all of the Existing Warrants, as set forth on the signature page hereto. The resale of the shares of Common
Stock underlying the Existing Warrants (the &ldquo;<U>Existing Warrant Shares</U>&rdquo;) has been registered pursuant to the registration
statement on Form S-3 (File No. 333-290580) (the &ldquo;<U>Registration Statement</U>&rdquo;). The Registration Statement is currently
effective and, upon exercise of the Existing Warrants pursuant to this letter agreement, will be effective for the issuance or resale
of the Existing Warrant Shares. Capitalized terms not otherwise defined herein shall have the meanings set forth in the New Warrants
(as defined herein).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company desires to reduce the Exercise Price (as defined in the respective Existing Warrants) of the Existing Warrants to $7.05 per share
(the &ldquo;<U>Reduced Exercise Price</U>&rdquo;). In consideration for the exercise in full for cash of all of the Existing Warrants
held by the Holder at the Reduced Exercise Price as set forth on the Holder&rsquo;s signature page hereto (the &ldquo;<U>Warrant Exercise</U>&rdquo;)
on or before the Execution Time (as defined below) and the payment by the Holder on the Closing Date (as defined herein) of $0.125 per
New Warrant (the &ldquo;<U>New Warrant Consideration</U>&rdquo;), the Company hereby offers to sell and issue you new unregistered Common
Stock purchase warrants (the &ldquo;<U>New Warrants</U>&rdquo;) pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended
(&ldquo;<U>Securities Act</U>&rdquo;), to purchase up to a number of shares (the &ldquo;<U>New Warrant Shares</U>&rdquo;) of Common Stock
equal to 200% of the number of Warrant Shares issued pursuant to the Warrant Exercise hereunder, which New Warrants shall have an exercise
price per share equal to $7.05, subject to adjustment as provided in the New Warrants, will be exercisable immediately and have the same
term of exercise after the Effective Date as the applicable Existing Warrants being exercised (applied ratably), which New Warrants shall
be substantially in the form as set forth in <U>Exhibit A-1</U> hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
New Warrant certificate(s) will be delivered at Closing (as defined below), and such New Warrants, together with any underlying shares
of Common Stock issued upon exercise of the New Warrants, will, unless and until their sales are registered under the Securities Act,
contain customary restrictive legends and other language typical for an unregistered warrant and unregistered shares. Notwithstanding
anything herein to the contrary, in the event that any Warrant Exercise would otherwise cause the Holder to exceed the beneficial ownership
limitations (&ldquo;<U>Beneficial Ownership Limitation</U>&rdquo;) set forth in Section 2(e) of the Existing Warrants (or, if applicable
and at the Holder&rsquo;s election, 9.99%), the Company shall only issue such number of Existing Warrant Shares to the Holder that would
not cause the Holder to exceed the maximum number of Warrant Shares permitted thereunder, as directed by the Holder, with the balance
to be held in abeyance until notice from the Holder that the balance (or portion thereof) may be issued in compliance with such limitations,
which abeyance shall be evidenced through the Existing Warrants which shall be deemed prepaid thereafter (including the cash payment
in full of the exercise price), and exercised pursuant to a Notice of Exercise in the Existing Warrants (provided no additional exercise
price shall be due and payable). The parties hereby agree that the Beneficial Ownership Limitation for purposes of the Existing Warrants
is as set forth on the Holder&rsquo;s signature page hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expressly
subject to the paragraph immediately following this paragraph below, Holder may accept this offer by signing this letter agreement below,
with such acceptance constituting Holder&rsquo;s exercise in full of the Existing Warrants for an aggregate exercise price set forth
on the Holder&rsquo;s signature page hereto (the &ldquo;<U>Warrant Exercise Price</U>&rdquo;) on or before ____ a.m./p.m., Eastern Time,
on December 11, 2025 (the &ldquo;<U>Execution Time</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
the Company agrees to the representations, warranties and covenants set forth on <U>Annex A</U> attached hereto. Holder represents and
warrants that, as of the date hereof it is, and on each date on which it exercises any New Warrants it will be, an &ldquo;accredited
investor&rdquo; as defined in Rule 501 of Regulation D promulgated under the Securities Act, and agrees that the New Warrants will contain
restrictive legends when issued, and neither the New Warrants nor the shares of Common Stock issuable upon exercise of the New Warrants
will be registered under the Securities Act, except as provided in <U>Annex A</U> attached hereto. Also, Holder represents and warrants
that it is acquiring the New Warrants as principal for its own account and has no direct or indirect arrangement or understandings with
any other persons to distribute or regarding the distribution of the New Warrants or the New Warrant Shares (this representation is not
limiting Holder&rsquo;s right to sell the New Warrant Shares pursuant to an effective registration statement under the Securities Act
or otherwise in compliance with applicable federal and state securities laws).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Holder understands that issuance of the New Warrants and the New Warrant Shares are not, and may never be, registered under the Securities
Act, or the securities laws of any state and, accordingly, each certificate, if any, representing such securities shall bear a legend
substantially similar to the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;THE
OFFER AND SALE OF THIS SECURITY HAS NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY
STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &ldquo;SECURITIES ACT&rdquo;),
AND, ACCORDINGLY, THIS SECURITY MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES
ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT
AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certificates
evidencing the New Warrant Shares shall not contain any legend (including the legend set forth above), (i) while a registration statement
covering the resale of such New Warrant Shares is effective under the Securities Act, (ii) following any sale of such New Warrant Shares
pursuant to Rule 144 under the Securities Act, (iii) if such New Warrant Shares are eligible for sale under Rule 144 (assuming cashless
exercise of the New Warrants), without the requirement for the Company to be in compliance with the current public information required
under Rule 144 as to such New Warrant Shares and without volume or manner-of-sale restrictions, (iv) if such New Warrant Shares may be
sold under Rule 144 (assuming cashless exercise of the New Warrants) and the Company is then in compliance with the current public information
required under Rule 144 as to such New Warrant Shares, or (v) if such legend is not required under applicable requirements of the Securities
Act (including judicial interpretations and pronouncements issued by the staff of the Securities and Exchange Commission (the &ldquo;<U>Commission</U>&rdquo;)
and the earliest of clauses (i) through (v), the &ldquo;<U>Delegend Date</U>&rdquo;)). The Company shall cause its counsel to issue a
legal opinion to the Transfer Agent promptly after the Delegend Date if required by the Company and/or the Transfer Agent to effect the
removal of the legend hereunder, or at the request of the Holder, which opinion shall be in form and substance reasonably acceptable
to the Holder. From and after the Delegend Date, such New Warrant Shares shall be issued free of all legends. The Company agrees that
following the Delegend Date or at such time as such legend is no longer required under this Section, it will, no later than one (1) Trading
Day following the delivery by the Holder to the Company or the Transfer Agent of a certificate representing the New Warrant Shares issued
with a restrictive legend (such first (1st) Trading Day, the &ldquo;<U>Legend Removal Date</U>&rdquo;), deliver or cause to be delivered
to the Holder a certificate representing such shares that is free from all restrictive and other legends or, at the request of the Holder
shall credit the account of the Holder&rsquo;s prime broker with the Depository Trust Company System as directed by the Holder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to the Holder&rsquo;s other available remedies, the Company shall pay to a Holder, in cash, (i) as partial liquidated damages
and not as a penalty, for each $1,000 of New Warrant Shares (based on the VWAP of the Common Stock on the date such New Warrant Shares
are submitted to the Transfer Agent) delivered for removal of the restrictive legend, $10 per Trading Day (increasing to $20 per Trading
Day five (5) Trading Days after such damages have begun to accrue) for each Trading Day after the Legend Removal Date until such certificate
is delivered without a legend and (ii) if the Company fails to (a) issue and deliver (or cause to be delivered) to the Holder by the
Legend Removal Date a certificate representing the New Warrant Shares that is free from all restrictive and other legends and (b) if
after the Legend Removal Date the Holder purchases (in an open market transaction or otherwise) shares of Common Stock to deliver in
satisfaction of a sale by the Holder of all or any portion of the number of shares of Common Stock, or a sale of a number of shares of
Common Stock equal to all or any portion of the number of shares of Common Stock that the Holder anticipated receiving from the Company
without any restrictive legend, then, an amount equal to the excess of the Holder&rsquo;s total purchase price (including brokerage commissions
and other out-of-pocket expenses, if any) for the shares of Common Stock so purchased (including brokerage commissions and other out-of-pocket
expenses, if any) over the product of (A) such number of New Warrant Shares that the Company was required to deliver to the Holder by
the Legend Removal Date and for which the Holder was required to purchase shares to timely satisfy delivery requirements, multiplied
by (B) the weighted average price at which the Holder sold that number of shares of Common Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
this offer is accepted and the transaction documents are executed by the Execution Time, then as promptly as possible following the Execution
Time, but in any event no later than ____ a.m./p.m., Eastern Time, on the date hereof, the Company shall issue a press release disclosing
the material terms of the transactions contemplated hereby and shall file a Current Report on Form 8-K with the Commission disclosing
all material terms of the transactions contemplated hereunder, including the filing with the Commission of this letter agreement as an
exhibit thereto within the time required by the Exchange Act. From and after the dissemination of such press release, the Company represents
to you that it shall have publicly disclosed all material, non-public information delivered to you by the Company, or any of its respective
officers, directors, employees or agents in connection with the transactions contemplated hereunder. In addition, effective upon the
dissemination of such press release, the Company acknowledges and agrees that any and all confidentiality or similar obligations under
any agreement, whether written or oral, between the Company, any of its Subsidiaries or any of their respective officers, directors,
agents, employees or Affiliates on the one hand, and you and your Affiliates on the other hand, shall terminate. The Company represents,
warrants and covenants that, upon acceptance of this offer, the Warrant Shares shall be issued at Closing free of any legends or restrictions
on resale by Holder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
later than the first (1st) Trading Day following the date of the public disclosure of the transactions hereunder, the closing (&ldquo;<U>Closing</U>&rdquo;)
shall occur at such location as the parties shall mutually agree. Unless otherwise directed by H.C. Wainwright &amp; Co., LLC (the &ldquo;<U>Placement
Agent</U>&rdquo;), settlement of the Warrant Shares shall occur via &ldquo;Delivery Versus Payment&rdquo; (&ldquo;<U>DVP</U>&rdquo;)
(i.e., on the Closing Date (as defined below), the Company shall issue the Warrant Shares registered in the Holder&rsquo;s name and address
provided to the Company in writing and released by the Transfer Agent directly to the account(s) at the Placement Agent identified by
the Holder; upon receipt of such Warrant Shares, the Placement Agent shall promptly electronically deliver such Warrant Shares to the
Holder, and payment therefor shall concurrently be made to the Company by the Placement Agent (or its clearing firm) by wire transfer
to the Company). The date of the Closing of the Warrant Exercise shall be referred to as the &ldquo;<U>Closing Date</U>&rdquo;.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company acknowledges and agrees that the obligations of the Holders under this letter agreement are several and not joint with the obligations
of any other holder or holders of Existing Warrants or other warrants of the Company (each, an &ldquo;<U>Other Holder</U>&rdquo;) under
any other agreement related to the exercise of such warrants (&ldquo;<U>Other Warrant Exercise Agreement</U>&rdquo;), and the Holder
shall not be responsible in any way for the performance of the obligations of any Other Holder or under any such Other Warrant Exercise
Agreement. Nothing contained in this letter agreement, and no action taken by the Holders pursuant hereto, shall be deemed to constitute
the Holder and the Other Holders as a partnership, an association, a joint venture or any other kind of entity, or create a presumption
that the Holder and the Other Holders are in any way acting in concert or as a group with respect to such obligations or the transactions
contemplated by this letter agreement and the Company acknowledges that the Holder and the Other Holders are not acting in concert or
as a group with respect to such obligations or the transactions contemplated by this letter agreement or any Other Warrant Exercise Agreement.
The Company and the Holder confirm that the Holder has independently participated in the negotiation of the transactions contemplated
hereby with the advice of its own counsel and advisors. The Holder shall be entitled to independently protect and enforce its rights,
including, without limitation, the rights arising out of this letter agreement, and it shall not be necessary for any Other Holder to
be joined as an additional party in any proceeding for such purpose.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company shall pay all transfer agent fees, stamp taxes and other taxes and duties levied in connection with the delivery of any Existing
Warrant Shares. This letter agreement shall be construed and enforced in accordance with the laws of the State of New York, without regards
to conflicts of laws principles. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts
sitting in the City of New York, Borough of Manhattan for the adjudication of any dispute hereunder or in connection herewith or with
any transaction contemplated hereby.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sincerely
    yours,</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>Enveric
    Biosciences, Inc.</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[Holder
Signature Page Follows]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accepted
and Agreed to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
of Holder: ________________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Signature
of Authorized Signatory of Holder</I>: _________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
of Authorized Signatory: _______________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title
of Authorized Signatory: ________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number
of Existing Warrants: __________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Aggregate
Warrant Exercise Price at the Reduced Exercise Price being exercised contemporaneously with signing this letter agreement: _________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Aggregate
New Warrant Consideration: $_______ ($0.125 per New Warrant)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Existing
Warrants Beneficial Ownership Blocker: &#9744; 4.99% or &#9744; 9.99%</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
Warrants: _______________ (200% of the total Existing Warrants being exercised)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
Warrants Beneficial Ownership Blocker: &#9744; 4.99% or &#9744; 9.99%</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DTC
Instructions:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[Holder
signature page to ENVB Inducement Offer]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Annex
A</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Representations,
Warranties and Covenants of the Company</U>. The Company hereby makes the following representations and warranties to the Holder:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>SEC
    Reports</U>. The Company has filed all reports, schedules, forms, statements and other documents required to be filed by the Company
    under the Exchange Act, including pursuant to Section 13(a) or 15(d) thereof, for the one year preceding the date hereof (or such
    shorter period as the Company was required by law or regulation to file such material) (the foregoing materials, including the exhibits
    thereto and documents incorporated by reference therein &ldquo;<U>SEC Reports</U>&rdquo;). As of their respective dates, the SEC
    Reports complied in all material respects with the requirements of the Exchange Act and none of the SEC Reports, when filed, contained
    any untrue statement of a material fact or omitted to state a material fact required to be stated therein or necessary in order to
    make the statements therein, in the light of the circumstances under which they were made, not misleading. The Company is not currently
    an issuer identified in Rule 144(i) under the Securities Act.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Authorization;
    Enforcement</U>. The Company has the requisite corporate power and authority to enter into and to consummate the transactions contemplated
    by this letter agreement and otherwise to carry out its obligations hereunder. The execution and delivery of this letter agreement
    by the Company and the consummation by the Company of the transactions contemplated hereby have been duly authorized by all necessary
    action on the part of the Company and no further action is required by the Company, its board of directors or its stockholders in
    connection herewith. This letter agreement has been duly executed by the Company and, when delivered in accordance with the terms
    hereof, will constitute the valid and binding obligation of the Company enforceable against the Company in accordance with its terms,
    except (i) as limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other
    laws of general application affecting enforcement of creditors&rsquo; rights generally, (ii) as limited by laws relating to the availability
    of specific performance, injunctive relief or other equitable remedies and (iii) insofar as indemnification and contribution provisions
    may be limited by applicable law.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>No
    Conflicts</U>. The execution, delivery and performance of this letter agreement by the Company and the consummation by the Company
    of the transactions contemplated hereby do not and will not: (i) conflict with or violate any provision of the Company&rsquo;s certificate
    or articles of incorporation, bylaws or other organizational or charter documents; or (ii) conflict with, or constitute a default
    (or an event that with notice or lapse of time or both would become a default) under, result in the creation of any liens, claims,
    security interests, other encumbrances or defects upon any of the properties or assets of the Company in connection with, or give
    to others any rights of termination, amendment, acceleration or cancellation (with or without notice, lapse of time or both) of,
    any material agreement, credit facility, debt or other material instrument (evidencing Company debt or otherwise) or other material
    understanding to which such Company is a party or by which any property or asset of the Company is bound or affected; or (iii) conflict
    with or result in a violation of any law, rule, regulation, order, judgment, injunction, decree or other restriction of any court
    or governmental authority to which the Company is subject (including federal and state securities laws and regulations), or by which
    any property or asset of the Company is bound or affected, except, in the case of each of clauses (ii) and (iii), such as could not
    have or reasonably be expected to result in a material adverse effect upon the business, prospects, properties, operations, condition
    (financial or otherwise) or results of operations of the Company, taken as a whole, or in its ability to perform its obligations
    under this letter agreement.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Registration
    Obligations</U>. As soon as reasonably practicable (and in any event within ten (10) calendar days of the date of this letter agreement),
    the Company shall file a registration statement on Form S-3 (or other appropriate form, including on Form S-1, if the Company is
    not then S-3 eligible) providing for the resale of the New Warrant Shares by the holders of the New Warrants (the &ldquo;<U>Resale
    Registration Statement</U>&rdquo;). The Company shall use commercially reasonable efforts to cause the Resale Registration Statement
    to become effective within forty-five (45) calendar days following the date hereof (or within seventy-five (75) calendar days following
    the date hereof in case of &ldquo;full review&rdquo; of such registration statement by the Commission) and to keep the Resale Registration
    Statement effective at all times until no holder of the New Warrants owns any New Warrants or New Warrant Shares.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Trading
    Market</U>. The transactions contemplated under this letter agreement comply with all the rules and regulations of the Nasdaq Capital
    Market.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">f)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Filings,
    Consents and Approvals</U>. The Company is not required to obtain any consent, waiver, authorization or order of, give any notice
    to, or make any filing or registration with, any court or other federal, state, local or other governmental authority or other Person
    in connection with the execution, delivery and performance by the Company of this letter agreement, other than: (i) the filings required
    pursuant to this letter agreement, (ii) application(s) or notice to each applicable Trading Market for the listing of the New Warrants
    and New Warrant Shares for trading thereon in the time and manner required thereby, (iii) the filing of Form D with the Commission,
    and (iv) such filings as are required to be made under applicable state securities laws.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">g)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Listing
    of Common Stock</U>. The Company hereby agrees to use best efforts to maintain the listing or quotation of the Common Stock on the
    Trading Market on which it is currently listed, and concurrently with the Closing, the Company shall apply to list or quote all of
    the New Warrant Shares on such Trading Market and promptly secure the listing of all of the New Warrant Shares on such Trading Market.
    The Company further agrees, if the Company applies to have the Common Stock traded on any other Trading Market, it will then include
    in such application all of the New Warrant Shares, and will take such other action as is necessary to cause all of the New Warrant
    Shares to be listed or quoted on such other Trading Market as promptly as possible. The Company will then take all action reasonably
    necessary to continue the listing and trading of its Common Stock on a Trading Market and will comply in all respects with the Company&rsquo;s
    reporting, filing and other obligations under the bylaws or rules of the Trading Market. The Company agrees to maintain the eligibility
    of the Common Stock for electronic transfer through the Depository Trust Company or another established clearing corporation, including,
    without limitation, by timely payment of fees to the Depository Trust Company or such other established clearing corporation in connection
    with such electronic transfer.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">h)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Subsequent
    Equity Sales</U>. </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
From the date hereof until five (5) days after the Closing Date, neither the Company nor any Subsidiary shall (A) issue, enter into any
agreement to issue or announce the issuance or proposed issuance of any Common Stock or Common Stock Equivalents or (B) file any registration
statement or any amendment or supplement to any existing registration statement (other than the Resale Registration Statement referred
to herein, the filing of any amendment or supplement to an existing registration statement for an &ldquo;at the market&rdquo; offering
with the Placement Agent as sales agent or a registration statement on Form S-8 in connection with any employee benefit plan). Notwithstanding
the foregoing, this Section (h)(i) shall not apply in respect of an Exempt Issuance. &ldquo;<U>Exempt Issuance</U>&rdquo; means the issuance
of (a) shares of Common Stock or options to employees, officers or directors of the Company pursuant to any stock or option plan duly
adopted for such purpose, by a majority of the non-employee members of the Board of Directors or a majority of the members of a committee
of non-employee directors established for such purpose for services rendered to the Company, (b) warrants to the Placement Agent in connection
with the transactions pursuant to this letter agreement and any securities upon exercise of warrants to the Placement Agent, if any,
securities upon the exercise or exchange of or conversion of any securities issued hereunder and/or other securities exercisable or exchangeable
for or convertible into shares of Common Stock issued and outstanding on the date of this letter agreement, provided that such securities
have not been amended since the date of this letter agreement to increase the number of such securities or to decrease the exercise price,
exchange price or conversion price of such securities (other than in connection with stock splits or combinations) or to extend the term
of such securities, and (c) securities issued pursuant to acquisitions or strategic transactions approved by a majority of the disinterested
directors of the Company, provided that such securities are issued as &ldquo;restricted securities&rdquo; (as defined in Rule 144) and
carry no registration rights that require or permit the filing of any registration statement in connection therewith during the prohibition
period in this Section (h)(i), and provided that any such issuance shall only be to a Person (or to the equityholders of a Person) which
is, itself or through its subsidiaries, an operating company or an owner of an asset in a business synergistic with the business of the
Company and shall provide to the Company additional benefits in addition to the investment of funds, but shall not include a transaction
in which the Company is issuing securities primarily for the purpose of raising capital or to an entity whose primary business is investing
in securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 35.7pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 35.7pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
From the date hereof until one (1) year following the Closing Date, the Company shall be prohibited from effecting or entering into an
agreement to effect any issuance by the Company nor any Subsidiary of Common Stock or Common Stock Equivalents (or a combination of units
thereof) involving a Variable Rate Transaction. &ldquo;<U>Variable Rate Transaction</U>&rdquo; means a transaction in which the Company
(i) issues or sells any debt or equity securities that are convertible into, exchangeable or exercisable for, or include the right to
receive, additional shares of Common Stock either (A) at a conversion price, exercise price or exchange rate or other price that is based
upon, and/or varies with, the trading prices of or quotations for the shares of Common Stock at any time after the initial issuance of
such debt or equity securities or (B) with a conversion, exercise or exchange price that is subject to being reset at some future date
after the initial issuance of such debt or equity security or upon the occurrence of specified or contingent events directly or indirectly
related to the business of the Company or the market for the Common Stock or (ii) enters into, or effects a transaction under, any agreement,
including, but not limited to, an equity line of credit or an &ldquo;at-the-market offering&rdquo;, whereby the Company may issue securities
at a future determined price, regardless of whether shares pursuant to such agreement have actually been issued and regardless of whether
such agreement is subsequently canceled; <U>provided</U>, <U>however</U>, that, following the expiration of the restrictive period set
forth in Section (h)(i) above, the entry into and/or issuance of shares of Common Stock in an &ldquo;at the market&rdquo; offering with
the Placement Agent as sales agent shall not be deemed a Variable Rate Transaction. The Holder shall be entitled to obtain injunctive
relief against the Company to preclude any such issuance, which remedy shall be in addition to any right to collect damages.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Form
    D; Blue Sky Filings</U>. If required, the Company agrees to timely file a Form D with respect to the New Warrants and New Warrant
    Shares as required under Regulation D and to provide a copy thereof, promptly upon request of any Holder. The Company shall take
    such action as the Company shall reasonably determine is necessary in order to obtain an exemption for, or to qualify the New Warrants
    and New Warrant Shares for, sale to the Holder at Closing under applicable securities or &ldquo;Blue Sky&rdquo; laws of the states
    of the United States, and shall provide evidence of such actions promptly upon request of any Holder.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 10; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>6
<FILENAME>ex99-1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
99.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Enveric
Biosciences Announces Exercise of Warrants for $3.1 Million Gross Proceeds</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CAMBRIDGE,
Mass., December 11, 2025 &ndash; Enveric Biosciences, Inc. (NASDAQ: ENVB) (&ldquo;Enveric&rdquo; or the &ldquo;Company&rdquo;), a biotechnology
company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological disorders, today announced
the entry into definitive agreements for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 426,390
shares originally issued in February 2025 and September 2025, having exercise prices of $36.00 and $10.98 per share, respectively, at
a reduced exercise price of $7.05 per share. The shares of common stock issuable upon exercise of the warrants are registered pursuant
to effective registration statements on Form S-1 (No. 333-284277) and Form S-3 (No. 333-290580). The gross proceeds to the Company from
the exercise of the warrants are expected to be approximately $3.1 million, prior to deducting placement agent fees and estimated offering
expenses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">H.C.
Wainwright &amp; Co. is acting as the exclusive placement agent for the offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
consideration for the immediate exercise of the warrants for cash and the payment of additional $0.125 per new unregistered warrant (additional
$106,597.50 in the aggregate, which are included in the gross proceeds to the Company), the Company will issue new unregistered series
E warrants to purchase up to 426,390 shares of common stock and new unregistered Series F warrants to purchase up to 426,390 shares of
common stock. The series E new warrants will have an exercise price of $7.05 per share, will be exercisable immediately and will expire
five years after the effective date of the Resale Registration Statement (as defined below). The series F new warrants will have an exercise
price of $7.05 per share, will be exercisable immediately and will expire eighteen months after the effective date of the Resale Registration
Statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
offering is expected to close on or about December 12, 2025, subject to satisfaction of customary closing conditions. The Company intends
to use the net proceeds from the offering for product development, working capital and general corporate purposes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
new warrants described above were offered in a private placement pursuant to an applicable exemption from the registration requirements
of the Securities Act of 1933, as amended (the &ldquo;1933 Act&rdquo;) and, along with the shares of common stock issuable upon their
exercise, have not been registered under the 1933 Act, and may not be offered or sold in the United States absent registration with the
Securities and Exchange Commission (&ldquo;SEC&rdquo;) or an applicable exemption from such registration requirements. The Company has
agreed to file a registration statement with the SEC covering the resale of the shares of common stock issuable upon exercise of the
new warrants (the &ldquo;Resale Registration Statement&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
press release shall not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein, nor
shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful
prior to the registration or qualification under the securities laws of any such state or other jurisdiction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
Enveric Biosciences</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Enveric
Biosciences (NASDAQ: ENVB) is a biotechnology company focused on developing next-generation, small-molecule neuroplastogenic therapeutics
that address unmet needs in psychiatric and neurological disorders. By leveraging a differentiated drug discovery platform and a growing
library of protected chemical structures, Enveric is advancing a pipeline of novel compounds designed to promote neuroplasticity without
hallucinogenic effects. Enveric&rsquo;s lead candidate, EB-003, is the first known compound designed to selectively engage both 5-HT&#8322;<SUB>A</SUB>
and 5-HT&#8321;<SUB>B</SUB> receptors to deliver fast-acting, durable antidepressant and anxiolytic effects with outpatient convenience.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
more information, please visit <U>www.enveric.com</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Forward-Looking
Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
press release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. These
statements relate to future events or future performance. All statements other than statements of historical fact may be forward-looking
statements or information. Generally, forward-looking statements and information may be identified by the use of forward-looking terminology
such as &ldquo;plans,&rdquo; &ldquo;expects&rdquo; or &ldquo;does not expect,&rdquo; &ldquo;proposes,&rdquo; &ldquo;budgets,&rdquo; &ldquo;explores,&rdquo;
&ldquo;schedules,&rdquo; &ldquo;seeks,&rdquo; &ldquo;estimates,&rdquo; &ldquo;forecasts,&rdquo; &ldquo;intends,&rdquo; &ldquo;anticipates&rdquo;
or &ldquo;does not anticipate,&rdquo; or &ldquo;believes,&rdquo; or variations of such words and phrases, or by the use of words or phrases
which state that certain actions, events or results may, could, should, would, or might occur or be achieved. Forward-looking statements
may include statements regarding beliefs, plans, expectations, or intentions regarding the future and are based on the beliefs of management
as well as assumptions made by and information currently available to management, including, but not limited to, statements regarding
the completion of the offering, the satisfaction of customary closing conditions related to the offering, the receipt of stockholder
approval and the anticipated use of proceeds from the offering. Actual results could differ materially from those contemplated by the
forward-looking statements as a result of certain factors, including, but not limited to, the ability of Enveric to: finalize and submit
its IND filing to the U.S. Food and Drug Administration; carry out successful clinical programs; achieve the value creation contemplated
by technical developments; avoid delays in planned clinical trials; establish that potential products are efficacious or safe in preclinical
or clinical trials; establish or maintain collaborations for the development of therapeutic candidates; obtain appropriate or necessary
governmental approvals to market potential products; obtain future funding for product development and working capital on commercially
reasonable terms; scale-up manufacture of product candidates; respond to changes in the size and nature of competitors; hire and retain
key executives and scientists; secure and enforce legal rights related to Enveric&rsquo;s products, including patent protection; identify
and pursue alternative routes to capture value from its research and development pipeline assets; continue as a going concern; and manage
its future growth effectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Contacts</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investor
Relations</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tiberend
Strategic Advisors, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">David
Irish</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(231)
632-0002</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">dirish@tiberend.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Media
Relations</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tiberend
Strategic Advisors, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Casey
McDonald</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(646)
577-8520</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">cmcdonald@tiberend.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>7
<FILENAME>ex99-2.htm
<DESCRIPTION>EX-99.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin-right: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
99.2</B></FONT></P>

<P STYLE="margin-right: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Enveric
Biosciences Announces Closing of Exercise of Warrants for $3.1 Million Gross Proceeds</B></FONT></P>

<P STYLE="margin-right: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CAMBRIDGE,
Mass., December 12, 2025 &ndash; Enveric Biosciences, Inc. (NASDAQ: ENVB) (&ldquo;Enveric&rdquo; or the &ldquo;Company&rdquo;), a biotechnology
company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological disorders, today announced
the closing of its previously announced exercise of certain outstanding warrants to purchase up to an aggregate of 426,390 shares originally
issued in February 2025 and September 2025, having exercise prices of $36.00 and $10.98 per share, respectively, at a reduced exercise
price of $7.05 per share. The shares of common stock issuable upon exercise of the warrants are registered pursuant to effective registration
statements on Form S-1 (No. 333-284277) and Form S-3 (No. 333-290580). The gross proceeds to the Company from the exercise of the warrants
were approximately $3.1 million, prior to deducting placement agent fees and estimated offering expenses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">H.C.
Wainwright &amp; Co. acted as the exclusive placement agent for the offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
consideration for the immediate exercise of the warrants for cash and the payment of additional $0.125 per new unregistered warrant (additional
$106,597.50 in the aggregate, which are included in the gross proceeds to the Company), the Company issued new unregistered series E
warrants to purchase up to 426,390 shares of common stock and new unregistered series F warrants to purchase up to 426,390 shares of
common stock. The new series E warrants have an exercise price of $7.05 per share, are exercisable immediately and will expire five years
after the effective date of the Resale Registration Statement (as defined below). The new series F warrants have an exercise price of
$7.05 per share, are exercisable immediately and will expire eighteen months after the effective date of the Resale Registration Statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company intends to use the net proceeds from the offering for product development, working capital and general corporate purposes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
new warrants described above were offered in a private placement pursuant to an applicable exemption from the registration requirements
of the Securities Act of 1933, as amended (the &ldquo;1933 Act&rdquo;) and, along with the shares of common stock issuable upon their
exercise, have not been registered under the 1933 Act, and may not be offered or sold in the United States absent registration with the
Securities and Exchange Commission (&ldquo;SEC&rdquo;) or an applicable exemption from such registration requirements. The Company has
agreed to file a registration statement with the SEC covering the resale of the shares of common stock issuable upon exercise of the
new warrants (the &ldquo;Resale Registration Statement&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
press release shall not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein, nor
shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful
prior to the registration or qualification under the securities laws of any such state or other jurisdiction.</FONT></P>

<P STYLE="margin: 0pt 0pt 0pt 0; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
Enveric Biosciences</B></FONT></P>

<P STYLE="margin: 0pt 0pt 0pt 0; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Enveric
Biosciences (NASDAQ: ENVB) is a biotechnology company focused on developing next-generation, small-molecule neuroplastogenic therapeutics
that address unmet needs in psychiatric and neurological disorders. By leveraging a differentiated drug discovery platform and a growing
library of patent protected chemical structures, Enveric is advancing a pipeline of novel compounds designed to promote neuroplasticity
without hallucinogenic effects. Enveric&rsquo;s lead candidate, EB-003, is the first known compound designed to selectively engage both
5-HT&#8322;<SUB>A</SUB> and 5-HT&#8321;<SUB>B</SUB> receptors with the potential to deliver fast-acting, durable antidepressant and anxiolytic
effects with outpatient convenience.</FONT></P>

<P STYLE="margin: 0pt 0pt 0pt 0; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
more information, please visit <U>www.enveric.com</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin: 0pt 0pt 0pt 0; font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Forward-Looking
Statements</B></FONT></P>

<P STYLE="margin: 0pt 0pt 0pt 0; font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
press release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. These
statements relate to future events or future performance. All statements other than statements of historical fact may be forward-looking
statements or information. Generally, forward-looking statements and information may be identified by the use of forward-looking terminology
such as &ldquo;plans,&rdquo; &ldquo;expects&rdquo; or &ldquo;does not expect,&rdquo; &ldquo;proposes,&rdquo; &ldquo;budgets,&rdquo; &ldquo;explores,&rdquo;
&ldquo;schedules,&rdquo; &ldquo;seeks,&rdquo; &ldquo;estimates,&rdquo; &ldquo;forecasts,&rdquo; &ldquo;intends,&rdquo; &ldquo;anticipates&rdquo;
or &ldquo;does not anticipate,&rdquo; or &ldquo;believes,&rdquo; or variations of such words and phrases, or by the use of words or phrases
which state that certain actions, events or results may, could, should, would, or might occur or be achieved. Forward-looking statements
may include statements regarding beliefs, plans, expectations, or intentions regarding the future and are based on the beliefs of management
as well as assumptions made by and information currently available to management, including, but not limited to, statements regarding
the anticipated use of proceeds from the offering. Actual results could differ materially from those contemplated by the forward-looking
statements as a result of certain factors, including, but not limited to, the ability of Enveric to: finalize and submit its IND filing
to the U.S. Food and Drug Administration; carry out successful clinical programs; achieve the value creation contemplated by technical
developments; avoid delays in planned clinical trials; establish that potential products are efficacious or safe in preclinical or clinical
trials; establish or maintain collaborations for the development of therapeutic candidates; obtain appropriate or necessary governmental
approvals to market potential products; obtain future funding for product development and working capital on commercially reasonable
terms; scale-up manufacture of product candidates; respond to changes in the size and nature of competitors; hire and retain key executives
and scientists; secure and enforce legal rights related to Enveric&rsquo;s products, including patent protection; identify and pursue
alternative routes to capture value from its research and development pipeline assets; continue as a going concern; and manage its future
growth effectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin: 0pt 0pt 0pt 0; font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Contacts</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investor
Relations</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tiberend
Strategic Advisors, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">David
Irish</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(231)
632-0002</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">dirish@tiberend.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Media
Relations</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tiberend
Strategic Advisors, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Casey
McDonald</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(646)
577-8520</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">cmcdonald@tiberend.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>envb-20251211.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.3a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 96Mps7xRiXgen8uDanwsWaeJ2bP9z5Z8qekhvWBxbemq3ywuoEc9niX2IXUmweIA -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:srt-types="http://fasb.org/srt-types/2025" xmlns:ENVB="http://enveric.com/20251211" elementFormDefault="qualified" targetNamespace="http://enveric.com/20251211">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://enveric.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="envb-20251211_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="envb-20251211_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd" />
    <import namespace="http://fasb.org/us-gaap/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd" />
    <import namespace="http://fasb.org/us-types/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2024-01-31" schemaLocation="https://www.xbrl.org/dtr/type/2024-01-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2025" schemaLocation="https://xbrl.sec.gov/country/2025/country-2025.xsd" />
    <import namespace="http://fasb.org/srt/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd" />
    <import namespace="http://fasb.org/srt-types/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>envb-20251211_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.3a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>envb-20251211_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.3a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="envb-20251211.xsd#Cover" roleURI="http://enveric.com/role/Cover" />
    <link:presentationLink xlink:type="extended" xlink:role="http://enveric.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Dec. 11, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 11,  2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38286<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Enveric
Biosciences, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000890821<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">95-4484725<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">Enveric
Biosciences, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">245
First Street, Riverview II<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine3', window );">Entity Address, Address Line Three</a></td>
<td class="text">18th Floor<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Cambridge<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02142<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(617)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">444-8400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common
    stock, par value $0.01 per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ENVB<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 3 such as an Office Park</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>24</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="form8-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://enveric.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>envb-20251211.xsd</File>
    <File>envb-20251211_lab.xml</File>
    <File>envb-20251211_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="form8-k.htm">form8-k.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="24">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>18
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "form8-k.htm": {
   "nsprefix": "ENVB",
   "nsuri": "http://enveric.com/20251211",
   "dts": {
    "schema": {
     "local": [
      "envb-20251211.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "envb-20251211_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "envb-20251211_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "form8-k.htm"
     ]
    }
   },
   "keyStandard": 24,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2025": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 59,
   "unitCount": 3,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2025": 24
   },
   "report": {
    "R1": {
     "role": "http://enveric.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "AsOf2025-12-11",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form8-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-12-11",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form8-k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CountryRegion",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Extension",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12gTitle",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>19
<FILENAME>0001493152-25-027541-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001493152-25-027541-xbrl.zip
M4$L#!!0    ( %&)C%M)[[\3)0,  -\+   1    96YV8BTR,#(U,3(Q,2YX
M<V2U5MMRVC 0?>],_T'UNS&&)@T$DLFEZ= A:28T"=.7CK 7T$26'$G&I%]?
MR3<N!A=HRY.T>\[976E7IG,^#RB:@9"$LZ[EUNH6 N9QG[!)UWH<V!>#JU[/
M0N=G[]\A_>M\L&UT0X#Z;73-/;O'QOP4W>$ VN@+,!!8<7&*GC"-C(7?$ H"
M7?$@I*! .])(;71<:V)DVSO(/@'SN7A\Z!6R4Z5"V7:<.(YKC,]PS,6+K'D\
MV$UPH+"*9*%6G]>SWV[T6R*]@MPZO@WEI_D#&4Z G437F,7R&</7QNB^]>OH
MQ\DKO$QGSY?S$02OS;<XXI^]%B/#1F_X&,30NTA#=J0WA0 C?1=,=BU37U9>
MW*QQ,7$:];KK#&_[@P1GI<#VG!+VL@GNMEHM)_'FT!)R/A(TEVXZQCW"$@IE
M[245>,*DPLQ;P?NJ("R#CYS4N0(E&Z''*93D4!_6<!*\VH3/'.W0^,91#HRD
M/<$X+,!C+$>):.98 4NARD!M7 ?9ZBT$N1&:NE8(G^^>+@LL,#U1Q#,MF8#<
MANOJN:(0 %,W7 37,,81U7F\1IB2,0'?0@J+"2C38S+$'E2+Y7V*&>.ZG?5(
M919C"T.B^[4P:).YW[;@%+[KQ)%9Z'G:&,'XG"NN#18B?M=*ETM:N9H/8\)(
M$CD;'Q?99E@B4Z1>)LR.LPXN*T42_&_L+%F' J2F)Q7UM2'C9Y!JKH>I%]&#
MJ(O\JIB9/3_'T@'G4_0 8Y1,7]OT2=>2Q#Q_5F:;"AAW+7WF(SN_SI^Z[)KN
MHQQB(E1,7W)'ZR>5!<XEL/!**J7708OP$(0BNIF7GH T=:(,_7XI##)QI(6<
M?U@YQ:-]*]<4H/^QY+[1+]?:<58'2^_7AZ^CR^5"(58:XJHG-'W\^]Q+I"HH
M9F?G/-N8;+=A-]W:7/J+3/=)8G$"^R61\PY(8LM#OBF^W 8WBZ2%=@VZY8-0
M&70CQP&J9&XY.(7ES\=?Y)#([)7$RG7Z2CA&PHA^M.NNOL3MZ?R)F>SE04W@
M\8@I\;9/(RQ3\LUAM['X\.]V$3D^O03S7^#0L =T03GXIA;H.*F:7OX&4$L#
M!!0    ( %&)C%N89#;N_0H  '^&   5    96YV8BTR,#(U,3(Q,5]L86(N
M>&ULS9U=;^.X%8;O"_0_L.Y-"XSCB8-=(-G)+C*>9&%L-DECSVS;1;&@)<81
M(I,!)2?VOR\IB;)$\DA*BI*<BQF/^![JI?B8I+Z./_VTVZ3HA? L8?1\='ST
M<80(C5B<T/7YZ.MB?+&8S><CE.68QCAEE)R/*!O]]..?_X3$GT]_&8_154+2
M^ Q]8=%X3A_8#^@&;\@9^IE0PG'.^ _H&TZW<@N[2E+"T8QMGE.2$U%0[O@,
M?7]T@M%X/*#:;X3&C'^]G]?5/N;Y<W8VF;R^OAY1]H)?&7_*CB*V&5;A(L?Y
M-JMK^[C[6/TIPS^E"7TZDW^M<$:0.%PT.]MER?E([K?:[>O)$>/KR?3CQ^/)
M/W^]7D2/9(/'"96'+2(C%25KL<4=GYZ>3HI2)364NQ5/U3Y.)LI.7;,H33KT
M#2=9<I85]JY9A/.BUWMW@T"%_-]8R<9RT_AX.CXY/MIE\4@=_.((<I:2>_*
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M+??+R))CFB5R .N%Q)0Z/]T S!JG'IHN*$X <_ I2:WW2\KBD:2IO!V :?^
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M0'R&6&,7)01?)<\L)95/!%6>8\ CA2)'?';HL8<S][*8U+P]]Q0OZP@1]Y6
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MNR_JIT@4=IM;.-(C/1_JK-W:WP_4T[VG+VYM.W_AY;R;HZG"_'N9%]%D>9M
MOTOC,1Y%.E&'Z7R>)NJR2$<?U7F9C69 6.K?80;T5N1W=.7V=E]$B>PR2L8:
MUZ+/[OYD!KV#D[XZ[)^<7)[W#H]/__7/[_:^H[_/>T='YN\OWN5U-"YF^.C>
M/UZI89H!>G=&:1R'BQP ,O_ZCM22UX.++W\!,+DB&H6QN15PY[\3)>?UX.BK
M ;YUK%_HEQ;E@Z.OA_ V87K]X<UQ,BZ! <%-8XC.)A.= 1)5_Q/(D@BN_$V$
M\.&-OR_XGPL^S"=TH][<#7'<'0MXD'SK2(? M9A[O?P&O.D1H/^NN>QZ]4MU
MBIE6/\3C/\KT%9 @$-@B3)9(23]D]&%71;E:Q!H(;8RTF!JB7*:EZKA?\H%[
M/PR\9>%9[QN0:9G*(]A+""OI;!XE:9Q.EUW5B;H* 4H7BS0KRB0JEOBJ#/22
MZ$JK!'9\+<2.GR\,!\AG8088 5&)OY9-_)#E^+8<.#MQC1RY1J 6\-*K,"YU
MN_7]WN[>WKX"3957:,"&93<5E(3)&& %8$. #9A6$<%C44)OM\SJ'% .2X:Y
M&NM)E #ZY D =:'A-U?X< 0W()FV6X:)=<TN[$9S7<"19L5,P4L *F,I]1 D
M-=.9!E34(#?K5GBC!7^FX[$:+ND( :91FN01'%Z(VVBWX%U*\R9P!7D./P5]
M?J;".#8@KKPE4&$-7GPLA[L>%B7@=Q%.M4"\JP:,BC#69CUWC(SY=HLY?0F$
MD<5+?%/C:V_:O;JDA:LX $B'6B< PA2>!IC&>)_R$I\'A/)!X5<&+WD1%B2=
M<%]OP<I1ESO/5.=M!!LXA?T\>_9LY^DO>R]^WNO6 ;KP%H+K).OX\# ZFI]#
M"AR560;_C)?ME@8*Y-L#US  2PN>U>;2K3N9VMY@Q5@7L&L53C--;PE W8"C
M'6KE7H"'CLM%.?X6;C/\S4=&>FG3FP37N^HP7$0%\+G_(-\ (L]5D@+JX#?9
M-4)JB *O UQ".'MX^RR$M^*R<QTFL*I_FX1ZD.V97;5;/GGQ2MW=;RYT_AHM
M^0$*(KCC[9:P9SBV/$)R)P:/FM_7LT^UPCU7"0!>\_U/NWLO'+N'VU,G4P1C
M7(.A2J;'-7YI:<22(( Y*>$N6XX)(&UBFNV6X<?X-<M1%1;T5S-$C5R6?VB%
M7B/3K?,E0[-F>7^K0.$)TOM0PVOLV8Q*VC2><^5LACI.KUDPXI.+<$F<J[HI
M@?0P3DFR' %_4PT$C)@"T;S_E,ZJW?(HOKX!_ZM#_UC\G02^5D O ;!(CZ%;
MD6LX' 0<N9PF88>*1IEXDJ$JCZS><;U& /D\JB)U?"Y\J5EO>-X)NYVG]N;"
MQV46%1%01F]4X*?[OSQ[1I(U!)R.]1CNK7M5]?':MCT5J5S@GZ%*2O3PX+(B
M;3=@M$%LUKP1((W^*,,8EWX*9K79@WM)=2E&\:J@K=]#.B22^B"59M%H5N'Z
MOJP(G>QKMQ9$'$Z=L[ 1X0<J+X>_ ]()$6-D>71' ;&+++V"JS-NDC&>7.07
MA4,0^-%\KL<17.!X27?'"JX<#JG=0H&'V[=,(9R@L"4BLM*5[C^\'3\-%XLX
M&M'2JZQKJ/%/LQ:HGO0T_ /N.OQDV5V/I78+ (=]@_*2%!%\L#1[1#]ME9%$
M5?5R9]]3,+^]4+US 0J;^!\[.^IM!-SWI3H'+OD*%OBC1/,(?OA*G2V0/O.7
M^"(AUE?J5S0=X&NULV,<)T?'OQHH;W)V_HB?B>O)?'80A\!3]@$9>1I'8]BW
M\W_Y_JZZ/TQ>N=:157-XK7I<G(NKP7%5/9-83^@7UD74Y)KW7@?/>K@U6'VE
M!LL%O+^7A<-H]$J= JTPYD]3Q.>^_Z,GYE?XC?/G&%_.ZR> ]H83&&8Z_+C#
M0NLER;ZJ"_K'M9& \^HAKH2$*F_T <4-\'7XEEK9GX]5W0MMT)<W([R&$[B(
MA>Z *F?X[EC'P"Y1#(-69)2'5>4C($:<ES4^B&)PJM'L@ 6!RZ$.X!F4+ 57
MW>PBJ1JMJU7Q &98$NL\)Q!*X+0Q/AB!( );"3[-M&]GTNL;A'W0;H%N681H
MD\,1 !*S):J[!<@UDABQGH(&P&\A2TK%83(M\?X5RP52,&F=(!0KVHNH*0*<
M]T4NMMII6B!N4$B,R1L!2 (C$= CUIG(:80N Z "(T3T%4K08A86A-<5.7Z=
MEO'8,_I&89EK7R6$A?6GD=:L-@YU D<Z CFETNL$]+-9M&BWXF@.EB3Q8M_C
M=. >/C,/JQ/[;$5MJ0@YHW@][>@-]D(G!>4CFGB2&=$R-IIY3=W6,2\:J%]V
M?_GE'S6=DQ66-$'I2THFW5*G):TQH@W:#:X0S831=@MMZ1N0.0\_1?-ROEX9
M6Z#KK2CX<:MO(5V!73;"SROJ>\#T0^<4QN@. #TG10(E^P40&P[UDMP$3 $
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M1:C4$8:P,Q?&;;C?)G33< W1?0&7F?D9:FP)V/T9,>D;.$Z[12S'<+KJ/:+
M&%K'=,DHF(T,@&@2)!]+#\\GQ.9XL@P<K9$'!]4_;VEC[X2@OPE;)IW5<X';
MY)-47.&BJV[SE>XC;;(2,'C7;[?.WK[M7ZC>Z9&Z[)WTU=E;-7AW?*DN^X<?
M+HX'OZEWO4MU>C90!_W^J;KH_^OX<M"_Z!^I?Q\/WL&C??/D<?^25NG_G\-W
MO=-_]=7AV?OWQY>7QV>GZNRB_J3_Y5OXW6_MUN6@-^BK8WS)R7'O]+"O/IS#
MU[U36++__GR S[Z].'LO0%STZ),/IT?]E=5[AP-<EJ-\ '_O?1\>.U(=?$XV
M7WW<1OB O$Z/X$>'AV<7&"<X^2VH(>1][S=!B"+<P;JPO\NS$]I[_WR@SC]<
M7'[HP5D-S@A\>.IP</QKOPHY[1< &S3N ># 35S4%^O]VCL^H6!&%2L!/@O(
MZRE8__02?HS?()R7'P[^%[P??A_0.RI 7/3_]X?C"P+CDL^^CDA""*U,**&#
MH;/OG9^?'!\2*'QTWN].>O^^W!6</C[J^?+0U]-ME.LNHUQ/__91KJ\FBX<?
M\SITZ@PH1^*8;C"2C.K%R@QY^R4RA!H3:S5U-[1\ZFS]<)A>H<<9TVK!^@;=
M/EQC.6#@"7.$9267EED/I[E$#L\:66]K4I*L<P62MK=YY7;+-WK(GM]__GSS
M*^ =T7I0*1,$#CDBXR;EF)PL:-?OA* ;SQ%&=.9C* ].9X/-W>5H2%H6@C T
M=MD(,PEAQF?#,9(&FXM"!YS7"9;>$.PO> K3,OAP9$U07FNPAIRVM&Z[:) +
M:%=I7,[)V(6[F0#_3"<[M'OKN2"W42>ZVHA!CL6 $@UVQ<V(V^BK<"EB!CT1
M)< D7XX@]+\PANHP;40062,=;\-"-FRPJ]J:GEWLG7&^FJQ%EHY/D;_#_U'<
M)$*Y ?:*"6%2""9+D[1,1K*:1+DDW 94.9DTI(/A#_N?1C-T?I"O"'Z&%Z4A
M:YV_J:;S&<2#813#<I1:-HHQAIA+XCW'Q@ W'+UT2QYI01*F+/FK2@RI&N?D
MN"3Z=-";DVM*P>*X9]ANP4H8WEU$"<7[V (;4.4HX+LWI</.8,$"4ZMLVE0%
M!#P[>U""->LB3<9/A )KJV)XE'@6?HFW9YY>A38"(,M[D=#4IF'BNP1CE7@H
M>33-5FR<+4HDN8K2$<CN'.$:89XFF*YE8A444JZ$>'?56PR6DANR>>?!6B)U
MK^?+-,$XGJ2>BG.R>EB>HQ.3_EVXIHYLQ@.]M\"\3XSDU0E'Q2G<RJQ./N09
MNS2A<?'N!O1\R/L+$Y4F6G7VNWA<G'UP%%;C1S8%9%E+*!7DF1TU'SOBP'<C
M5+T':^0N(U$"3&%#$H;J$ XF40;WHK.?%Q9^0-JR3D G_)L+N7)U,@K,!A7E
M#%-8/ZVDOM0NRJ8=L3]$$@C8[<.7@0+Q>!W\W7BI).+!QKR'3?<>Y "3.?GD
M.7M1_+:5YZRK<Y'AK1EFZ4>3@\-W;)'F49'"H0XR4+[L*5XN<U!*UN<A;+V/
M]U:[/0:A;#(1JLDK]C+P70NOPB@6J8HQ8UQT-6%F$2XY+<(P7-010,M@C3;,
M.7<!Z"F.@.N,*;@S#N=@J.0L[E"@8]ZT6N@DC L@2RIN0K_B]_O!WMX>WM@F
MC_Z0RMTDKOOKOWOG7FV9"]'(]Q3@6JO.HOH)4L!DVC3)NZZ7XC:AR$1%,JTR
MGP# WZ-$9X_GD/*!4H;86JJ^?UIY1-@J+M)Y46%6N0@;VH+@CQ.:AWI:TD%B
M!*[478<^_[U.5#6P.<D%HK4]ED4I(6[71F$U#EM781=5:OK4!.X-:7>=L&MT
M"GC4L,_..O[9K>52,4=IMYH@_G)I\35LEG8XQ W"'=F(00]LD\Z/&AN:@J!\
M@.H,9/\1C#YJOQ%R;IL?[^FN"S%B2$P0A^','!34?&(60*E)MD*MAD.*63(R
MYDS:UDK>?_,;6:>R)F!#-4(ZH0(A!Z/-X?_ZM[I8KA&><)@8?$2"Y-I2/%N;
MIR9WC84_W<JD*0V3.%9"<>IP3N+/PLIY7R,TAII%8I$6\*0MSN",$L]X8&&)
M'I>1U>:%I_$M K#0F%O ]C1&U.$:Y,A$.4+2M4;H&HSDKC)D?.-[U9K7HH5<
M?R]Z$3@K*$NQ,!;?W.EUZPF/ZVC()_7K,'?JI'=5ZX3,&1*-A)PP/V4]W?M1
M?>EZ(3&^ B0=1HJ()I9. ?6MP$#-R[B(J!:CW0(ZZ1QP_?*UQN@N)BQ?,3;Y
M@#%]LPX*V=2T]YNN\2/,SMGLAWZV]4/?I1_ZV=_>#_VW\CP?3Y!1VA1+RM!!
M-X0>6Y><KT",TU')SBGRGU+.H+/$JCF$+ DEHT@<-_#O%,0'^UQ]4][^M-WB
MWPY!PHI?F\L)JMZ!C1F/%16<4]":# E1%!6EL (+IW86F/(SXFH2%B%S?"F:
M$URN+I+;0TI.3G@]7\2D.IB,Z60LKYFPB_U07)87&A45VRW@YYW_<M:OY[[S
MP<!5O@8,\5A5XP$ #OZSZ9VT:%-B+5I+"0IV+@(L)&L5UY!$='(!U9UOUBW9
M&Q6-3BS89*[G41(:Q8T4@LIY5 _.I9B1ZP.K<DURF5?^R5YAN&^"1+S,'@K1
MTY3L-/C6G>4A:U>=B('1-"FC,?=*SK%0" P#G0&EL7LBQ7_B8:1+=*?A#Z?L
MU*5*\42*3>PI?,9!4I6YL:,#/]"RX/O>;GTQ/D'J)>EUK,=3\23[>8[B-R7<
M 4@3C$JA88W]5[Q>+2G@<2I>; *4\^S\%A(SJ;3*T-QE,R3#<QCJXAJ[;520
M[&'XLASFT3@*LTAPR%\55$3E5?PW81^@F+(Z5CF&W@0)  -MADN@HW'&>4:P
M63QV^?_&AVDC_#C?.&Y5 \]4_:CNI@9>DFPU_Y939NGXO$1U0X7$D?FX;G#J
M>@5PUK]KXX&YM.>PD1W*!Y=8'ESPK?OLGHOHT[3=\B0?\_!&_W+=/4YN>A84
MPNV$(6+Y09,$\80&1=E,5:471N*/JC$D*60;C4H7$XC3$7,A*64W!47\[+PL
M2LJY(RZQJSYPG:37!\9S\K[;/=P%$HB2:TZ/_2&<@VI\F(+8/SDYK >ZSD&5
ME^@UN=&J'O4<1%LL2<*3];3%>[F*0K/PD;'T?@4V4^:@,%-=E\DW]S!T].MY
M%3N=:%?O!C>VN3#EJNOTE 98O33+J+'8) GG;.^"V,@H>FV3NVM!$O@]<F<.
MQX^-L+"2O!8\X=.)EV85\?1C>:Z8Z_84Y!<L.R81+<F*%</ZBOD?.5P6A959
M]>ALTYKB#C;*)15;9FF"1E1L;?.FY01LDQ(;F/JW.9>M D(I(6 F@L]V64*6
M.P_'NHX\05(=OH[DL(\ EY1$ 60[[^+3UU$FE#=!<5E=3J*G/O6:2U.[LK8\
MR H$@%QGHL (X:W0;CW.M&7]]Y;U#_S.2!MU-=)-/$6LXF#,_;CKJG*/H0A,
MW9;L?@R/_)Y&2>&T4V]EJHEW=10S\?^:?^5-A<NY=3R[WCC5KGRJ@_$#O[H'
M[NL9_6*EA6#7US(E<&0W XPK]"(J?M(),0+7FZ?^GA6BZIE%JQ+$F,75L"<B
M;<A=J+#A$#6#8>OUFN2RN#]U1M:&EVU?.S3\A;]O6\K"65*XA69P4=H)O%2Y
M3W7ZDAUFY$-C?S<^<B4&?A%^!'V\XMSW"D[8[@M6BJ$!V[:\4OO<W6++WU,N
MT3?0"*1VF-WE>9Z.HI"MFU"N()K^I*UDWJ7[&*'K>:)0I!1LEF&(JS#&?#E?
ML"MAU<7?"$U6.2S$!.".#36,^=#+$>)IEI8+I@HQ/FQ&4>48LQ7-BELX6)N.
M\-M(B[4TJ K-?_YN*,+9L V@F3^W#_5YVY#3NHFP=MLMWV2J4A:;G-E\9=M8
M H8<=Z&)[8)8)MW2A&Y$$TKT-"VBT(\(K=T(]EHCIXUE>.'X2BKN31&:25IB
M;>HJRL'&9$%M7/:VKP#>RIBIH@9GEA94JH:U_NAW&'%"%*FU:"=:3XW+(W2]
M#%@)XF?AE+D/)SZRSFW#M&U=(\*B$HT1*.PA,JD<DTV>H>902'UH6>9$F:Z-
M *)Z::@%]H-])4BU2473DK+_1QB6>/ *A$N?(+^%4>G)3:(F&M?)"["M0 A\
MTGY\S_T]+KE.2U]%IO_&JB_+1L5$GJVTL[7=0 >-W,-2$LF4K!1?M% ,]Q2A
MBK!J3J@I'L-_4Y=4$U+\+<T^.H+B D_V'R*+ ;.8U1'ZO52@Q@A='U,:^,(+
M?XA M[Y*1Y2NQ]D;N1?8C<L<G5&_ET";XVCDLQY;S&;K*(&?9.C%S*/"\&EB
M_.1<\^$^2#D!$SY\'R8S+,%U[26Q8=TX&EDV1QTTHWQ1%EZW/"Z3]8\*OR*\
MI9E7&>L[^AM<VG\3.V%S]/'Y-OIXE]''YX\I^O@(!M5L9V[<]D2+&IXK@S8.
MSQ#-I__\[NE7X/2.5:++"(T(C9U^$%P,C^1!\UR-[8'=AP-;A7M[0O?IA#Y[
M.AIN9?.$M.W9WK.SO>_49R7P"U+4OLEI?36(_[CSPSI8;IY\M5E=_Q*E3O;T
M_!MLBL_BKO_WOM[P>WNK[_C4R:!Z2 !OK]%?#-8 G=7W;_+?IGMQ"X/['M/D
MT;]T+__7Q$$O;6-3\H:\I52D_/\]CEU^A:?PQ=93>)>>PA>/R5-XZP[T>\^S
MOLW4T9[4,G"-',6=,2Q[RPW]UFSC[HM#;EMQI-P>F=%*%19?\Y\M;E>YY_$;
M*QT)Q[VRF*49#4'D+U*.EII<I^,WGX'_+:+77^(F!'_QE=XBN-E8N#T,;U'<
M<(>IX)=PO))'V83@+0I7Q;Z9SN R3NJC,C<.TJQ/UI-DB!16TFF9QY(HMG$8
M1<-1;4]JTTGYQ?^5H9TOU?>"0-5Q T#]9@'=!Z:6/DA=>G4H>?,8H(,8VT"
M OG#__SEI^?/7ZGG./H*,XW,!S0+:TL,JYQ?7SODKO /U?%GJ7*KD!N'@GX;
MRGC :-[>X=M%[M'@L-TZIK1-3K2^/5O[_CD 'Y0#QSIJ:Q.HBE3U3W\]4,<)
MZD*4@'N&E<>/Q'/[^L">G9<Q\3D.W!^W#MR[=.#^^'=VX-Y;DGBX6S*CJMHM
MFE7U>/;V:(I1X(0N:K/IK")F.ED?VN88U0)1/-)J@PTIR9B''S47.KOF![4)
M>/XTLDC7YN=^^^$^?TWU\S:3NP+PWN[3NT7[K>2^W3Z48?=AI 4!K[CL'S)\
MW#$K;V !84[=M<;26)4>"U2.(PK+&)?'Q%HN:RNDJ;ZK:G.]S/RFCT,M2U9[
M/S$D;MZ$W]K*[[#ECZDP$\7WGV%;6C >]U]TQEUN,($=R4P1%S8@6N)@L@5V
MP1A7VK?( ,V.E%<R&/D,-LI##*-T;!H]-';(A%W$X;4,-C2#+P$V:DI&!9NF
M*U:7&ZF@*C5-$0;S15[O("9MP'(&QC0#H_) BU+X19JAQU3JA*DQ!2EXA0R/
M=_7W<-#^&=NYLZJ7-W9[0L3D7 U;OR,R+$**!&.O;9K\/G?U@DV3&_QCE<KX
MQ);J>W &/-&3;DK@RNP9%CR$,L'"16\((S6VM=!@/UUJBN :0$N)8.V9VM6D
MA\86A[""*^>EOTT)+\*!HM%5'_(^Y9>!J3>,J:..;' 497!^/)G ](RPK4GA
M8L%/J?])0+7$\RB/-?4>JE*EC,RP75,,4KB/3>:W@C&S6?>?/\?>W>O&N>QN
MTP,? UC;7-+[>"JW"=;PX6@7)GY-$O$5@]KG"G/3\V55V;!B(X\*+$\7":<6
MZ;7TXPAYV8):8Y$IB)-^6#I*EY1R/C?]VS=TI$!X-K8)<;W2<%VP;I;4#(+Z
M57A-/+SVD8.9:=E*?=E<@_SEVA82'ARK?3KL9G"YVC.?VR95!@J + 6-;6G0
M]Q]6&E" 6_DF8D3*ZA/;5*[>24CZV4S*C%L#C<S@Y36C@0)"V3 -,^HI8QM(
M*NG>E6.7;=/<"!OB(Q@-M?3KNAG@O7$;K+?,]: 6G<(U(5W3YX :P#(81I,T
M \BE P\]=@7DPXT3AA$-P?:N11UGTEJ!1F^$4U!E\FK3]09(J/4!0A(P*#(_
M7$9P4-<2WN54)]3P +%/TXV\'@M,,FZ8UC!,/F;EHACAJ21Y&E^!RDB3?=-L
M&B9"K8&:(]G!/2GGCA08#-,$PKQ5%N<;SQU3,3[F")WF7=',&CAS:9QGFJS(
M(CAUF*9.5#=&KZ)^4S):@QHR\ B3")ND,D38>0HT3QP<X?=_P@W^7B9F<#?H
MK!/7)<OAR@Q",:,O</8%(&824DLB]"',$YY)86@:J<R.+*=V?S(F@%5":F+G
M[<+#/FQHJVD]"K"VFM9]/)7;!&OT<#2M4S%'#TVS':=;66TD<*H(]>*L]\EK
M$JQ?KI58AOQ9JLDXY3YJ-#DSIOY9+TF^F:Y!RK30N8K2F/O[+!W'K<E8VY.U
M,NZ(X(%-X>U'>8@-QZSGA/ R7+)(,Z+!%X0AS;X9S4+R!EGGRRN:91G5(>4^
M>4Y)"+'U;%C&HN1UJ!N8--NGGFNT/=@U=4++%'ER:5<13P\= D3J.BUC;%X[
M2N?>DF++H^3.X4_C;: N?5ZK(I!Z.&ET%(>1521R-OV7/"%3Y^AL$:F8P :'
M&7LGX/WP+O+H< -MIW3"$2PT=QNFSGVY7NTWN=JZBM SI6;NY-9*^:TYS_EA
MA0 7D7;?W*40\#V65FNCD8XE8XWG]0&8L3C<.GZS)=32&:M!,TZ[\$'@7$G6
M(>0U=I,I>Y-P1)H&DL^P<)?$_B2B3 PBEXXW5MA@H?(K'@JULH;G^43/T%B4
M'?8+D0?1<_R$TB\KI5E:_(Q0!1[)TA[(RGF@"EZB+I>)GJ;'YAY[%YF!,=AT
MERL4&O3O5G@-UZ^,=>"Y/@-VD04XAW7*J#1J&#.A$?5/-SCPVJ:;9:EOER7<
M*4XV2G A/!_?]G,C?;PMYN7P=UT="&OZ@=&\"'(!YL[W1:3/_9C-#G#&L(==
M=TV^"L6!Z.W6'XCM)ZBU)O8^JXR"C;I.!Y5YHR'-<HVI9:P8)&C.T<G8L:;8
M$?'3@IMY U[\,W,W>PQHA!?+(%8ST$ -RSQ*P/P+<'?LOPT\\@YPT%DFH42\
M(]RF4/C9!,@TH<2NE1O.0! ]NQ5J^ JD%RIUS+P& U 'TD@-31]1\6E,% NK
MNN5=C1@T"+ UNO8M%+?6(Y$_W=-13C]M,VSN,L/FI[]SALW]H8%MZ'T;>D<H
MQP_'9+N@P1(L%QG0,R?8V'SK@3:3\G@/3]@O,K2HV)W4H>[#_@@O,R\*I&IG
M?P^TNC &_3D$31['S8KX=7,/&F1F-[!!Y]J0#)FRE7F0^]%7F;9UN?.,#!UI
M&[] 72+# 3^4*> 'NMTO]H/ZN-E(A#N:AP7Z;'%9L%^GV/>]RR:@[8K,,0,S
MW!3_\BM=9""%V*E>#_W:@WE]S,D%+6F"W]ZF+\VFJ['TP0K&<!XNSO/$4@%T
M<KIS)$6,PND46J#!N50M1;MH?INUFL04=..IY-1QP>4.3QI^_J)^^ V3:[S4
M!UDBIVMD%OEI_2+NDO@K\9QH.@;!XZ2DO)&K2%^;22YF4,":B^0<"C(TK6M"
M.Q^U7JQ#$\-C<>4A!\=L 0P%T2@/14Y2.U6AX1JDUPF;I-5/LX9;M77F/@JP
MML[<^W@JMPF6?CB:@1T;CS"^IPGCSIV[WJ6Z:?X,I6Q)22WQ0A28I8D.>IX/
MRP_#?!S^H0[#1508_Q2#LN5XCP*L+<>[CZ=RFV!-'@['>TOS<DUT BO3;1YQ
M#^V'JS!N2$V6)$@_?3,=8I*H.)%IE4!=AQCT"FS>BPT?<"8GYG9,24V$'W',
MP.C9Y(RD#$_\3H;Z<IJOTULYKF'=ULZQ+5YGR8P.:%JC\Y.N<VO;[\_!2#%:
M[9HA()\3VFO*&6J<8R-C2&9APA$X2E3F<[$H9FC\_.LUB[$KV^6%X-1"3*3E
M0!>F;:'OV\N+,!,V6<98HRZ6VNL&+=UXY<=-MA[]7I;D7/#$>-\I"H0_ _PD
M%'\PUX=CDH&$0]S^\>UDIQXU370.'""=Z*K+EHU!7,BSHFH9QC3?4":..10T
M1B:VTO91@+65MO?Q5&X3K.G#D;8GILF(9&H@+R,W4SKZN+8&T S"3,FG-=1Y
MX3NPYB!U2?)6F':F_BC3PD:,#=\T[U)FI#K"41, *.8HNAL5*.?=>%A<7,L<
M\<K<6,>:>01KTY1?Y+843\15#'R:+*)TXAQ:#0(%'53(V&M@DK3-9#@NL6Y=
MEUN\^)>MNRLX\39@<VWI'%;<I21'^'PH/KR":Y2&((!,%@>M57TI)NER%@[Y
M6]E-JZT"PM%H/]5ST\8"E].#(5X9?.AG"V-J9>Z5UE@W:/.ZXMZSLX6'6JZ"
M/<:Q16;3[O!]]J3PWVE.(T2KE]UMGZ"F.\/@.@>\^*4K@ .514E9/7OR60H,
M,N2P?OO#IOLDB<9DL$N%U6IA52WCB6'BZCRZ^Z*YN$H\/U_=U0"YS"?V!@C>
M:[>Q@B+'""I$SZ[Y:D[NRB5$M<R-D';C\8H9SU_#'QS!)O*(NC4.,N!_3G7%
MW"G)4LHQ<S?*9]@XS$Q^KJ1TN2F/+IVE/NH156-@EC3<<FGRE"?:52]O L6[
M:#=!4U7?O?0:6J,!']\N:^&>)BW\O$U:N,NDA9^W20OW@ 0>><Y"+<9O4'!/
M$P=FMZ.^WW9Y?CG,B3I%_>ECS<I2788@JUE3?_R2XAND)]6[A=SNU,=.U&VW
MWH+JN1(LYU@T1]I?=#F^'DX*T<W$CE%'Y#U,="0..J>*)3)<&J])-(Y0&64[
MI]/K<B5X4*V/!-7,Q81P=#8^PXI5DI;2.8 ^Y;* C!)!4^S/ZC[D'-VJ*IM5
M_\9[>H5I QPV[QQT)7<$T[PK,7LO?83W8M.]6<D">\-"2TDNIAOCFMR!CG-C
MWIQ/P1T3R*^)=I-4[5<=?S?"="-(/ +<I$-(5]PY:=8N(0+@()/<*OCGH*WP
M[WLT.QI,%MQ)+J.D<<V;$W%^;O(<$QK!NDB7&@UY;,U8J$4<)MU==9H6^(Q)
M0@>\^.TJ G;WFIX;G5D7'<5N\CF;UU%B)]X3_K#S+YA=ZEANT*Z785/[RDNG
M47,-RG#E/E*_9FSSD8OM/%FYA>F"+1ST,,L6,8-Y,HE&FLM-O=K3J@7M>[7)
M8U!=DS!$]:5 0^,4)QZL#&0GDP)3KG\77SZ_(4F3'8OPN<;6T_;M!Z8F]LBO
MB5U=P_M92!E%V-.",5)9WFW/MTKJ@/('.KN*L,PCTV@/LG>ZDIS=&79-3R=K
M$]7O9<VV<16T?ISZQH@!%ZDF2]_]31GJILLJ;OP&4,@G@G #5ZFM(L$262G#
MA'QN09).I& '<^.]"@1O >*18V_2-X#ZQ$9IO ?E!>3+]]Z!?[=;$XHWR9L*
M=#PP3UYSE>6E9+Z7A:T)D:UL3-\+)#>.(AK ;>C<'9CM%OF'D%RI8IIX&SR;
M1X;];UR=I$:"-4:2L)90*W6;TN7A T,P*9=[F(?M&2RP!S@<E#T(^J!V%O+9
MZLH^DV]@<$RY^2*.6/P N0REG(C#4,@=/A5:BMFPVH@(J?8:=F%U1MV&VU!A
M%B-N5L#I$W ED",#9QY5:8 2(:^D('B%OL>P@M1BH3A:QZ5N.%P*-IF[DQL^
M:RIL\)3MHX;-=N"Y,8B I-HJAE+NVBWN>9"D55$CE5H$@82V2%? LJVB07ZN
MD5/5HRM,D3\PV<PD*<)NJ0\2\19IQ40.IQ4Q%!A?K(<=HF3$D%5>6%:E"=?,
MX.%)G)52((6O4&7XTLL3-0]U33U0E%-' QT3^S#>*^ID8%0QN4"F]H4\0IX?
M"W,,F6S"1$J)J%S'5..H? G?(]K@'EFF:K_E6]%N^869O#?!0(V7JW#,=3MA
M;$1^3B^4C\WC$1!?7EA?&# \V,6P+#PA+WYA@-6[WH"2I+D<"U&/N_<N*= U
MJ#^@2]LPKQ%+\,XLC$CK'7'FD9 KJEF@+!=8D94R_YBCNFL1@F\BV$EKH3Q6
M\[[=.S(HGKW8_>FO:F2_V7WVR]9]=I?NLU^V[K/[0 ./P#%P@V< ^^)U]KO<
MN+":O5]U#JQ&.H=.=J+^C^_0MC4+:J=("_AO\0S4' -2),H\7&1G+9.HP?G0
M8)"M=0M0*;ROFBG:-K4\Y(R=";9AN4KC*PID 4?+(M*M+Q!/ R=[?'MR[4.K
MEF5%?JDF\=5NH7E+ZA0K=CJ.N2[ U'2SIN#+-M8[,KVBZ0<5@X -!&<O !N0
MRE<6KI2?2VT#L=$@MJR,KN"</2F^QG 0+Q$Z@!"0%74ZJ.G@%6N(^FQ9TX:_
MIPUA63/H\* 0HCD5&!/HBM0<R8 3HX\[=&9D6+)U97, <BOOUP O*AMG:%D_
M6 27@NKLG0<*+#Q4Z]8?@SB=V-_A(2%H-@.K6S45Y!1E9L<.ZF>H;F/5S:2D
MQOYC:BZQ$4RU 4K2 ZUQFHXXD4%^QKV,.+;-L66RM:DT)Q<;/U[RA3%_X37A
M1'#1Y6K*HA^\=!XH>R1UPJ4,/N(2N=Q?W,*$NT%4:4?:4-C@,%FAJ(29$"QI
MD*@[FIY(N!RJ=(P1,!6T:Q&E:NZR'8!N1X U?C*A9.KF1=DI_OZP_Q([-GVK
MEZC!')WF#A-HR#%1X("D;!P+MF!5-N[YFOK&'F=!>(W','%T5)14W$4&M6>Z
M-ZXJ=]>MP3=._/RP"G>UP-8,P-",08/\*\ /9NDU7(.,_\8;&]0D@_ZTB#++
M4:4RCCLL *QB0\%])I\$-AE+Z@Z]<)A>B5 !B*CK*7?70YJO7.\USHOD<_V=
M1*#L9+S!W^GLCR&>'W;LVBP3,&6!NX\[B4@F1%S)%'8-PHA^L$-84W,V;$$
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MDX.SH]^0RIZ\&[P_>?/?4$L#!!0    ( %&)C%NA /0N&%$  +L2 @ )
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MWK]?1J-T_#PXB:8)S_Q)@?.Y9__H1_4K_,:82\I4>O$C3'O+"HQ 5?JX/4I
M-8*V9[2J]JK\U!ZN@ Z_=Q=1/E9;Y[W[1KNC. #>#@_VK#R 86GI?I#"%4UJ
MGR7>Z1ZOV$A#$1^378"RD=7..*E)56?9S$9&6=7*H##JP3B+0/BRS1=$LUF6
MHF-C*QJ@58&/V@HKJ ID..1@F56@.J#0A][0WW)C<@1OH_)C(IK(*(V-*NPW
M2/TGY0;M,[@ X A5K.++%WF":G<-38 12HWC4 ?]GAA3[BNQ&]>7*=XM_ILZ
M>PZW49F :5'S7!UD13$=)>5%\&;G/5ARHZCRAX>&$5DN/S][O-OO1<KB"WR#
M#S2W)\]V'QF;T'\"[!10V7&JWYT?_K\#[!7^Y9\-*\Z9TJLBF\-T72?H(<(1
M@#R$,]WO+9]G8R.NF%P<K=<?F"3:'.-HE,%&VQJW[@_I-EHT;3--BRWC:7D%
MW/W0)HVATAO#:1Y5!6I:+YCL@O=I_A'N/_A&]@&,$!8FJ%(X?6!3%^4%J+W_
M9NL1C\P%2.H%SL@XX8'#4J$O8S+/Q^)OF,A;\%ONU("G?UK E.&,@;5F=O<,
M=!-MY9F>]WO<]:K0G0ZQ!UOQ@!0>L/4*-)@#]/!6HKQ':8GB" ?"'AAH,NJP
M(<D2M ][E*->E\!DH&C"92LCL!S)+9*!6L":UD51Q/@B4,Q$0+"[IN)W3:,_
MBA*W:9JS&I@8X2&&AIRG8EY7-:P=3A,N(=QGH.3!-H&>P.S.:MPQRH812SVD
M'1),DH3=/LDGZ"U*(7@#'U]M!<^B5(LP^?5WHN\]@&&9.ZR(2KC%8'F/R. H
MRJIQF?%M@0_B-HC5<]9QVBS^?1J66?QY!;*IJL@3V5QV5E\6(@9!#P')%M7S
M,D:WY1D8?1$9E_PU_4/=\6AFHELL DD1Y1_1IT$N.+I?8=OH"Q?E9C2O+T&D
M_1L='M!<"=HZ;#&2+5ETC0*J3*81M##."KCQGZ-;1OE9L=,A?G!97"=7[--F
MW0O4)Q@^.E)2M&P;/6(YAE?Y")6R9(I.VP+_<<O^!/&<I*A,*XC<!?JV+XMI
M(M,9ZN\NDPPD-BSM]@QLM<;W>9%OPW*@(Q[ZF4QG6;%($NTW$(V2Y]M<H'PW
M8$?!.D_5)<F7-'9QSG<3_G1VN:C0/ M&<$_ .F7%6)SX4<V.:#K<=!?S+RX*
MF-4<';'P*YF9>@$W5@$_QHN%I0/=7V61IV.\J.,JX# I]G,!NL:T"K;2?)S-
MZ3+"Y;E.46.0ARKRV-YXTX"* &I5ED$WZ-Y%[0+;!'49%VD,QP@FOZ3(A*A6
M&^ET;X9E!P^F:57!9FSQGN&F^Y"GJ#.=U: :5[;K"367X:<Q"*P+UO:XF<T>
MN"_#<O: 5M7;%1-Q:5:D<[LJ20A*J@J5_F5W9W?/V (A;1(C3N&ZJ$BCJ<PV
M O6Z4%HOB!%4T_5W4Y#R.IJ&MP;(36P"X[1D6?'NBS=[[KX,JWW/!4.X_6$'
MP4M;%&/</]:F<'>?NH//YJ,J%5>];*?K8I[%*N!.#UV2C<<16FRF !N-] ZX
MXZQ N6U@AH&^4L, '?E@\%F!^9#UMV148U@Z@6L6E9B*?TD0%C!W9_SDM80X
MM3:7DJ>?XJ\2EG;[,2YR<O6B!4G'!'XI( "R*NF?? 3HWW ]A[KU:PR7RN"K
MCM$+LB%TX[@/;]<]],.D 1)H8]1-1ZD'?\!_G285G#?XXR*%3<B>(;KC:3MN
MN0%V_,&;I$8AO']1)O3,(+B$AT8)J(4Q2F7<]XGIA_%9;/2">S8LLZU$N/1[
M^^.Z?5-9^J#6!>%A%-)[/S]^0L'.:(J^N#C4N*5RGHG^6"87\TR,([ VI_/L
M F/R+*,HX+G9-O=E6'K;L*2 3:-$1=O6 3&$B#NT\#.6+)%Z'(1*?8URA3!:
M@D1C]ZR"JZF=I%70.))8!OK8X%;#$$:PMQ?V>XCB#!&65,WQ\G643;]UZ@)Y
M*#36S@8$7&O/;V%P3H*M:OBEW1["Q:[;!GDXURYAKP<VE.4[V?K+ _N/-C'\
M=<;P'VUB^)][+$PW'\CAU *<@4JM:"K"3%VE,6(ST?XVJ%1R ]0Y_/0RG84!
M&#953<:3/,(&^SQW/@%;OABG\OL_"C!R@BL8W1Q=!V1DP3-9"ELW(W_H6(E[
M?I2]$?I#XT6E""]T5N*<%/P=8;^KE".F>(D,C"%&9M)">6,_PAB_$]G[ (:E
M=RT"Y?J]O2=/FNH&8>C@&T?';%@HCI+0Q-D9X!XUA[XIC&.P<LMP0I#)LS(A
M4"D!),B*Q\;@3[+,R94A,074@CFBH'1@R]<5Q<6LO9.7T16Z]Q%67D<4P\CX
MF0JZ@D.8%9(BP-88:!Y6MS?[^KX,2^]KLPMO9H<9\^OQQOSZ'O>+\H0N.O#0
ME7[ ]Z52#A*&;,. P?4VZ"G*JD*<H0E[/2F,:0.IES2-R9P2ZQ6?:]R>BK39
M<?=E6"8MRDJU:G'?NZB%5F0B-- .HMSLAOLRK.9NX!5LC^<T@+B,]ZOLF$:U
M?-.LPE<JN4()/@I8^XP^/OG];!CL3S'M#H=&'T55'/TK.(QF*8(P;+RI?/5+
M5HR6?G-&^ P-Q67)IO 4.M*EO*1;2AU$$":8026YE9RY@>L9[)R+]>6T;0[!
M&@\!@6[0"]KJ <6()[K^0-Y!WXPCDX+M\[*DH*""]Z =6S?"[BJVKG?0\A]L
M=M%]&9;>1;_^MO^^J<1]Z;0'+W> =+A5:0]Q!$/O0NJO2(BX,5!_DP6QR8+8
M9$'<:1;$Y28+8G.;K>DV4UNF%6AJ44 0M0@=!V>/ZXBK#L-2(-7?& TOK@]<
M^4YVSO*PZN--6'6=8=7'F[#J-WHL[C>7ATV?\DC3IRAV'/K@08WW@=Z)$9@N
MUKJAQF-1DNT$]A>U3:I$B&(R54 70V$EMY]U>TI<<AK%"8;?094J.,X(?\<(
MO<,)1K9<3;WWV<%:*< LVB\63&Q^>;18V*<XR9#&:^$I?:Q8QG-0#)-/R7B.
M(WA_] I#^S.*3$S36D:5;$_!B"0S1?X:U74TOF3PJ<S,25&+M:/[*7A5##@@
MF1B\)J;0 G3$(\YJ_MCFM]KI]WX#S5B: R,)C.02']Y*!P0+V]H;.-8@SLU6
M"E^2534G"!H\;CU2$5BA3"LR-C!LATHSIGR>@9*2,?KM/6P:4,LM""YY, W)
M53S 'C#CV\"F.E*!%'BIX8H#Y1H7J@(5.K02G46YEF6B+Z(+4)$P .C1;2DS
M#&P'QKI5LV3,*1@R.<8J;%L06$LG$8V (U%U"=/YU[*BE+U@?)F ZA"7T77.
M9K:;=H2I:L$\SRB-DEQD\'O\EQGHK"S ?,4T/*=[9MK 6ATE,%5HG]YN!#OP
M&3SX<1NL(9 B<"CX&<KHU</4UHK*90S!#%;SC%M_FL3P5^S,Q3S"LYJP$2Z9
MGZ!0X$O-=_ 5V-%1*2;K0.%3FAWL]ZS78F]KS%2P++(%[N,+V3/J2!(_450N
M6K:%9&SJK$P$/$I68X;'%/V3/EP1'N*U44=]GM=P:*VV$3"N1%G,5J]C3 K)
M7!!=P6FGM=!Q:!V\5H]J\+G: +24DWF6A71<)$46WM0RO,X!^"%+: #TMDS@
M&==*')2X<H\'[M&6L? )E Z(B6OM&5=45>H \AS;]BUHDR5GJ,K3\@:KOS!7
M\XQ<$VFN)U9L=W):<(8I'=VZP+"&D4HWF'*>*TV=QG 2_"T<(I!1(G%LT[^S
M>>D<OJ#?,V\@RJL@FA:P55S"/^L\KFH4=_RY66$/>"NCP%1B AN7R1C,C IE
MF9&:JU^AFU4"EOQH>LZY!^XKE6BE6X](%X7-SIQA5X!XSDR\4LC_-$[26:W?
MF=,O0>\[>.F-FB+X1$::P*8?:==+KMR!-DL>6&IY<9TE,;H,Z==H'P=,D@:_
M90^.5D P$[Q2+C%J"70)^$DTNPR]*T@K*RW[T)]?EW:RW[O!_L13J5]AR0=6
M:BY@RG/&78DB1+<$I=73ON*]5M61Y3B<1&,+?; ^ZNP':@E]M6&-/#5:LT3Q
M<;14@X9OMLE#&K33D/[E;SN[3T.;F;>--;5!_MOLDU8K']PR?(;[Z<G&_;1.
M]].3C?OI&ST6]W]88Q:ZA\H <YQ/P?%$D9S0'6Q;HBKMF%E[,49H\D41B6KR
M4"N=A\H?D[(9*D0-Z")HOM7S"KT&I-4IR"K&J21FZN@+A'KEA-=V/<3A  LY
MIM7PJA  <F3NE=CX5\B/8CM8F. 5IV"T$,0'J4-R0S3,5P4.2>W0M6.SC'0V
M=VRE;D.3#9VIWY-1.1HUAE]30H6,9,K02X.Y'*BX_=?6_O;!(-CZY^"_\?.M
M_8% 0-?&A?R-G<M-^9!F"0Z\K,P0UKH*=U<WQ.GTG6\>.!AKZ/,:ZGW\@[OF
M0#:>D>L2A0$"B]KL3;LB@L&#V';O:G>?*L>@3%SLAN?T0,^I<7S8 5OCKHL&
MZL8@?R!BB%7M!A<4<\0$:5N/5K3)/6DT;#>C2UF08V.6Y 12F2BIS>D2!KYR
M6<!;E.3V*!,H1^BGW5U$]D +ISK3@KMQ\O;,R;@PY-Z3)$;>+9OQ)(NNJX'F
MV;(Z'!I_\V5Z<8GPC(,T%J]M&P)(EAS&F8_3F2J X\&G5F"A+&8[]8U3%D)Y
MR:X+6A.:)-49I128VTUY@+DG.FK0[=Y?M5O<[=?M;HOGY,)REY9[X:QOJ!:8
M^-1:AF9")D15MVJ_F/;\W8>;.)7UY([8Q_16![#AJ6J?C:@1OW ?]NHC.?.W
M:AUD6IRI<AU%-YHN#10A,=(\ LX58BHT?8M7Z;VY/N]%1]=?(VNSH;[%CFX=
M#+AG_PCNQZ[2TMR+JC9=\I7X%B5@33K!<Q3+FRWY36_)C8S;;*B[E7'_O*\R
MKC. 1[8;,S*.$D+NDOI*11 3!^YD>=TP/CS&>"W%,*F,$ED15#BI\?!$"$2Q
M'[K):_0VNCXX=+Z9!\JHUL3;41-7LM-^5#850+\-=][S8!2-/UZ4!5R6Z%@K
MRF?H0*V3'UX>@_GB1Y'+1('&4S$E6I9<,JH0?H&_,8'RP(V3MVU/90D]!DMH
MZV<%4^OW?"H1E6M!>24,^.KP3">$[^!.2TB[ACY)]+KH;,GB$;/!"4)$QDX4
M_'GTD;/Y9T7%]?84+(@;M^KB(81J7='+O=W'.T]U^>>E.VC[\1X^NCD:*X?E
MX< 0Y[$""*9<@AZ@,^P(CD?S&CI2"RS,(+&NTI9CI3T&5'OT>]Y9RV/C3S>Q
M\77&QI]N8N.WEDS;NSN/'F1T? T#BSD^_C9!GH=T7/GP\J^._[EOB[GWU>[/
M=(>6\L@*2GC:V0<T7UP$1!,(.L9<^S;=SJ!+#8Z1J^,05%ZG0C"*6%%*!,0H
MH>YNP0A@198RP8K)XEQ'Q71N."#<8(LJ71\GC!;5GX^BC'19]6O2:7%$1PGI
MAT4)G7$8*P)5.1?;DZ>P>4R=0#@_%K2!A[%:3)R"B<65:NPHTM%O^X=. ,GD
ME-,+5,Y^Q"HYQJU0AU *O#1(&<0IF7);^P.#,H%7KD29S%#=J?74D7&:C[NP
M(LS#SW 2 O"VXTED83"H<S!H1;F76-$GO4@52D40*@X619<<D'1_I"+&I)9R
MNYALT^.F%D'5[]E!&4UZN!7!@*9$^]#0R;QL[D%HLF^O)7=#ES.R@W,1L3=S
MZ2=0#Q5.APPK)PM ;RV&7JH'5=Y%'OD!07]OAAK!T^U;*)J@&:REH/$R]K30
MIM'C5W#S."YQ7DQ>B+L*TMOVY!8=;%/Q:3=?J-_K3!@R_&?=V5(=[[U]LA&2
M$'1F&_V9KFQI3@FV:QL9W[Q.@9*CC2(%@QT6I*NCORVY'*:P&+&BH+Q5_+**
M#9-V".4QC!*8$[L6"!U@S@GH..XD N$O,X'_JIUFV4/-7)0P2$OY#<J=PHW(
M^N/T<%MAH JO\8Z:18NI1>?3F::U9960DPT[UCC\QM$?X$X5%%EL4EM@FWSQ
M5#<3%K9FAJ5(6S+6L<<L&*59I2EQ)&\!%DJGMCD79<L*V]CN]N2J1?-G>C=K
M ]F_]F?1PGTWP05Q'2C4DZ7_FJ=,6Q]'T^A"6# (VX*1^5F21UF]8/&71.C8
M_,M>N+N[VR( K1&XXLT0UQC43S<LY,80@T&(G=DE2+V]+;#\'"Z <*G\Y5'S
M$7D5[#;8"NW"<,D\#_1LJ-\2Z:#\F,:^Y->2D=9\C"]C@VV =\AV@>_&*9;:
M<^;5U?+8H49>#9UF%/E<7.IN<+08=4Q?[9^=XZ&_**-IX!3]<[*]L/6JP;5B
M503:"?:A'W.E4:9Y: GC[@/83BE;J><K\SP[&$/D:L'[DOVH48<$"#4_DZ\+
M@%R8HH?1 Q[YHK:Q3R,J5Z@2T?*E0M4"L0P;OORO9*%L_WR/_)9?T>YJ,;SP
MUYISJ,7L.O:B05;R8C--E&':#9$=*NPZYKTRUQ'R1UDI=A2N,MFC?@C*T8D]
M''S'I1^H.[_]NH*S908.5S.J!?E8W:E"!^#JSW9Q$OQXGAL[TY-ZZ+<5Q<FC
M$0A%S['>+E.*^KTAK)+36E%0#[<#60H2J5M_*9.OMT<?[-&3LW>*%Q\SSI_2
M+K..F:][P8XS/HX6-X4X,U9K8JVH745X<$,M+'>M9SN#F8X+)T_0K>Y=Z@]N
M,3\C^/#3)OBPSN##3YO@PS=Z+.[_L-(KEMPHFY.\8B<G7NT'\\7V,=&JO )Q
MC0PI( *QL6RAY.<-_-K00A3'J4UB("H *R$FXT[Q@&BK=ZUW1@=&R# 6D(O'
M9\^)1L65FTL0V3@DG^%HZ:4CG*66#2K>0,L9J:E4R)N _LU167STM+4MYL.@
M4NO"_$GS$(T59:EVS Y4-J3GV.=6\;A.TG)J.7(U544H%>MH6ASKRO*9H',=
M-E UB4R=^J#%.]WA,O.=L5BG!BU>=':PRPDU6%2F^SW/81%9%BMO7-M1:-WP
MKK,%??[H<!$/2\NV8>8'VHW$GHVL1-3/K4\#>[_JJ63&%+TX3"*PI:L!6U,]
MUM5Y*M7^0'NM.^H#5H45_DD^(0,M+,G68F!UUDG5G"+5RRQ;X*O1';?<(Z[*
MO*I9NHXJA\VGW=I("?V3*\U+'R;#)E6KZH4DG#"S@P\;S@T"_/3*5PG:"'AQ
M(R<'=KH4?[O#G )#!"')L@K[J$C!^%01UEM&PE6475LG5"$?]'50/(>[T\XY
M0LX276BZ>_)PY:P:D8GV V('T3]W6>0%SN.6PS/DN=Y\[[3HG$E,1[?;.6FZ
MU;YS<*]J**6Q;P4A=AFY[#<UBWGTQ6:I^'E)_"1V(,'8IGHU+&Z6G> 5566(
MH(U$B?-^3_IL>(><_2UEJJ+V8P1C^LL>>S/Q(BB()T==5+X;"(&9=9U,J2"6
M';GJ$F34 )5_4YYR$EW\ZION1NKB+G8QE.P\)DTG42,[RTJ71-YME2])S'QX
M&S7EE$^J%3GBE!V\#IV1^)(Y(. >Z1+CP[D0 E$-GG%4DTO4B!#DZ5G8Y,OF
MI*L9EK'(Y,-V"-G-89P@]FOAR+$/PGB*IRK03'.9%55%%&27U!5!FO$P*%89
M1+ZDU789W<>)K5O@T4D35[N _6L3!\%AR*)K83C$N27":K]F>[_G%&W'FM6(
MX\1><\QOC,Y-) WD '@>_T@M_D%<X!0[A@,TZ?)1.N[-B5&SY/RIX]ZU8UM@
MT);<LD2W3V[,4.CU5D[::.IW/"Q1U,$D?%6R@H758T3:E\'9N$QGK'3#(Q/S
M2*4?J? 10P.*0J?YG)8X<C?0)K.O<T$OV$CA?5V%1K4GNA\IO@W%CF\A"R[@
MDE1HN2I^4^M^=-ROQ"PI_E>ZG#)60?3]CG)2@/L6_9(KQ*AYIMK3?6\GF.,G
MU3.B6*6BFV.W_$PM$$0(,(=AJ'.7PP81:E6:FLW9NR?#NA+_YB&LV@4^>!Y]
MDM#K4 H0B+UKH8#\<*LZ6$BRJQ$Z8VK1NV=56)JU9KM$3QU](M88ON@P'Q]'
M3'R/U(V6*]H&)K4$,4-%J2G'5 ],5U985E A9!K MN"H+TB68W?DH/.W)?U9
MX1TFR0M<*=!'V#Q''FL%>\ %"&F5+HOK!.Y-^B!@;D+%QWNEHZHMH5Q&T9GN
M1M(= Y!H'X '=+\&8Q,M5(GW2*BDJ>*C P(GT0(.[1,1(XFI5\1$3-S%AHK8
MI4!VK6J?PA)FKM\3%8#31-%,4[X8;E EK6BH",CL^13^-P'5)A6O"JABTQ%H
M$ FJ4&IKVCO2WH?2L)<]8K -^*?GN*%:'EI7H7(S,,7;,5%K%%BD2@@UVFEL
M.;\&FJ5VY" 9Y*%;*@N,91J 5'"NL,1(6N$,C[,D(FX'JSJU4NY(/9=Z,+K,
MRZ"CSW0-E44.NN'RZ-UW(OV7AP[^M@D=K#-T\+=-Z.!SCX7IYL,XG%<J2'L(
MQK9(U(.B^%@U$>@4 $6?%9.MH')=H<5Y*;!Q_!7#F8D6F17FA6",19$ (P,O
MVTK#&:Q<KX8)$6Y,U(>0.IAP%HOGJ-$7]1L#.N_*>L!-)T@M_+ KQUO*6#;I
MYU74'C0?Y1ZR?)8+U\G;M?]TV,<)GH1J:\(4:BV2PS?B'92.*UM1*=Z@(M-3
M=G6%*B%5JKY4@+2ER$D'P+Q5%Q<)J2_:T^Y-^#YH;QDZ&"M3[I.&T>^]3\H*
MW;1HQ3):, HP#QI-U/96 U'XVE-"S*L$T"TOL"&$^W5=IJ,Y3>E[SH^VHS,(
M"U4I_GF">B?EA1;79(ACD*/28*4#_43P[AID3769SJQMY="I4=F& ;NA-:2[
M\*KD:J]K@TJ\(P+C][%5#4>!:<T,?M0R"1H:Q<71C1N?Q&/'^V_(@="./^<P
MHY3\XQE+5;(XEWZ!'DJW8.*Q6^P67CDMW'X'4P.&3GTW)>-2R=>:%[G!V74<
M4*Q5L6+BS3[UIA^^:)M]C48W72O10@+-K;+B0'.K<U@9$GK+#]5N;XW[V>+@
M<[W@5AQ0>Y@#Q\&LVW F=ZC#3V!T"&J;@,.1]>N D_!U[VUYDT=9<5',M75D
M_<IPX8K/_7;SW.^MG&@L3(05!5RQERI.03_\$2JN?NO .DG?R2"T.DE=)#F@
MK,P1)C!D8R1.%#.^@VUA[S%6TI0ETA6V]\>U-J7+>28;I=1,C)7#P%A;(86T
MYJ,$\MZP/_BSUXBQ"C.EXY7UXWN*&EB-2PXN!5XQ1-<Q-IUGUCHX@S( (PFU
M,Q07,#Z=64:W,GH?:!;L -0(@0)98W9I,K ;<+/;5Z4$'SMW7IHWUUC5%Y;"
MP([,(F=5(EX9F\M%!RA)]FR1+TRF"^$ES>/9LKW=>Q#G8+4D'W#^F_*A=<@P
MKW_6?I7#@.L0Q&DU+I.VJ+5:.*IW52D9U99\T@@C2WYH\_YV)I;VRV?,;(O<
M^Y,3"XK*GYA9<O=1NH=$V'6>RPUTB-!WI*EU(M4R+^QH+[1XA:KP0JX.0L^0
M-C>&J8C&"^US=>;9@45Q6-'>WI&.IK!FAA %I"V/*CHS"9QXDCV,1K*66I?R
M7:_0(Y7 B?*OD-9IKCO7K)UC)Z:T*Q>A4?31&URBK"IR7S%9W0Z'1">FD+&D
M_#8BL7:59LY=2<=\[>48"V*:6Y: %MSE4.-Y0L["D40Z]F"'E- ;0=N4S\IM
MSV$KC;'98@X+13Y8KRPM)@(?^K_S8O@JU=OZ3=V$QV$^#D7\Z/J]D5)G3:GD
M6N+/U-O1-BII.III#VV9;9(LB(F!=@:7.C;85L8Y@@B0*=/6F_ &O:[)_>[T
M_9C]$Z:NUZVV3=L)Z[#[:-&U$D:1&@=ZTJ49A@9[X-FE#=WK9LIME2HD":(*
M279H(<J!EMO,P+5%[LQ6NP6W6RY.G;+->B:?[/S\\W]@&3M!C:C0+=6?4H-U
M>+7M*!:NI<KJ"8.?L2TMTFZSJ?L]F[E\R9(Z(;0_8Y?9(!T9>BZ$YUZ9<Q(;
MDAB9,/9+_GX3.[BE\I8KDMU<8;?)?J^US32GXAL401/H(<_]LJE7@K%M^H,5
MLZ_GY ;3O]P:ODRRKFC9BIGBP\\E0])\3C%"U$P7.\%^;BV0:'"KUD4[5D>)
M13!A2A[^M/?B[,/[EU7]XD?\D_CK#4(8C4]&;2VK 'C>/BI=><W(,QA459=S
MJ5.7(E!ORN5A*?@I[ER#TY <<3C'('#@=*#HQNA8O>AB672FDC![94GGRNW1
MEE@;2KUCM^] Y)4* 2=JOBA>C)U'4@@T+_3;4[0A<5NO6@@Q=HT-PI)FBKQV
MK!,Q8F8^DTD!*RU!3Q0FH-)IK-)2(<M@MD%-0#0?%I+SW8#&Y.&UL:@W6FP@
M?YEHLW&2.;2&/8"W7UHXZO6GRWUC15>6QQ/_OHDGKC.>^/=-/%'_[ZO'$K]^
M-?G'NIK\(>Q/I##8UT"[:E-8_IZ(62DLSYK444I([9A= &>S+&W/XG4JPN--
MG24-GXRE['$5H1E2O$0<3.8R8DD>.U&V?@_O8'PH1M(M9=?@E6O]FPK/&U40
M;2)7RRPM7[J@NPO]-RN=P[+(%.0]52TW ==;I)"PASJZ*M)8::5Q,1_5H16'
M5$$=,7^[+(;$Q].U*[*:DG@@M7NJ^8AGK[J)^09:$<4*$&E8-M3T4.K'C(OI
M"%21RLE6PAP@*2B,1BTZ+=DFQGTQN,7+JRFR!K2]G0K87 UX/BJN(CS.L"0Q
M<2*(N\\Q*?H]UZ_C3/(XFJ6(1...^G8V>@=<]V#=A.X:J*9&^;)E:L.;K5+=
M,*BDC.K"8I>ZD2VZQ4$VLOK1CIB7"STM*B.LRV"2/$.&1U^1&NRX2MEMGA?D
M5KQUSY:;:>:EQENJFR0SGW(L;Q:J-/!24*/9 )!WJ;(67!91&:J=3%:-D"&W
MS)%&,+)8KX_9<K, X83'=?$GENF"G-RZC\0#9@RWYLQP:).(P2B=<X(AP]8(
MA@6HJ5IK-++?V)*1CD DU.TM>M7OF0>H9PVN+Y$I[,!D81 IV5LFV^Z1_$YL
MC?L_+*EV?38?5:2LUT+,$;R#[8!XUZHS4=L<D5:.#3X9%(1@:66I _:-=L%^
MNGY/!#S*HB3+*GJZ*\Y-FXX[:F>$5!P/N-;./]NCJE#Q;([7A![&0@V1<I'P
MP>SWU*D35R+M[&52NG8<GN]59PS#24NBL4TEXN6W1&/&9/=[.K>&O286!D@Y
M#[R7A9X$]+YNIMJ,3<*GO#96F?7RQ&6$,X(.LAM=#-R*$>L4@ ;9UBW?MQ32
M ?M<QFIWV6X0ZWK@W+]B8GO$VZ 2-_"V#=KN2^42QW?R;$5*8",')^B>N1':
M%^R#-_[',E#E@-M7IV#B@EQ6SVLX-&^W_?'6G6'MS"X=U"0J6.$(E39N=7AE
M;X,MY00. \F84-D23:!;:ZZ[R<!4Y'1\KY ^UGRCP(-@5*!5J?M'=B$[E%5T
M<%6(EGKC_-YHWGXRF=NUMFX9_D,:[A:1.#3Q)7H>]<GPU="*]A*-KGW.O5<-
M3/'$Y5W2*A*=4YSA4;*@':FWJLR#Q56(@IAV(Z\LLN#5>LTDGX17A/$G?W95
MUE:+8:,3K*<8^WNX'D_Q>CRR+6M6!XZXSJDI2.[S2KK6?8.NA7=LC(9<*?S3
M4C'&TF@5(L>U]-F<ARLY01GEZ %RA5D/4%2A(36;" +;D*WG96X9BB:?CH(<
M-\'H^1UF>M9*N1Y\.$QH5!+\=L:7GNE2I"<%)%LUPR#Y9!(VS.#0XB@&:Q'7
MX8)B$R'!M#@KS?K8ZHKD+EF\, .7-,7> HY&0TP:6J\S1HY+=VY'K%$T&P2.
MX-:Z2)A7B6J[7SH>B*E6#@K;5KB,PF.U)T ]:+6A_ 2?H_N(ZG;7RD_P.;I/
M>[AVA?(S6:;\-*?^1II-OW<KU:8YO<LT&[.8$HMN]#'8NFDR: N._W.T&^?E
MW;H-6-ZW4FX:-L2M=!NG4ZX:P;F/TK<N#6>)P[)-OUGRNH&)L1O4'H>QG5\M
M56ZLOGI5*?ZLJD.U(#:ZSI^)M?Z\B;6N,];Z\R;6^KG'8DWQUJ]V.*4\U*MY
M'D=33K0_-[J<"L_=,B074DC.B8XPS4*V8(B-^A=I<XC;1)5=@*@,0;84RDH\
MT.S7FR84:V)8-!UD[?BVS00"[M"[2#%B;953R$)3*L("MN(?Z,M,0;,ID7VB
MJ\=V9] +$L*A)2TT2\=(:X&WA.):"#6;0<CHS87R]FC[1->YQ"N2..K07XXS
M65.FC+!;.[:+GC1TKL/"\I7:-G4J!&>M@3V>T*(:FU O:\4D/N%)3@3(C>XB
M_&A+H?B;<&)WEJF>AU)C7:(HUN LM:VAK$D%)%9&T*>K.B; 5P&7P^M216)%
M=WK3/B*.GL)RW:+JH ND1&/,'S*Q4JM/%R#?:L7.\7178Q$=E*<?&N[ZT55!
MF.,9:(R:I'+,OU4Q9"^:2('+&YX@K&O IO"-3E#3^@/3H+R(\O3?5EA&;%C]
M61OBDD\-+O(\JZ@6%_,RZ05JKGJCD;0R 29B!E09<'1RK=6.;[C"(>V1K9M/
M7[!R]E#2S*=3SB<QUC@/5I\@JKOAF,?]WFA>8>2[<L)>*QT!WH*$C>4 NQR,
M^6TRYHU ;+75!_0*#.':IY,W*^: P-,J=?<:%=J1V"#M3XN?I+K)\>@DC+S#
M@Q)LD2_ =C@LN<K<:(H*D[#9I:-8W9GA#<NIC<F=0JRF2HY'U=O&E<GQ*Q/X
M<'D[;6/;P:T7F E4)C;_4L?0=>V'-LY2[4A 2I]V3P*>$0=O6[B\;?Y,#?Q4
MB"XH /?#H$]1H- &(^%JT^4494-"IG@EJO)FU;R\8H2W]2N3HZX"D%%&9QGL
M>&G7B\#M9[ I$20 K[$>L_<.3A.N,:U7F^':L0@,\[#QM3>8(4/]ZFE;:/J;
MK+G6/;*T,RN]1S==<P,@:B9L:7^&2[+7 "PLP\E$,Y3K9>H!-Q187@VTW^M8
MNL"I.&6X0;L>UT?1I3O#*X+%?1.%U)AI+$EI'SZ//DO#K\5YT3)\Z*>X"SK[
MF=/.P^)BU%V!U$L6FBZQQ[F4(&BNT)Q6BQ*GJ,NAL,.[&\:6FZHM'2\DD-XR
ME0T!ZI(,=5G0&%12.&@%RQ0R=LSIRF\TL$Y!UN[!&JG7:Q^NWP<S+%3:G(FL
MU;NK0%\'G5Y74QINV?$BOEF[U'F@*YV;5"XN<:Z=19S^0C[[9:-OFBQ*> [1
M?[=H(:KPB@GYI5=G$OBT!8IM[4%7^:)!Y0D'1< ZR;E[O(N9)!6[[T,U-%:6
MK-/=*8;$^8LZ5VF[>N5W;7F,1:,@7$?K@] N/&0O8EE,[4V$146C12,I$'4F
M2V+0QM6<G>3*(X?2V1AI-RMV6+5-?^'Q4CC$#UUYQX6I)J:3[?V97;8%FP2&
M00=_X?(5$A(!7N[V2JJTEXO,CBU0U4"4W%<-'*K^V4$1<9'+(]+%B[)JT;"*
MG&(,;3"V?D^OXZHSH<5"O9B1JH_)1;2FKC(@*:+Z<8,;'.CCT[+H>H%NL+ \
M[88<A:QJR9,B%DS96UVBUE-_NQCR.T6(2<*/:F_XABY 3X\;?11C3]LQM0HJ
MD9:BVDT<&%3'/4';F66T!4RD!>6[+Q)Y31\7DODU]J] ,_:@;>C.1=Q^(B;S
M$OMM3@0>B!M./@X'=[I:0[S5< EYGJRNFNK0G>M"WW:]5V&]#.<"&0_ZSA0+
MR<$E-R\&@14WOI L.'MD-[OF!FW*CWL/6MF\]KGI]^C@M!=ZU*J*(Q =/8X:
MVU:'\!V;-:@Z4?7&(DXR4ZM"2PGIR[M?U2L5X2;5A3S(B@*U<;#)W^R\W[$K
M@NNOG++@=LZVUIYBCKNWW8&K+RR0:*08\3"T)LV$"5JO0VZ!".L%?-R>(&4\
M9B:6F"9/X7O*@T2VE=BZSS[LG.W BP0'7@I\F(JZ4L%;YU;#2Q])D>KK)&G6
M8;W9C>RP271=+4HO/K>L :Y@0X0&.?$$CXD6XJI -3:3% O3U[U=TC\"ZWM<
MB\;2O_[U7*]V8"]VL&4MXQR;^#>7B7C\TU/.D25F!G&[P )%>%,-K!6W&0=L
M.\P<H;N=MA!I&_@B)IX,KL#"M21FBM(_F$MER0:YCP/65UZ88J(=]DC2JY;:
M:].]L%3M8)!M4L%FELV] XRB)"_R;5*='(EHU;WQ6UUJMSJ%GJE^<$?-BSO>
MJUL2,+[YP?:,0 PA<QUKS+0YHB.L%4+QRY"ZW3B+P9\ZBIQ@_MEGD2=\B-W]
M=U)BFC57X!B!F"FN)27<K0?>IA7C!88RA3,B$)^$8"O-](S1#3NU0!?7@#,;
M,U3+\DDZ&VE@E0IG,T+MY@FJ#@?*_THEP%6.CV<":8X(9W>IJ;Z%/=/&.\E5
MQ<05(A<O:;,+T@HZK;U %_-Q]#U6QXW+"UW=K@_+O]^=2PO])A4,)[&H4'2$
MB5R$5L4=3]WAJC.N(VI5L3-]C1MH?SQPPP)"^J*]YQ7-"ZF@#&*E8-@X,=Z.
MA2D&AC3<7H5:=/EYIH?GZ8216)X34!:BQ:#;;^8<9),=L]2IVE4^EVDG.3;"
M&!1K,B,5UEATZ7"ZX*[*&E.3EQ+= IU")WBH\7GM,ZHRD@R_?$KLH@XE%VL*
MCE[1SF;92(^CF6SJH4(U,XO( \5G86"G3BHPWFJL'*M&VAV[/!WL9HBYI8[M
M&^X2]OFILD^Z-;Y0!1[')'3NZ_@!38&EW],UQUM(JEE''RF7C@+=<!CGN6#J
MF[Z_);-J'\F5-[!SR2_K82CU]%9O%XU7]R:#U0.-U6.=&'\.)[PVGLX@ 3%=
M3.$Z;+4>7#X>)XQR&Z?*0!96'9,NB=1UVFQ O<5[Y49RM-=\J1NP<:R,QSR.
M#7<+ZK;J;M .&.%,:I'G6U7!1C!;XGELX7+M7I:WFK:0(V%4^H.*%NC[(<!4
M!Z<'8.@D96G9+JV=#U0"YH2$:E4G$0V9WN-;Z;)A&S,&?].?]7OT(7FH_RA2
M\G72ZF&'49(.PILU%*QH)[!9W0P?DTE2XAGB@"(YA>Q0J!J3[& !(-ZN8RK^
MP&I ^]6O/5KM+VS9.7I8#*$6HNW*1^_K8W[#2>SW6F<Q)'PU03BP:$JL:/'4
M:QB2S1$ITH=;4NK;H@BVFQ&_%WRHF8]5F@U?+9D02Z,::CG&3/>0L-940HGF
M<"^5Z;^3>%D<D#37M+L*D)2((_U5O;1;NZ337+FB\#A/46TPP2BT #9X5/KA
M!I"Z3D#JWNX&D;I!I#JE'@Z-TTHRQ_;)FC:?VM>0%L)>,31='B\B%^E8T%GV
M9WL_PKZM+SGT2O)7L:SV>Q;-Z@H^VL<WQ+PXM,E"U$+L&A9NBIV+D81*. 3H
M^.TL)]V=,(&T]^,[D?SW?UB3@=3OK"6>QFK-6EFR'N8:?KVZ/5)!R9"<X3JZ
MJ""6@K]=@DYZ)0JE!QL">:014K9!SQJ\L;E:19='2HZTW+/:JA7L>K)&8+-,
MHS3#4H:\[YHTT#ZHR3#\6!PY"J+'*#H2?_I+G9?961N=K0+[Q5$P*K$P,I5?
MM_W2:)RK8@,ZLFG>M2D%=4^&I8J-&7&WCY$VL]M@:UH"$'%K'AV[ET-NDJ0U
M76Q+]CBYXV%+X5% Y\Y ,\6[^> 8NUSV+BKO'6'695ZBNY<K0V* S.2OYYS:
M428Q5IGO@-]3()#5% ]9J,Q)B?%%NO0'898-QL!O4>7#(YQ#>'#8'3C"^LXC
M=@6S$B2(=SNE$[4ESP%L<>"4ZM^E$)I@#$Q"52"9HDR[OFSV*L\+T:Q9W\2
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MQ)@!A%:LE<B-%FPD:IVCCCY9-.W: I@RLD9IS>IQ06XP[D5/:(2Z:3K1.H%
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M"[-7?M7B9#\>O#OZ'8_)CZ_/W[YY^?\!4$L#!!0    ( %&)C%L(/7FZ"U$
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MHB\^J-W\XL</+Y4N"I(,SN$DA3[4EU$=P@O+X"K*YDE0)N,DO4KBT-KP\%\
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M5;/Z/#A?S.#]^V4T2L?/@Y-HFO#,GQ0XGWOVCWY4O\)OC-&D#*87/\*TMZS
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M0?Y Q!"K8@LN*.:(&<VV'JUHDWO2:-AN1E6@8,?&+,D)I#)14IO3)0Q\Y;*
MMRC)[7$<4([03[N[B.R!%DYUI@5WX^3MF9-Q8=BX)TF,1%DV14D675<#38SE
M%*+0_N;+].(2X1D':2Q>VS8$D"PYC#,?IS-5M\:#3ZW 0EE4=.H;IXZ#\I)=
M%[0F-$FJ,THI,+>;\@!S3W34H-N]OVJWN-NOV]T6S\F%Y2XM]\)9WU M,!&@
MM0S-A$R(6V[5?C'M^;L/-W$JZ\D=L8_IK0Y@PU/5/AM1(W[A/NR5-7+F;]4Z
MR+0X4^4ZBFXT71HH0F*D>02<*\045OH6K])[<WW>BXZNO[359D-]BQW=.AAP
MS_X1W(]=I:6Y%U5MNN0K\2U*P)IT@N<HEC=;\IO>DAL9M]E0=ROC_GE?95QG
M (]L-Z90'"6$W"7UE6H7)@[<R?*Z87QXC/%:BF%2W2.R(JC24>/AB3!^8C]T
MD]?H;71]<.A\,P^44:V9LJ,FKF2G_:AL"G=^&^Z\Y\$H&G^\* NX+-&Q5I3/
MT(%:)S^\/ ;SQ8\BEXD"C:=B2K0LN614(?P"?V,"Y8$;)V_;GLH2>@R6T-;/
M"J;6[_E4(BK7@O)*&/#5X9E."-_!G9:0=@U]DNAUT=F21?QE@Q.$.8R=*/CS
MZ"-G\\^*B@OD*5@0-VX5LD,(U;JBEWN[CW>>ZJK-2W?0]N,]?'1S-%8.R\.!
M(<YC!1!,N00]0&?8$1R/YC5TI!98F$%B7:4MQTI[#!",]%WOK.6Q\:>;V/@Z
M8^-/-['Q6TNF[=V=1P\R.KZ&@<4<'W^;(,]#.JY\>/E7Q__<M\7<^VKW9[I#
M2WED!24\[>P#FB\N J()!!UCKGV;;F?0I0;'R.5L""JO4R$81:PH)0)BE%!W
MMV $L(1*F6")8W&NHV(Z-QP0;K!%*LX'<<)H4?WY*,I(EU6_)IT61W24D'Y8
ME- 9A[$B4*5NL3UY"IO'U F$\V,%&G@8R[O$*9A87%K&CB(=_;9_Z!:W=YFC
M5,Y^Q"HYQJU0AU *O#1(&<0IF7);^P.#,H%7KD29S%#=J?74D7&:C[NP(DR<
MSW 2 O"VXTED83"H<S!H1;F76((GO4@52D40*@X61=<(D'1_Y [&I)9RNYAL
MT^.F>$#5[]E!&4UZN!7!@*9$^]#0R;QL[D%HLF^O)7=#UQ^R@W,1T2USK290
M#Q5.APPK)PM ;RV&7JH'5=Y%'OD!07]OAAK!T^U;*)J@&2Q^H/$R]K30IM'C
M5W#S."YQ7DQ>B+L*TMOVY!8=;%/Q:3=?J-_K3!@R_&?=V5(=[[U]LA&2$'1F
M&_V9KFQI3@FV:QL9W[Q.@9*CC:H"@QT6I*NCORVY'*82&+&BH+Q5/,F*#9-V
M".4QC!*8$[MX!QU@S@GH..XD N$O,X'_JIUFV4/-7)0P2$OY#<J=PHW(^N/T
M<%MAH"JE\8Z:18NI1>?3F::U9=5\DPT[UCC\QM$?X$X5%%EL4EM@FWSQ5#<3
M%K9FAJ5(6S+6L<<L&*59I2EQ)&\!%DJGMCD79<L*V]CN]N2J1?-G>C=K ]F_
M]F?1PGTWP05Q'2C4DZ7_FJ?,,Q]'T^A"6# (VX*1^5F21UF]8/&71.C8_,M>
MN+N[VR( K1&XXLT0UQC43S<LY,80@T&(G=DE2+V]+;!>'"Z <*G\Y5'S$7D5
M[#;8"NW"<,D\#_1LJ-\2Z:#\F,:^Y->2D=9\C"]C@VV =\AV@>_&*=;&<^;5
MU?+8H49>#9UF%/E<7.IN<+08=4Q?[9^=XZ&_**-IX%3I<[*]L/6JP;5BE?#9
M"?:A'W.E4:9Y: GC[@/83BE;J><K\SP[&$/D:L'[DOVH48<$"#4_DZ\+@%R8
MHH?1 Q[YHK:Q3R.J+Z@2T?*E0M4"L0P;OORO9*%L_WR/_)9?T>YJ,;SPUYIS
MJ,7L.O:B05;R8C--E&':#9$=*NPZYKTRUQ'R1UDI=A2N,MFC?@C*T8D]''S'
MI1^H.[_]NH*S908.5S.J!?E8W:E"!^#JSW8U$?QXGAL[TY-ZZ+<5Q<FC$0A%
MS['>+E.*^KTAK)+36E%0#[<#60H2J5M_[9&OMT<?[-&3LW>*%Q\SSI_2+K..
MF:][P8XS/HX6-X4X,U9K8JVH745X<$,M+'>M9SN#F8X+)T_0K>Y=Z@]N,3\C
M^/#3)OBPSN##3YO@PS=Z+.[_L-(KEMPHFY.\8B<G7NT'\\7V,=&JO )QC0PI
M( *QL6RAY.<-_-K00A3'J4UB("H *R$FXT[Q@&BK=ZUW1@=&R# 6D(O'9\^)
M1L65FTL0V3@DG^%HZ:4CG*66#2K>0,L9J:E4R)N _LU167STM+4MYL.@VNC"
M_$GS$(T59:EVS Y4-J3GV.=6\;A.TG)J.7(U544H)>9H6ASKRO*9H',=-E U
MB4QA^:#%.]WA,O.=L5BG!BU>=':PRPDU6%2F^SW/81%9%BMO7-M1:-WPKK,%
M??[H<!$/2\NV8>8'VHW$GHVL1-3/K4\#>[_JJ63&%+TX3"*PI<OW6E,]UM5Y
M*M7^0'NM.PKZ5845_DD^(0,M+,G68F!UUDG5G"+5RRQ;X*O1';?<(Z[JLJI9
MNHXJA\VGW=I("?V3*\U+'R;#)E6K<H,DG#"S@P\;S@T"_/3*5PG:"'AQ(R<'
M=KH4?[O#G )#!"')L@K[J$C!^%01UEM&PF6/75LG5"$?]'50/(>[T\XY0LX2
M71FZ>_)PY:RBCHGV V('T3]W6>0%SN.6PS/DN=Y\[[3HG$E,1[?;.6FZU;YS
M<*]J**6Q;P4A=AFY[#<UBWGTQ6:I^'E)_"1V(,'8IGHU+&Z6G> 5566(H(U$
MB?-^3_IL>(><_2UEJJ+V8P1C^LL>>S/Q(BB()T==5+X;"(&9=9U,J2"6';GJ
M$F34 )4Q5)YR$EW\ZION1NKB+G8QE.P\)DTG42,[RTJ71-YME2])S'QX&S7E
ME$^J%3GBE!V\#IV1^)(Y(. >Z1+CP[D0 E$-GG%4DTO4B!#DZ5G8Y,OFI*L9
MEK'(Y,-V"-G-89P@]FOAR+$/PGB*IRK03'.9%55%%&27U!5!FO$P*%891+ZD
MU789W<>)K5O@T4D35[N _6L3!\%AR*)K83C$N27":K_(>K_G5%G'(M.(X\1>
M<\QOC,Y-) WD '@>_T@M_D%<X!0[A@,TZ?)1.N[-B5&SY/RIX]ZU8UM@T);<
MLD2W3V[,4.CU5D[::.IW/"Q1U,$D?%6R@H758T3:E\'9N$QGK'3#(Q/S2*4?
MJ? 10P.*0J?YG)8X<C?0)K.O<T$OV$CA?5V%1K4GNA\IO@W%CF\A"R[@DE1H
MN2I^4^M^=-ROQ"PI_E>ZG#)60?3]CG)2@/L6_9(KQ*AYIMK3?6\GF.,GU3.B
M6*6BFV.W_$PM$$0(,(=AJ'.7PP81:E6:FLW9NR?#NA+_YB&LV@4^>!Y]DM#K
M4 H0B+UKH8#\<*LZ6$BRJQ$Z8VK1NV=56)JU9KM$3QU](M88ON@P'Q]'3'R/
MU(V6*]H&)K4$,4-%J2G'5 ],5U985E A9!K MN"H+TB68W?DH/.W)?U9X1TF
MR0M<*=!'V#Q''FL%>\ %"&F5+HOK!.Y-^B!@;D+%QWNEHZHMH5Q&T9GN1M(=
M Y!H'X '=+\&8Q,M5(GW2*BDJ>*C P(GT0(.[1,1(XFI5\1$3-S%AHK8I4!V
MK6J?PA)FKM\3%8#31-%,4[X8;E EK6BH",CL^13^-P'5)A6O"JABTQ%H$ FJ
M4&IKVCO2WH?2L)<]8K -^*?GN*%:'EI7H7(S,,7;,5%K%%BD2@@UVFEL.;\&
MFJ5VY" 9Y*%;*@N,91J 5"*OL,1(6N$,C[,D(FX'J\JZ4NY(/9=Z,+K,RZ"C
MSW0-E44.NN'RZ-UW(OV7AP[^M@D=K#-T\+=-Z.!SC\5Z:IY_31U&*3%@;(M$
M/2B*CU43@4X!4/19,=D**M<56IR7 AO'7S&<F6B166%>",98% DP,O"RK32<
MP<KU:I@0X<9$?0BI@PEGL7B.&GU1OS&@\ZZL!]QT@M3"#[MRO*6,99-^7D7M
M0?-1[B'+9[EPG;Q=^T^'?9S@2:BV)DRAUB(Y?"/>0>FXLA65X@TJ,CUE5U>H
M$E*EZDL%2%N*G'0 S%MU<9&0^J(][=Z$[X/VEJ&#L3+E/FD8_=[[I*S038M6
M+*,%HP#SH-%$;6\U$(6O/27$O$H W?("&T*X7]=E.IK3E+[G_&@[.H.P4)7B
MGR>H=U)>:'%-AC@&.2H-5CK03P3OKD'65)?IS-I6#IT:E6T8L!M:0[H+KTJN
M]KHVJ,0[(C!^'UO5<!28ULS@1RV3H*%17!S=N/%)/':\_X8<".WX<PXS2LD_
MGK%4)8MSZ1?HH70+)AZ[Q6[AE=/"[7<P-6#HU'=3,BZ5?*UYD1N<7<<!Q5H5
M*R;>[%-O^N&+MMG7:'33M1(M)-#<*BL.-+<ZAY4AH;?\4.WVUKB?+0X^UPMN
MQ0&UASEP',RZ#6=RASK\!$:'H+8).!Q9OPXX"5_WWI8W>905%\5<6T?6KPP7
MKOC<;S?/_=[*B<;"1%A1P!5[J>(4],,?H>+JMPZLD_2=#$*KD]1%D@/*RAQA
M D,V1N)$,>,[V!;V'F,E35DB76%[?UQK4[J<9[)12LW$6#D,C+454DAK/DH@
M[PW[@S][C1BK,%,Z7ED_OJ>H@=6XY.!2X!5#=!UCTWEFK8,S* ,PDE [0W$!
MX].9970KH_>!9L$.0(T0*) U9I<F [L!-[M]54KPL7/GI7ESC55]82D,[,@L
M<E8EXI6QN5QT@))DSQ;YPF2Z$%[2/)XMV]N]!W$.5DOR >>_*1]:APSS^F?M
M5SD,N Y!G%;C,FF+6JN%HWI7E9)1;<DGC3"RY(<V[V]G8FF_?,;,MLB]/SFQ
MH*C\B9DE=Q^E>TB$7>>YW$"'"'U'FEHG4BWSPH[V0HM7J HOY.H@] QI<V.8
MBFB\T#Y79YX=6!2'%>WM'>EH"FMF"%% VO*HHC.3P(DGV<-H)&NI=2G?]0H]
M4@F<*/\*:9WFNG/-VCEV8DJ[<A$:11^]P27*JB+W%9/5[7!(=&(*&4O*;R,2
M:U=IYMR5=,S77HZQ(*:Y90EHP5T.-9XGY"P<2:1C#W9(";T1M$WYK-SV'+;2
M&)LMYK!0Y(/URM)B(O"A_SLOAJ]2O:W?U$UX'.;C4,2/KM\;*776E$JN)?Y,
MO1UMHY*FHYGVT);9)LF"F!AH9W"I8X-M99PCB "9,FV]"6_0ZYK<[T[?C]D_
M8>IZW6K;M)VP#KN/%ETK812I<: G79IA:+ 'GEW:T+UNIMQ6J4*2(*J09(<6
MHAQHN<T,7%ODSFRU6W"[Y>+4*=NL9_+)SL\__P>6L1/4B K=4OTI-5B'5]N.
M8N%:JJR>,/@9V](B[3:;NM^SF<N7+*D30OLS=ID-TI&AYT)X[I4Y)[$AB9$)
M8[_D[S>Q@ULJ;[DBV<T5=IOL]UK;3',JOD$1-($>\MPOFWHE&-NF/U@Q^WI.
M;C#]RZWARR3KBI:MF"D^_%PR),WG%"-$S72Q$^SGU@*)!K=J7;1C=918!!.F
MY.%/>R_./KQ_6=4O?L0_B;_>((31^&34UK(*@.?MH]*5UXP\@T%5=3F7.G4I
M O6F7!Z6@I_BSC4X#<D1AW,, @=.!XINC([5BRZ616<J";-7EG2NW!YMB;6A
MU#MV^PY$7JD0<*+FB^+%V'DDA4#S0K\]11L2M_6JA1!CU]@@+&FFR&O'.A$C
M9N8SF12PTA+T1&$"*IW&*BT5L@QF&]0$1/-A(3G?#6A,'EX;BWJCQ0;REXDV
M&R>90VO8 WC[I86C7G^ZW#=6=&5Y//'OFWCB.N.)?]_$$_7_OGHL\>M7DW^L
MJ\D?POY$"H-]#;2K-H7E[XF8E<+RK$D=I834CMD%<#;+TO8L7J<B/-[46=+P
MR5C*'E<1FB'%2\3!9"XCEN2Q$V7K]_ .QH=B)-U2=@U>N=:_J?"\4071)G*U
MS-+RI0NZN]!_L](Y+(M,0=Y3U7(3<+U%"@E[J*.K(HV55AH7\U$=6G%(%=01
M\[?+8DA\/%V[(JLIB0=2NZ>:CWCVJIN8;Z 54:P D89E0TT/I7[,N)B.0!6I
MG&PES &2@L)HU*+3DFUBW!>#6[R\FB)K0-O;J8#-U8#GH^(JPN,,2Q(3)X*X
M^QR3HM]S_3K.)(^C68I(-.ZH;V>C=\!U#]9-Z*Z!:FJ4+UNF-KS9*M4-@TK*
MJ"XL=JD;V:);'&0CJQ_MB'FYT-.B,L*Z#";),V1X]!6IP8ZKE-WF>4%NQ5OW
M;+F99EYJO*6Z23+S*<?R9J%* R\%-9H- 'F7*FO!91&5H=K)9-4(&7++'&D$
M(XOU^I@M-PL03GA<%W]BF2[(R:W[2#Q@QG!KS@R'-HD8C-(Y)Q@R;(U@6(":
MJK5&(_N-+1GI"$1"W=ZB5_V>>8!ZUN#Z$IG"#DP6!I&2O66R[1[)[\36N/_#
MDFK79_-11<IZ+<0<P3O8#HAWK3H3M<T1:>78X)-!00B65I8Z8-]H%^RGZ_=$
MP*,L2K*LHJ>[XMRTZ;BC=D9(Q?& :^W\LSVJ"A7/YGA-Z&$LU! I%PD?S'Y/
MG3IQ)=+.7B:E:\?A^5YUQC"<M"0:VU0B7GY+-&9,=K^G<VO8:V)A@)3SP'M9
MZ$E [^MFJLW8)'S*:V.562]/7$8X(^@@N]'%P*T8L4X!:)!MW?)]2R$=L,]E
MK':7[0:QK@?._2LFMD>\#2IQ V_;H.V^5"YQ?"?/5J0$-G)P@NZ9&Z%]P3YX
MXW\L U4.N'UU"B8NR&7UO(9#\W;;'V_=&=;.[-)!3:*"%8Y0:>-6AU?V-MA2
M3N PD(P)E2W1!+JUYKJ;#$Q%3L?W"NECS3<*/ A&!5J5NG]D%[)#644'5X5H
MJ3?.[XWF[2>3N5UKZY;A/Z3A;A&)0Q-?HN=1GPQ?#:UH+]'HVN?<>]7 %$]<
MWB6M(M$YQ1D>)0O:D7JKRCQ87(4HB&DW\LHB"UZMUTSR27A%&'_R9U=E;;48
M-CK!>HJQOX?K\12OQR/;LF9UX(CKG)J"Y#ZOI&O=-^A:>,?&:,B5PC\M%6,L
MC58A<EQ+G\UYN)(3E%&.'B!7F/4 114:4K.)(+ -V7I>YI:A:/+I*,AQ$XR>
MWV&F9ZV4Z\&'PX1&)<%O9WSIF2Y%>E) LE4S#))/)F'## XMCF*P%G$=+B@V
M$1),B[/2K(^MKDCNDL4+,W!)4^PMX&@TQ*2A]3ICY+ATYW;$&D6S0> (;JV+
MA'F5J+;[I>.!F&KEH+!MA<LH/%9[ M2#5AO*3_ YNH^H;G>M_ 2?H_NTAVM7
M*#^39<I/<^IOI-GT>[=2;9K3NTRS,8LIL>A&'X.MFR:#MN#X/T>[<5[>K=N
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M;JON!NV $<ZD%GF^515L!+,EGL<6+M?N97FK:0LY$D:E/ZAH@;X? DQU<'H
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MZ])<",U8OVL$V;D'45U'6!\RD(!S/.<:W^-YW4!U29>H'W2]U751Y@E'C!E
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MM6(;]C;8AF_T8-S_80D)_XD1;0*6.+=%LJISE[*7@1P)5))%0,KL']::!BE
M4C2<507QDJ@Z&;@+*\QTU$JBDQG<K0TJ;R;I&0M=LC>:2BC/T4?,C6A);MNC
MQT(<%"V^352UVA5ZX5(+P*CPT2"TZB5K5=$I'$C^[RM+75)E+HCCQDJ57:+^
M!3?6_KS,@:3U.?%U\DI;W6BOW>SXJ!!?8]['D!#4A&7HE4W&5!GG8JQ8<.$%
MC!_4($7QK;380*9 .1X,E-+*EV0]:#PNJ\+ FK7#.)_8<OA.;OC[/RQA#O>#
M+DJ8^8>G5$$9-[>>)!=[O]510(>BI(-ZE'5\C*):AT>V2+TUF51MG3$44BWV
MF/C=E<[/0I.34*EV24%_NN-!48*@,+9T,"&3M6PUPD2WUS#9V<*(1A1W2YAM
M5[^U&?IQB$WD,>4H]\AVC1@-V3RE)"",4I)45RBX$%].((YQ/:>8MNUC55;6
MY@S>DV'%KM<,]CV7XS403&$"Q=6E':URBCK=2BT<#<YUVL*.8=Q9@KIO&/^*
ML#JES8@@>^NPN+@GR]'O>,\,.DB!2!.\^Y6[;W_,U]2<.2=MGR#^T"L.-,*,
MH^KC@KV$"H,/5_I%JA+H4%_*$FV38MA\*M4+D+=INYALTP.E->6DITGTA ,\
MF!FI(SS*1]$LHW0ZAY;VGCQQM0X4-/(3=A$9/Z8 $RS&!T-;ZM/@D^4MWR8M
M)'DBE2SDK*X)7OF^"EB?8@9: _< 4]>J) LM-Z"3/Z5#HO(;"Q2[(C74TDNM
MZ(\96M=V#.(BJ839F^M#.)M(=D=S[VPDWCT9EF#-3Q/'VG'\RT8#4:F]\C5S
MQVK/54%U-:0=MF8,B(IX92B0K_D- S<_D=S'3?XQU3(QP*@B);;N[RO 309)
MYJ)$4P@4!)4A2OU3Q$X@"JY2F#.""I%SS5((T %.\BO),BT>O+>+%H&1!AU1
M!\E_E1:9@[[R)*S\;(ET[?= I(;*$'!R5"-D%[#D/ADGB 1)XDZ9OCF7]R D
M:4=CG^IH[-NT0B<_0Q$V<=A[LCTCE9F@*L.!=G!F )[!!ZJTH9"[SX,3K %9
MUQFK9B!"#J/JLL6AI>]E08K8"HIX;(1)6."F2.>NJD\K"),*PD::U-EE9_5R
M7Q6"QS6@HHX8\*.M> "::6@Y,31*! DQ6W[R>"?XS8[\2@!+H]H0>&?&J#C3
M?%&<&S)D!&Q1($IU6F5/*T%*T2W3X_$@*)RV"?$E$<SV2ITR3+I.W,^N!A)T
M(TLY+P1<PRJ;/;TC,G8UD"K(86[HQ17M!(=!P=//OA-YOB)^\V@3OUEK_.;1
M)G[SC1Z,^S\LB=^\*2IX"(R,"5C01^@#F(\51N,MTM)I-=I&HCE^Q'$!\M58
M&\H3FJ0P/K]6QT3A,6S+&?,57-/9%,;*J'\U]R]V^S=U^N>2V)8FI0,.)!QG
M0@,K:AI#\N%>8N)S9(8Y$OK6^QFVHGL04N($+,\T%Q8)3:*TQ"F0UD*'J=VX
MZDU6;T+E8$!%@^%9B:!7JEJ 072!%7DL]" >R H_$G2*GB#'?L+N^I-#6 F9
M5(QN.9@+L@.EXN62L%%SQG$2TX]("$/@G#R6N U#S84FT/24YB5+D[G?9;(0
M&\U_)Q?Q_1^6A%G.HGI>8JH*/(D$(?B7UX3-Q[\E]5BGSM'IQR07W#6S&9*Q
M)#$Q8ZH(0ZU1<F3,:[G VO(L+?76U\JL!:\J2LY0$ZQ?FKL^WLAA\!/^=\[<
MY!<I\EK*=U$\@?R2!HI(8'TYS#"3\3%5I'I#OP>OV.SD>S(L"5;L&^X<OCPV
M6>^W3R:XV:#V[G9(Y_:]YFHO84M^AZTF-$I$UWPQHI>R5#SB!/XPNX/#.0)K
M< D%$5JI <(-0@T$@'+\0HL\MT1QPP;7 &+;;B5/@D(KBDG?Y-':Z?=LI4[8
MR7WE+A6 1EN99)4AJ3.'"(VI9J(6]:<2Z$Z)59\*PM1 S\H+001Q4".><^X3
MODIC=1*DZ,*$SYL,VH%H=@_:461I)6M2<1CU2LEDFJY3T1!62KZ;'@FYJ2JS
MU.:I5L =(3RI3.J5W#XZ0F?[KBF;UW)39]$U.\4OYDI=LA*<[;!<X9)$OXW*
MCXDHYQWUT*2'&?JUXPX57[( (P/8T:!7!Y[$H[SQRNCPA<)*./QNB%%V"#8-
M*=HMVN$Z!PN%*FY=I"Y8,(*-,!' G.J0<_30>%%@,-SM"\7#CS&.'%.J*ZEK
M@E &#%LROR%MM$\HI$#5S3EHP\>@"L;$C=T C;AE@90P2%38 RLAUY>JL!GG
M%;@_<</?8\T P"S-1:F3[0Q B]ZPML+ 7T?Z?PL7VIW?TD/R];+UZI8"!TES
M'5&M!N'.Y-.!$"4[V-B&$R1->&$IUU:AE8Y<(3A=G&^/@MZS N&W;EVU^K(L
MYA>7(KO<NH,.<X$P$W2D\3KY_WPF\'A'&<L)%S%A.#8,@8"FSD6N1C;DDX\D
MT^D#G)ABA/>[*J$*B@&!(2S>5#F2F.A=^1=CB-4815$0X5G3^L+YO"A PYA$
M% NM*A"]QBU0EH13Q3D6^@8&2- KK-0:RPQ2SZCRD2UW%1D^5FTST3)JE7IL
M?/Z*Q,"+,[A"]0*3@J'3L&_2DMALFJ$$;/8BR9% T^0T4\F)Y**@O53[MS!Z
M]L7Y@3>P>#^BTF7X]REY1H54193:22JOBD0DROQFC+J#GU=2D.3EG,O&[U8U
M?$5-<$S"-M7 FVU*!H]5&1QKW/T>_E0N%5K>++G@]#3:TDMOEYMI1-YER/5Y
MD<Z",IC+L53]M52>9(++3IHHE[:PABQ7821L"!P"U^@A%C25HO-=J)H!HKF@
M-VQ4Q N5(_,''-$J9OB1NM'0&5=I)(^C;"6Y6E>];7 ;\[%D)=-BDV_1^[X)
M\>_R)ZZ(M3S>Q%K6&FMYO(FU?*82<\]5IP>I#Q[0'@1KC74#RS_*=AH7 I;Z
ML2C6<YL93P',NY(>.HO#.N4;-.E)O^?R\;7IFLNO%X.QHG^I"\*Y:23O(FR]
MA?$:XM3KCGL(P;1%C$KBDAOIV[@VUA_SO_=.2T%7_@+Z8$EYPF^B:T/E"Z*]
MXHV$%4;E"<D;L,)[BH0'=!O$/DN=(U:\X=*9P6YK#SZ:TK#T?@PVC%BEDQ>(
M4U":;<V/XJPFJD28";I;D(RUF%,X&[\7Y4=CB9GJ(K4A5,@25<!P OM>".71
MC:3V=#",B"T "96H%(ZX^G ,I(*B>2 1B\:,N3-1-:<*B9!RX_BQB]M[!:)\
M?\V6HI(?D95H; VANE,,#>P934OEZD#X4#29I!GJVQ6:A[K(I_(\ANQA%2XK
MT#.QP9R^F"8H\W @T*]BD8C5B*E\U<"LK'#^0+>)Y+B"EQHB"<:2DL<GP6I1
MZ!.=HQI=I<P7*L\=BC6D5G('!*59"V'92\LRN2K&'$R>CZ9I71D+7U[M"BN5
M&O&9O8#I."C8,(=/WT;Y)7)B&$HWO"=BB]Q0LGAF\]HN(,/"W\K 4,XT5<+7
MN*/D8G(V P^>;%5H>SRO*NTHY7AWR^R0FZ.2TNN\D84C#BVE4NXYG,44LP5T
MN-!L[U#Q1J93"SE-#$YH7*!5Q%0,.HL3)\2??%U&A>8[M%S"W6_&NQ-L:.(I
MH+DC'@3TF.1729X2(RW\99X8UZ7YL7.$.R=&CR! 5X8PK% C5:6%4R*9G.IS
M+H)#L8U8YD\<XTO&,L*4CS1C[H-Q,3-D9U=IY"&GQ4<$_R#^1'1FD\S& Z^Y
MTJA^DD&.0$/JJP$!"87OA"28) H+S6*J\G!HWCA+K!(<1DLM$6OK6*LFT]4(
M;Y#OAC-%5! ' 9:MDZL2U)30/2F8'D1XU?P@M%-RE1PI:O=>1PLKG(V#I\"3
M>I=:(_9Q26WV&=(/UB)D0?93?%V2F'C:U-A8JI$ZJ,O#IK6WOF2 DYAW^9W;
M'%]\$R57LA_X;:D326]]AY5@DTY'\[(R#O'"ZO?$DOXF4"/YUI74V>OW)HFD
M>:LZ?I4D2B"[85Z1*XX2GF+[]KU"->%"O(TP"'AEI"M105_1L^B :]I.PR8B
M?$^&-5$9.7[JH<G @07^F!?761)?* G1$H259)G.\)>=LY9.),E+R42ZOAPV
M 8TXYR*QC(UVP-62I".5F:TT/H'B47X?W"Z%'**F9N#QC6WV[#T9UH7*<LCI
MCF=XW5!D&N_>DX+TD$JNS2B3O"IF*<TB,GT-JZG9J^:2L;2Z7#GB:RM"("Q1
MJ+L(AVP42'^49.2&5/[#-5?92TB1M%,H=&%4Q=5--<@J#GFCFSZI.E(5Y%)0
M5U$C@3?TZX'AD6&?.LX9'FMH"IE&82HJ3="Q,+IJLXR!;II](>Q-45>PYDE%
MGN5I=&%R4+L#;K/(KRG*UPI%,RB:HZ]%EU@.X_.*MKOM:I.8'<>A4);0W)%V
M$2Z[.8,)T;KI%J!K*J5_-B/$9F);AZ&Y1EVF/#(%,JDCSGX8-:AX;G%G&),.
MXR1ZJ["VH9>:^<J[MXC9L-^)(%L1.GBR"1VL-73P9!,Z^-R#\=!*B%W:!9%4
M]3"I/BF0"K) =28@FESS7-PI%:<8D&F;)HI'1@/%')EJ4[@V41G]GD_A*D5+
M0'@.M=IHN)!T26X;W8^<%MKK0=GGR39:Z2%C)/):V!'I+>0901J:BYQ0C]J,
M1S<?*)=4!H),XU!9YZ;:I5W98&\W.,R2*U!-,+.O!F,<;M@/.5B(^X@9QTCU
M%=S=T,S;_6#WT=Z3QV&PCQQ?V(MGP7\F5YB]B8"U!%VW7"J(7_BLW_LXYF_^
M3X*%*M+Q#BQ J.';O";.;TA7,D4;[$L;HPQ"*&:Y952=MM'"8Z61=:,-P4B=
MN]H1=O%1WA&W6EER3W_.T@;>RKH+2W4T3"4,,H2VNZ86 6PT?^H'5!/#XE0?
M%<5'OV@'GRW#O-\R@=[\M<R0^%FXY!T97U:5!+'?HA)+9I/.B\B4VF:A01>F
M,-"3DNE5 W![DU;6$J W3,U(V_QXV;I.Z2R-5'GZ[/%N,-N9[@1;RH/++EWL
MX" 06H>8TGL8N:(2$2QZ5JO8<NNX^KT['5@+H$B-B[*(,<F#_:]L^4:JKY0H
M@2]'S5.@CC>; &NPH2!?R$F.U;MC9RHFA>*C(22R1%O$H<DK3(X^." ?=LYV
M;GM&N-X-)BDSYP;S5WGY<NS<HD) Q=29^+0*_-H/M'-O7.C!G(#/+_$0M%9X
M8&09O'+MM1V"):4=O@^-__X/*Y7\4ZVFX"E[DSJ$^2>%976KF+^$K8C_S> O
M,>)'N_-* _5=$[2KH ?S;"L<N9<.*JY[,$#GTT2<OZJDR\2!2Z+O(06])+E(
M]"VE#'W>]1=$!99R]2CL<J8&JUE,7VN.:1?=/BM3,U*WY$ZYBD0BU"6YZ8B9
MEZ:5Q,4:>@0=9/AH#$(FQ<BI?^T^N,WX0,_8'\JES7Z1)J$4NJIB86(CU1)%
M>FL-'**^Y+VNLB8YEF1[A_#^HX =NAK9Z<6^Z69E+>;['_M0:N/869FM8\?I
MX$ D7 M.7&V,;U*IG#'<F%3+&'UZ25[Q09[(=84IWH[CBAUB3'N"=CD<&XRH
MZKR+[H"7'9I6_2O8%ZIYK_#6EH T*1@"D!"OH<@N,B?:YHCO=79U4;03H1P\
M6FNDFQ-Z3X;U4;*B,2>XJHJ27;?[5*:@:E2-Z:X0$S:WH74[4>33 D2K2+K>
MJ^+!3W,) I#!!6;R))7,(=I=(RZF:.):E=MM$V;F.@N-*IJJ6ZM^1]Y[EE%\
MYI>=N))12'FLBYNK^],9P4+?KCXK;NLAEAD9*>=S0K/>J/]BKEQ7<]@<P'LR
MK$R2N3%Q"4%K?.;>F4PZPRT%QB1GF.C*,.J[IUO9(+0R(-6],Z5="?94$3/&
M!;%/E(SEG=<I%@9"RFCK0?FU(C2PCH" :22M2UM+BNI><#P-/5 .+5R5P261
M/JKCJ+2!0M"Z[$;!9S;;^)X,:RKW2'+EU1S[#3<+!@=GH.6D5)6)%)K.:*;M
M.A1LIU5F0 !%D?)$&E<9;B9"S/9[K+FY6<MA@*''=+(\E&I>#H]<IJ-4]$P*
M"%+K07OC"A$GS1KIG>:FBVYBI I-JS>)LU#>0[A?!:R5SR*=S<;5(F,KP&W?
M4*7U##FMNJ^OS0&[)\/*^8"]3LA1:)E2E_())M(URZBB=J+4$8WE9%.G3)#'
MFOZ1"PI!I]V&VCB1<$)H/-5@/6@ QGJV4G<@F#YK!E&_X?WS5<?ROUO^>Q@C
M>W&L%^KXY8,9TM89U9:<8^841<=?42R@&CRH478NW H8R=,-C&2M,)*G&QB)
M_M\]NV4^@\C[CEE-CD_ZO=^.ST^&9V?!;Z^'I\-WK]S0&]8!'4>DI/A%/)FJ
M3E>XM3B:.%]AGJM"N#:KE5O2<Y*6F)J%]C'ZD2A!:(UE+EMG>/T;Q,@F6Q;Y
MLNK60W1$5:=(^X%.GR6X;OZ"%A'W@SK+1JS=M+TUSC/(.=.MPW<XS2?_^.'1
MK>?T[KHH.XWY:(H2Y.5\-DM*9&V%EQR\'#*.B'M]D!;5F#1\:.\X'\/^/WAI
M#XZ$^#>RC'K?/:4KZXLLZ6=W\9OOX9-U=''Y_P<W>:@YUF]I#WZCJWJG5 R+
M9TO[M%PAY@:__E1N-LT7[18;!]]HYS:[XRMWZQQQ%,NERK<Q6V9?B-UZ[TV
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MPP,>EX.V#DN,9$L2W*" RJ,9>@A'208G_DMTRRC?,S;:QR^FV4UTS7Y^UKU
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M,:X?:U&XJT^=P9>+81&+JUZ6TTVV2$(%0J"+IF3C<= :'Y.!C49Z!YQQ%GC
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M-NKM>K 'W\&%'W?!(@(I IN"KZ%<3=U-;;&H+#4?3&$USKCT9U$(?V)C)HL
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M7Q2@8_,O!_[^_GZ# +1ZX(HWPS9C4#_ML)"-(08]'QNS3QAX>UE@)3"< "%
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MOAK=<:L]XJKBIAJEFZ!PZ'>:K8V8T#^ITKST9C+T3R5#D83D"S,[>+/AV"#
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MB$&VM<OW'05%P#;GH5I=MM?#.AXX53$;VS[K)BS#!LZU7M-YJ7W6F4H:#I3
M1LI0T#U3([0G["4W_L;<4]6+FV<G8YZ%5&:O\F"_V6-NG1G6RFS304U>A14O
M4%GN5H/7MM;;43Y?WY,$#Y7<44>B-:;FFX11Q:7'YPKI8_4W"@X+>@5:E3I_
M9!6R_U@1:JV+H5)KG/N-YEW-?7.;UM0L0]=(W=TASHD& (@:1[TSJFIH06N)
M>M<\YI57]4RMQ]5-TBH2[5,<X6&TI!6IEZJ,@T6MB(*85B//+)+VE7K.)/V%
M9X01(G]V5NZM=,16)[B?VO'G<#Q>X/%X;%O6K X<<UE64S^]2H/I6O<U=AE>
ML2$:<KG094N!&TNC5<@.U])G<QZ.Y AEE*,'R!%F74!!A)K4K(?X;4.V7.2I
M92B:]#^*:6P"HJLVF-ED"^5ZJ.)5?*.2X*]S/O1,DP(]*"#9BCF&L<=COV8&
M^Q:E,EB+. \3"D7 JT?3B)/HK*^MIDBJE45CTW,Y7NPEX&@T1/RA]3ICY+CL
M['9,&46SKTUL 9:U<4:O$]5VNS1P#3/#:M@O)Q6:%![K>0(J@:?6E!_O<W0?
M4=WN6OGQ/D?W:<8JKU%^QJN4G_K0;Z39=#NW4FWJP[M*LS&3*0GEM39Z.YOF
MKC8 [3]'NW%>WJ[;@.5]*^6F9D/<2K=Q&N6J$9RJ*6UKTW!6."R;])L5K^N9
MD+K!U7$$U+EKI7)CM;521.//JCJ$7]CJ.G\FU?3G;:KI?<9:?][&6A]V MJ=
M5[-ZLTC#8,:\ %=&EU/AN5N&Y'P*R3G1$6:%2):,J%&?2)M#9"6J[((499"P
MI5 6XH%FO]XLHE@3 Y=I(VO'MVTF$%"'WD6*D9U%YIO*%A;T%/]!7V8,FDV.
MJ+BV%MN-02^(#YN6M- D'B$+!YX2BAK"U^0+/L,KE\K;H^T37983CTBBU$-_
M.8YD2:DL0L;MV"YZT-"Y#A/+1VK3T*D0G#4'=G]\BQEM3*TL%?'YF <Y$J0U
MNHOPJQV%LZ^#=]U1IO(C2HUU>:U8@[/4MIJR)@6;6!E!GZYJ&)E4JDW8@%AQ
M;M&97K>/B%(HLURWJ#KH>B[!"#-\3*S4:M,$Y%NIR$2>[VOHH;7,*UX:>$O;
M3=<9@8+GH#%J3LT1WZMBR)5H(@4N-]Q!6(:!3>&-=E#=^@/3()\$:?PO*RPC
M-JS^K@E@R;L&)WF1%%0ZC&FD] 359[WVD+@P 28B,E0Y:K1SK=D.-YQAG];(
MSN;#YZT=/90TB]F,$SZ,-<Z=U3N(RH0XYG&W,UP4&/DNG+#76D= 94+\VG2
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M[BK_!UUN+Y54V<:8A23 4<=K0A7)<H'LUGZ49V1;QXPTD30XWE]_3[=F[,%
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ME%B[>/9Q+N,Z-3'&OL5BHEMC#S7=2,))6I&BTY;.E8BWR;/#=9G0YXV'L$T
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M%@  97@Q,"TQ+FAT;5!+ 0(4 Q0    ( %&)C%NA /0N&%$  +L2 @ )
M          "  51"  !E>#0M,2YH=&U02P$"% ,4    " !1B8Q;"#UYN@M1
M  !R$@( "0              @ &3DP  97@T+3(N:'1M4$L! A0#%     @
M48F,6^U*** -40  5!$"  D              ( !Q>0  &5X-"TS+FAT;5!+
M 0(4 Q0    ( %*)C%L!&^2(TPT  %)"   *              "  ?DU 0!E
M>#DY+3$N:'1M4$L! A0#%     @ 4HF,6XC1_;J-#0  &SX   H
M     ( !]$,! &5X.3DM,BYH=&U02P$"% ,4    " !2B8Q;CTBRI0(D   '
M"P$ "P              @ &I40$ 9F]R;3@M:RYH=&U02P4&      H "@!+
) @  U'4!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>form8-k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="envb-20251211.xsd" xlink:type="simple"/>
    <context id="AsOf2025-12-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
        </entity>
        <period>
            <startDate>2025-12-11</startDate>
            <endDate>2025-12-11</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:AmendmentFlag contextRef="AsOf2025-12-11" id="Fact000003">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="AsOf2025-12-11" id="Fact000004">0000890821</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="AsOf2025-12-11" id="Fact000009">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="AsOf2025-12-11" id="Fact000010">2025-12-11</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="AsOf2025-12-11" id="Fact000011">Enveric Biosciences, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="AsOf2025-12-11" id="Fact000012">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="AsOf2025-12-11" id="Fact000013">001-38286</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="AsOf2025-12-11" id="Fact000014">95-4484725</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="AsOf2025-12-11" id="Fact000015">Enveric Biosciences, Inc.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="AsOf2025-12-11" id="Fact000016">245 First Street, Riverview II</dei:EntityAddressAddressLine2>
    <dei:EntityAddressAddressLine3 contextRef="AsOf2025-12-11" id="Fact000017">18th Floor</dei:EntityAddressAddressLine3>
    <dei:EntityAddressCityOrTown contextRef="AsOf2025-12-11" id="Fact000018">Cambridge</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="AsOf2025-12-11" id="Fact000019">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="AsOf2025-12-11" id="Fact000020">02142</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="AsOf2025-12-11" id="Fact000021">(617)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="AsOf2025-12-11" id="Fact000022">444-8400</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="AsOf2025-12-11" id="Fact000023">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="AsOf2025-12-11" id="Fact000024">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="AsOf2025-12-11" id="Fact000025">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="AsOf2025-12-11" id="Fact000026">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="AsOf2025-12-11" id="Fact000027">Common     stock, par value $0.01 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="AsOf2025-12-11" id="Fact000028">ENVB</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="AsOf2025-12-11" id="Fact000029">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="AsOf2025-12-11" id="Fact000030">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
